Author index*

A

Aaronson KD, Shroff AR, Russman PL, Koelling T, Pagani FD. International survey of routine surveillance biopsy practices in adult heart transplantation. 1999;18:80 (Abstract)

Abbal M (*see* Dambrin et al). 1999;18:524–30

Abbatista AD (*see* Parisi et al). 1999;18:275–77

Abejón D (*see* Planas et al). 1999;18:55 (Abstract)

Abel JG (*see* Cook et al). 1999;18:420–24

Abel JG (*see* Pamboukian et al). 1999;18:367–70

Acker MA (*see* DeNofrio et al). 1999;18:46 (Abstract)

Adachi M (*see* Tomizawa et al). 1999;18:637–44

Adams B (*see* Ikonen et al). 1999;18:73 (Abstract)

Adamson R (*see* Jaski et al). 1999;18:1031–40

Addonizio LJ (*see* Bernstein et al). 1999;18:69 (Abstract)

Addonizio LJ (*see* Helman et al). 1999;18:89 (Abstract)

Adler FR (*see* Cahill et al). 1999;18:86 (Abstract)

Agelan A, Katsetos CD, Sakkas LI, Goldman B, Oleszak EL, Platsoucas CD. Apoptosis in rat cardiac allograft is predominantly associated with cells of the immune response. 1999;18:40 (Abstract)

Aggestrup S (*see* Svendsen et al). 1999;18:388–89

Agostini D, Babatasi G, Belin A, Amar MH, Massetti M, Hamon M, Grollier G, Potier JC, Khayat A, Bouvard G. Low cardiac neuronal function and predicted value of maximum oxygen consumption predict for high risk of cardiac events in cardiomyopathy. 1999;18:47 (Abstract)

Aguado JM (*see* Delgado et al). 1999;18:607–10

Ahmed D (*see* Partovi et al). 1999;18:85 (Abstract)

Akdemir H (*see* Wildhirt et al). 1999;18:40 (Abstract)

Akindipe OA (*see* Faul et al). 1999;18:384–87

Albert NM (*see* Peacock et al). 1999;18:92 (Abstract)

Albert NM, Spear BT. Intravenous (IV) inotrope and vasodilator therapy in a critical care setting utilizing a heart failure specialty team care approach (HFSTC) with "hemodynamic goal" protocols vs. a general cardiology care approach (GCC). 1999;18:75 (Abstract)

Albert NM, Spear BT. Treatment differences and clinical outcomes of advanced heart failure (HF) patients with a critical care admission using specialist team protocols vs. general cardiology care. 1999;18:76 (Abstract)

Albes J (*see* Wittwer et al). 1999;18:684–91

Albrecht S (*see* Wagner et al). 1999;18:74 (Abstract)

Aleos JC (*see* Eisenring et al). 1999;18:58–59 (Abstract)

Alexander JA (*see* Baz et al). 1999;18:60 (Abstract)

Alexander JW (*see* Gibson et al). 1999;18:185–88

Alexis J (*see* Freudenberger et al). 1999;18:1228–31

Allan JS (*see* Mawulawde et al). 1999;18:53 (Abstract)

Allen-Auerbach M, Schöder H, Johnson J, Kofoed K, Einhorn K, Phelps ME, Kobashigawa J, Czernin J. Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients. 1999;18:211–18

Allen MD (*see* Iwata et al). 1999;18:37 (Abstract)

Allison KS (*see* Menard et al). 1999;18:71 (Abstract)

Alphonso N (*see* Stamenkovic et al). 1999;18:1246–50

Altinger J (*see* Brazelton et al). 1999;18:59 (Abstract)

Altinger J (*see* Doyle et al). 1999;18:86 (Abstract)

Amar MH (*see* Agostini et al). 1999;18:47 (Abstract)

Amor R (*see* Keogh et al). 1999;18:67 (Abstract)

Andreuzzi B (*see* Gronda et al). 1999;18:654–61

Andreuzzi B (*see* Oliva et al). 1999;18:75 (Abstract)

Angermann CE (*see* Behr et al). 1999;18:904–11

Angermann CE (*see* Rieber et al). 1999;18:65 (Abstract)

Angermann CE (*see* Spes et al). 1999;18:391–97

Ankersmit J (*see* Lietz et al). 1999;18:80 (Abstract)

Ankersmit J, Schuster M, Edwards N, Burke E, Kocher A, Lietz K, Mancini D, Oz M, Itescu S. T cell activation in left ventricular assist device (LVAD) recipients occurs via a CD95-dependent pathway, and results in loss of Th1 cells and high levels of circulating IL-10. 1999;18:56 (Abstract)

Ankersmit J, Schuster M, Shah S, Olson K, Lehman A, McCue J, Kocher A, Lietz K, Modak S, Edwards N, Oz M, Itescu S. T cell apoptosis and defects in cellular immunity induced by exposure to biomaterials: implications for left ventricular assist device (LVAD) implantation. 1999;18:56 (Abstract)

Annalisa A (*see* Sartori et al). 1999;18:693–99 (Abstract)

Antonio G (*see* Sartori et al). 1999;18:693–99 (Abstract)

Anyanwu AC, McGuire A, Rogers CA, Murday AJ. Assessment of health related quality of life in pulmonary transplantation: application of a simple generic tool. 1999;18:51 (Abstract)

Anyanwu AC, Rogers CA, Murday AJ. Development of a simple risk model for predicting survival after adult orthotopic heart transplantation. 1999;18:37–38 (Abstract)

Anyanwu AC, Rogers CA, Murday AJ. Variations in cardiac transplantation: comparisons between the United Kingdom and the United States. 1999;18:297–303

Aptecar E, Garot P, Dupouy P, Teiger E, Benvenuti C, Pernes JM, Castaigne A, Loisance D, Hittinger L, Dubois-Randé JL. Coronary vasomotor response to the selective B_1 kinin receptor agonist des-Arg^9-Bradykinin in transplant patients. 1999;18:64 (Abstract)

Aquilino T (*see* Keenan et al). 1999;18:55 (Abstract)

*January, pp 1-106; February, pp 107-74; March, pp 175-278; April, pp 279-390; May, pp 391-498; June, pp 499-610; July, pp 611-734; August, pp 735-818; September, pp 819-926; October, pp 927-1030; November, pp 1031-1150; December, pp 1151-1354.

Arabia FA, Smith RG, Arzouman DA, Paramesh V, Toporoff B, Sethi GK, Copeland JG. Criteria for selecting type of bridge to heart transplantation: the University of Arizona experience. 1999;18:89 (Abstract)
Aravot D (*see* Ben-Gal et al). 1999;18:75-76 (Abstract)
Arcidi J (*see* Bhorade et al). 1999;18:79 (Abstract)
Ardehali A (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Arendt RM (*see* Weis et al). 1999;18:64 (Abstract)
Arendt RM (*see* Weis et al). 1999;18:1071-79
Arens MQ (*see* Kruger et al). 1999;18:82 (Abstract)
Argenziano M, Chen JM, Cullinane S, Choudhri AF, Rose EA, Smith CR, Edwards NM, Landry DW, Oz MC. Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation. 1999;18:814-17
Arita M (*see* Wada et al). 1999;18:499-508
Artemiou O (*see* Zuckermann et al). 1999;18:432-39
Artermiou O (*see* Takahashi et al). 1999;18:304-9
Arzouman DA (*see* Arabia et al). 1999;18:89 (Abstract)
Asfour B (*see* Baba et al). 1999;18:57 (Abstract)
Asfour B, Hare JM, Kohl T, Baba HA, Kass DA, Chen K, Tjan TDT, Hammel D, Weyand M, Hruban RH, Scheld HH, Byrne BJ. A simple new model of physiologically working heterotopic rat heart transplantation provides hemodynamic performance equivalent to that of an orthotopic heart. 1999;18:927-36
Assandri J (*see* Raczak et al). 1999;18:399-405
Atkines BZ, Hueman MT, Meuchal JM, Cottman MJ, Hutcheson KA, Taylor DA. Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium. 1999;18:1173-80
Atkins BZ, Meuchel JM, Glower DD, Taylor DA. Differential effects of cellular cardiomyoplasty on systolic diastolic performance in cryoinjured rabbit myocardium. 1999;18:43 (Abstract)
August C (*see* Baba et al). 1999;18:57 (Abstract)
Aurora P (*see* Gassas et al). 1999;18:83 (Abstract)
Austin PC (*see* Kavanagh et al). 1999;18:846-50
Awad MR (*see* El-Gamel et al). 1999;18:517-22
Aziz T (*see* Burgess et al). 1999;18:44-45 (Abstract)
Aziz T, Burgess M, Deiraniya A, Yonan N. Orthotopic heart transplantation: Which technique? Comment on the prospective randomized trial of CAVT by Bainbridge et al. 1999;18:1253-54 (Letter)
Aziz T, Yonan N, Deiraniya A, Campbell C, Rahman A, Haselton P, Hutchinson I. Transforming growth factor-beta (TGF-β) and allograft vasculopathy following heart transplantation. 1999;18:37 (Abstract)
Azqueta M (*see* Roig et al). 1999;18:91 (Abstract)

B

Baan CC (*see* de Groot-Kruseman et al). 1999;18:52 (Abstract)
Baan CC, van Gelder T, Balk AHMM, Maat APWM, Weimar W. Functional responses of anti-CD25 blocked T-cells during cardiac rejection. 1999;18:69 (Abstract)
Baba HA (*see* Asfour B et al). 1999;18:927-36
Baba HA (*see* Plenz et al). 1999;18:923-24 (Letter)
Baba HA, Schmid KW, Takeda A, Wichter T, Gradaus R, Erren M, Plenz G, Grabellus F, Tjan TDT, Deng MC. Metallothionein: localization in human transplant endomycardium, relation to cytokines and allograft function. 1999;18:963-71
Baba HA, Tjan TDT, August C, Asfour B, Plenz G, Schmid C, Schmid KW, Hammel D, Weyand M, Scheld HH, Deng MC. Metallothionein is involved in reverse remodeling after prolonged left ventricular assist device support. 1999;18:57 (Abstract)
Babatasi G (*see* Agostini et al). 1999;18:47 (Abstract)
Babcock GF (*see* Gibson et al). 1999;18:185-88
Backer CL (*see* Crawford et al). 1999;18:470-76
Backer CL (*see* Pahl et al). 1999;18:725-32
Backer CL (*see* Ringewald et al). 1999;18:70 (Abstract)
Badimon J (*see* Freudenberger et al). 1999;18:1228-31
Bagga A (*see* Ross et al). 1999;18:627-35
Bahlo M (*see* Nägele et al). 1999;18:957-62
Bährle S (*see* Szabó et al). 1999;18:54 (Abstract)
Bailey LL (*see* Dearani et al). 1999;18:70 (Abstract)
Bainbridge AD, Cave M, Roberts M, Casula R, Mist BA, Parameshwar J, Wallwork J, Large SR. A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty. 1999;18:407-12
Baker CJ (*see* Kim et al). 1999;18:74 (Abstract)
Balfour I (*see* Webber et al). 1999;18:69 (Abstract)
Balfour IC, Tinker K, Singh G, Fiore AC, Jureidini SB. Coronary artery to pulmonary artery collaterals after heart transplantation. 1999;18:1027-29
Balfour IC, Wall D, Luisiri A, Sotelo C, Gross TG. Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease. 1999;18:492-94
Balk AHMM (*see* Baan et al). 1999;18:69 (Abstract)
Balk AHMM (*see* de Groot-Kruseman et al). 1999;18:52 (Abstract)
Banas R (*see* Zeevi et al). 1999;18:82 (Abstract)
Banbury M (*see* Hoercher et al). 1999;18:45 (Abstract)
Bando K (*see* Flaspohler et al). 1999;18:91 (Abstract)
Bando K, Flaspohler T, Caldwell R, Darragh R, Sharp T, Turrentine M, Park HJ, Okada Y, Murphy D, Brown J. Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS). 1999;18:70 (Abstract)
Banner N (*see* Long et al). 1999;18:92 (Abstract)
Baran D (*see* Lietz et al). 1999;18:80 (Abstract)
Barbers RG (*see* Chan et al). 1999;18:85 (Abstract)
Barbers RG (*see* Uppal et al). 1999;18:54 (Abstract)
Barbieri P (*see* Gronda et al). 1999;18:654-61
Bardsley V, Stewart S, Goddard MJ, McNeil K, Wallwork J. A post mortem audit of deaths occurring beyond 30 days following heart-lung transplantation. 1999;18:41 (Abstract)
Barisani J (*see* Trainini et al). 1999;18:42-43 (Abstract)
Barisani JC (*see* Trainini et al). 1999;18:1120-25

Barmak A (*see* Moscoloni et al). 1999;18:58 (Abstract)
Barnes D (*see* Sheffield et al). 1999;18:39 (Abstract)
Barosi A (*see* Oliva et al). 1999;18:75 (Abstract)
Barrett-Stull L (*see* Ogletree-Hughes et al). 1999;18:63 (Abstract)
Barr ML (*see* Chan et al). 1999;18:85 (Abstract)
Barr ML (*see* Kim et al). 1999;18:74 (Abstract)
Barr ML (*see* Taylor et al). 1999;18:336-45
Barr ML (*see* Uppal et al). 1999;18:54 (Abstract)
Barten MJ (*see* Gummert et al). 1999;18:53-54 (Abstract), 1999;18:72 (Abstract)
Bastürk M (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Batista RJV (*see* Kawaguchi et al). 1999;18:67 (Abstract)
Baxter K, Howden B, Saunder A, Jablonski P. Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW). 1999;18:769-73
Baz MA (*see* Zander et al). 1999;18:646-52
Baz MA, Caridi JG, Guevara MS, Friskel ED, Alexander JA, Staples ED. Results of expandable metal stent placement in lung transplant recipients. 1999;18:60 (Abstract)
Beer SA (*see* Eccleshall et al). 1999;18:46 (Abstract)
Behr TM, Feucht HE, Richter K, Reiter C, Spes CH, Pongratz D, Überfuhr P, Meiser B, Theisen K, Angermann CE. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. 1999;18:904-11
Beigelman C (*see* Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
Belanger MB (*see* Wittnich et al). 1999;18:675-83
Belin A (*see* Agostini et al). 1999;18:47 (Abstract)
Bélisle S (*see* Carrier et al). 1999;18:664-67
Belland SE, Sangrigoli R, Jeevanandam V, Eisen HJ. Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy. 1999;18:54 (Abstract)
Belloni A, Caforio ALP, Piaserico S, Bombieri L, Peserico A, Livi U. Risk factor analysis for skin cancer in heart transplant (HT) recipients. 1999;18:77 (Abstract)
Bello-Puentes R (*see* Gutiérrez-Carretero et al). 1999;18:372-75
Ben-Gal T, Pinchas A, Zafrir N, Sahar G, Aravot D. Long term physical training in cardiac transplant candidates: is it feasible?. 1999;18:75-76 (Abstract)
Beniaminovitz A (*see* Maybaum et al). 1999;18:44 (Abstract), 1999;18:62 (Abstract)
Beniaminovitz A, Itescu S, Donovan M, Burke E, Webb J, Leitz K, Edwards N, Mancini D. Use of daclizumab decreases the frequency of early allograft rejection in de-novo heart transplant recipients. 1999;18:45 (Abstract)
Benigno M (*see* Cargnoni et al). 1999;18:478-86
Bennett LE (*see* Boucek et al). 1999;18:1151-72 (Registry)
Bennett LE (*see* Hosenpud et al). 1999;18:611-26 (Abstract)
Bennett LE (*see* Novick et al). 1999;18:50-51 (Abstract), 1999;18:425-31
Benson L (*see* Dipchand et al). 1999;18:83-84 (Abstract)
Bentlejewski C (*see* McCurry et al). 1999;18:72 (Abstract)
Benvenuti C (*see* Aptecar et al). 1999;18:64 (Abstract)
Berger R (*see* Stanek et al). 1999;18:358-65
Berger R, Frey B, Stanek B, Pacher R. Sequential evaluation of big endothelin plasma concentration in patients with advanced heart failure: effects of therapy. 1999;18:47 (Abstract)
Berger R, Kuchling G, Frey B, Grimm M, Laufer G, Pacher R, Stanek B. Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation. 1999;18:75 (Abstract)
Bergmann S (*see* Maybaum et al). 1999;18:62 (Abstract)
Berlinski A (*see* Sweet et al). 1999;18:82-83 (Abstract)
Bernard M, Caus T, Sciaky M, Lan C, Cozzone PJ. Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis. 1999;18:572-80
Bernocchi P (*see* Cargnoni et al). 1999;18:478-86
Bernstein D (*see* Dubin et al). 1999;18:781-84
Bernstein D, Naftel DC, Hsu DT, Addonizio LJ, Blume ED, Gamberg PL, Kirklin JK, Morrow WR, Pediatric Heart Transplant Study Group. Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study. 1999;18:69 (Abstract)
Berry GJ (*see* Faul et al). 1999;18:384-87
Berry GJ (*see* Hausen et al). 1999;18:73 (Abstract), 1999;18:79-80 (Abstract), 1999;18:150-58, 1999;18:714-24
Berry GJ (*see* Ikonen et al). 1999;18:60 (Abstract), 1999;18:73 (Abstract)
Bethune D (*see* Parry et al). 1999;18:121-25
Beyersdorf F (*see* Martin et al). 1999;18:597-605
Bhorade SM, McCabe MA, Martin KL, Lonchyna V, Arcidi J, Hinkamp T, Garrity ER, Loyola Lung Transplant Team. Successful lung transplantation with the use of marginal donors. 1999;18:79 (Abstract)
Bibidakis A (*see* Fedalen et al). 1999;18:56-57 (Abstract)
Bieda H (*see* Müller et al). 1999;18:70-71 (Abstract)
Bigard AX (*see* Zoll et al). 1999;18:71 (Abstract)
Billingham ME (*see* Gummert et al). 1999;18:53-54 (Abstract), 1999;18:72 (Abstract)
Billingham ME (*see* Slauson et al). 1999;18:1251-52 (Letter)
Binkley PF (*see* Wang et al). 1999;18:48 (Abstract)
Birsan T (*see* Zuckermann et al). 1999;18:432-39
Birsan T, Kranz A, Mares P, Atermiou O, Taghavi S, Zuckermann A, Klepetko W. Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension. 1999;18:304-9
Birsnan T (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Bishay E (*see* Cook et al). 1999;18:38 (Abstract)
Biswas SS (*see* Bittner et al). 1999;18:87 (Abstract)
Bittner HB, Chen EP, Biswas SS, Van Trigt P, Davis RD. Mechanisms of brain death associated myocardial dysfunction. 1999;18:87 (Abstract)

Blair KSA, Zorn GL, Zhang JP, Joseph KJ, Collins BJ, Marsh JW, Qian QH, Pierson RN III. Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF). 1999;18:54 (Abstract)
Blaise G (*see* Carrier et al). 1999;18:664-67
Blanc PD (*see* Jonosono et al). 1999;18:972-85
Blume E (*see* Ibrahim et al). 1999;18:83 (Abstract)
Blume ED (*see* Bernstein et al). 1999;18:69 (Abstract)
Boehm DH (*see* Wildhirt et al). 1999;18:40 (Abstract)
Boehmer JP (*see* Kirklin et al). 1999;18:47 (Abstract)
Boeke K (*see* Gummert et al). 1999;18:72 (Abstract)
Boeke K (*see* Hausen et al). 1999;18:79-80 (Abstract), 1999;18:150-58
Boeke K (*see* Hirt et al). 1999;18:542-48
Bogers A (*see* Welters et al). 1999;18:53 (Abstract)
Bojic A (*see* Stanek et al). 1999;18:358-65
Böker KHW (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Boksch W (*see* Hummel et al). 1999;18:49 (Abstract)
Bolling SF (*see* Mulligan et al). 1999;18:59 (Abstract)
Bolman RM III (*see* Kulick et al). 1999;18:65 (Abstract)
Bolman RM III (*see* Nguyen et al). 1999;18:55 (Abstract), 1999;18:1021-23
Bolman RM III (*see* Park et al). 1999;18:60 (Abstract)
Bolman RM III, Park SJ. Temporary ECMO support following lung and heart-lung transplantation. 1999;18:55 (Abstract)
Bologna M (*see* Kerman et al). 1999;18:38 (Abstract)
Bolys R (*see* Wierup et al). 1999;18:127-32
Bolys R, Ingemansson R, Sjöberg T, Steen S. Vascular function in the cadaver up to six hours after cardiac arrest. 1999;18:582-86
Bombieri L (*see* Belloni et al). 1999;18:77 (Abstract)
Bonavida B (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Bonser RS (*see* Eccleshall et al). 1999;18:46 (Abstract)
Bonser RS (*see* Pagano et al). 1999;18:67 (Abstract)
Bonser RS (*see* Rooney et al). 1999;18:73 (Abstract)
Boraso A (*see* Cargnoni et al). 1999;18:478-86
Borkon AM, Muehlebach GF, Jones PG, Bresnahan DR Jr, Genton RE, Gorton ME, Long ND, Magalski A, Porter CB, Reed WA, Rowe SK. An analysis of the effect of age on survival after heart transplant. 1999;18:668-73
Borrego-Domínguez JM (*see* Gutiérrez-Carretero et al). 1999;18:372-75
Boucek MM (*see* Boucek et al). 1999;18:460-69
Boucek MM (*see* Frazier et al). 1999;18:69-70 (Abstract)
Boucek MM (*see* Hosenpud et al). 1999;18:611-26 (Abstract)
Boucek MM (*see* Pietra et al). 1999;18:48 (Abstract)
Boucek MM, Faro A, Novick RJ, Bennett LE, Fiol B, Keck BM, Hosenpud JD. The Registry of the International Society of Heart and Lung Transplantation: Third Official Pediatric Report. 1999;18:1151-72 (Registry)
Boucek RJ Jr, Naftel D, Boucek MM, Chinnock R, Morrow RW, Pahl E, DiSano S. Induction immunotherapy in pediatric heart transplant recipients: a multicenter study. 1999;18:460-69
Bourge R (*see* Grady et al). 1999;18:750-60
Bourge R (*see* Keogh et al). 1999;18:53 (Abstract)
Bourge RC (*see* Jaski et al). 1999;18:37 (Abstract)
Bourge RC (*see* Kirklin et al). 1999;18:47 (Abstract)
Bourge RC (*see* Lake et al). 1999;18:81 (Abstract)
Bourge RC (*see* Rayburn et al). 1999;18:47 (Abstract)
Bouvard G (*see* Agostini et al). 1999;18:47 (Abstract)
Boyd D (*see* Del Rizzo et al). 1999;18:310-19
Boyle GJ (*see* Robinson et al). 1999;18:786-90
Boyle GJ (*see* Webber et al). 1999;18:83 (Abstract)
Branch KR (*see* Jaski et al). 1999;18:1031-40
Braun-Dullaeus RC, Feussner M, Walker G, Hopmann H, Kraemer H-J, Grimminger F, Tillmanns H, Haberbosch W. Cyclosporine-induced coronary artery constriction dissociation between thromboxane release and coronary vasospasm. 1999;18:328-34
Braun PR (*see* McBride et al). 1999;18:90 (Abstract)
Brazelton T (*see* Briffa et al). 1999;18:66 (Abstract)
Brazelton T (*see* Doyle et al). 1999;18:86 (Abstract)
Brazelton TR, Doyle RL, Poirier C, Wong RL, Newmark RD, Bush C, Altinger J, Hausen H, Reitz BA, Theodore J, Morris RE. Analysis of risk factors for chronic lung rejection from a twelve-center, multinational database. 1999;18:59 (Abstract)
Brazelton TR, Doyle RL, Wong RL, Newmark RD, Bush C, Theodore J, Morris RE. Heterogeneity and reversal of bronchiolitis obliterans syndrome. 1999;18:59-60 (Abstract)
Bredee JJ (*see* Bruinsma et al). 1999;18:1189-97
Bredikis AJ (*see* Pinski et al). 1999;18:292-96
Brenchley PEC (*see* Onwu et al). 1999;18:74 (Abstract)
Brenner P, Hink M, Huber H, Schmoekel M, Reichenspurner H, Meiser B, Hammer C, Reichart B. Effects of prolonged storage time in xenotransplantation. 1999;18:1211-17
Brenner P, Hinz M, Huber H, Schmoeckel M, Reichenspurner H, Meiser B, Hammer C, Reichart B. Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption. 1999;18:59 (Abstract)
Bresnahan DR Jr (*see* Borkon et al). 1999;18:668-73
Bridges ND (*see* Ro et al). 1999;18:83 (Abstract)
Bridges ND (*see* Ro et al). 1999;18:1232-37
Briffa N (*see* Hausen et al). 1999;18:714-24
Briffa NP, Shorthouse R, Chang J, Brazelton T, Morris RE. Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts. 1999;18:66 (Abstract)
Brilakis ES, Olson LJ, Daly RC, Cooper LT. Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices. 1999;18:43-44 (Abstract)
Brilakis ES, Young WF Jr, Wilson JW, Thompson GB, Munger TM. Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension. 1999;18:376-80
Brooks NH (*see* Densem et al). 1999;18:52 (Abstract), 1999;18:77 (Abstract)
Brosseau L (*see* Lands et al). 1999;18:113-19 (Abstract)
Brown J (*see* Bando et al). 1999;18:70 (Abstract)

Brown J (*see* Flaspohler et al). 1999;18:91 (Abstract)
Brown RN (*see* Rayburn et al). 1999;18:47 (Abstract)
Brozen SC (*see* Jaski et al). 1999;18:37 (Abstract)
Bruch L (*see* Waurick et al). 1999;18:1243-45
Bruggeman CA (*see* Tikkanen et al). 1999;18:62 (Abstract)
Bruhn PS (*see* Wright et al). 1999;18:913-15
Bruinsma GJBB, Nederhoff MGJ, Van de Kolk CWA, de Groot MCH, Slootweg PJ, Bredee JJ, Ruigrok TJC, Van Echteld CJA. Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus 31 magnetic resonance spectroscopy study in the cat. 1999;18:1189-97
Brunnert SR (*see* Choi et al). 1999;18:1103-10
Buda T (*see* Kaplon et al). 1999;18:63 (Abstract)
Buda T (*see* Marullo et al). 1999;18:42 (Abstract)
Bull DA (*see* Stringham et al). 1999;18:160-65
Burchart G (*see* Zeevi et al). 1999;18:82 (Abstract)
Burckart G (*see* Zeevi et al). 1999;18:81-82 (Abstract)
Burdick M (*see* Fisher et al). 1999;18:88 (Abstract)
Burgess M (*see* Aziz et al). 1999;18:1253-54 (Letter)
Burgess MI, Ray SG, Aziz T, El-Gamel A, Deiraniya AK, Campbell C, Rahman AN, Yonan N. Left ventricular diastolic function after bicaval and standard cardiac transplantation. 1999;18:44-45 (Abstract)
Burke E (*see* Ankersmit et al). 1999;18:56 (Abstract)
Burke E (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Burke E (*see* Lietz et al). 1999;18:80 (Abstract)
Burton NA (*see* Myers et al). 1999;18:1024-26
Bush C (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59-60 (Abstract)
Bush C (*see* Doyle et al). 1999;18:86 (Abstract)
Buyse B (*see* Verleden et al). 1999;18:1139-46
Byrne BJ (*see* Asfour B et al). 1999;18:927-36
Byrne GW (*see* Lau et al). 1999;18:65-66 (Abstract)

C

Cable DG, Hisamochi K, Schaff HV. A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm?. 1999;18:177-83
Cabrera Fischer E (*see* Trainini et al). 1999;18:42-43 (Abstract)
Cabrera Fischer EI (*see* Trainini et al). 1999;18:1120-25
Caes F (*see* De Somer et al). 1999;18:1014-17
Caforio ALP (*see* Belloni et al). 1999;18:77 (Abstract)
Cahill BC, Liou TG, Marshall BC, FitzSimmons S, Hoidal JR, Adler FR. Optimal timing of lung transplantation in cystic fibrosis patients. 1999;18:86 (Abstract)
Cai J (*see* Zeevi et al). 1999;18:81-82 (Abstract)
Caldwell R (*see* Bando et al). 1999;18:70 (Abstract)
Caldwell R (*see* Flaspohler et al). 1999;18:91 (Abstract)
Calise D (*see* Dambrin et al). 1999;18:946-51
Camici PG (*see* Pagano et al). 1999;18:67 (Abstract)
Campbell C (*see* Aziz et al). 1999;18:37 (Abstract)
Campbell C (*see* Burgess et al). 1999;18:44-45 (Abstract)
Campbell C (*see* El-Gamel et al). 1999;18:828-35
Campbell CS (*see* El-Gamel et al). 1999;18:517-22
Canobbio MM (*see* Eisenring et al). 1999;18:58-59 (Abstract)
Cantarovich M, Elstein E, Magnan C, Chartier R, de Varennes B. Clinical benefit of neoral dose monitoring with cyclosporine 2-hour peak levels compared to trough levels in stable heart transplant patients. 1999;18:78 (Abstract)
Canter CE (*see* Frazier et al). 1999;18:69-70 (Abstract)
Canter CE (*see* Ibrahim et al). 1999;18:83 (Abstract)
Cantu E (*see* Schulman et al). 1999;18:107-12
Canver CC (*see* Love et al). 1999;18:87 (Abstract)
Canver CC (*see* Onsager et al). 1999;18:448-54
Canver CC (*see* Stringham et al). 1999;18:587-95
Caraos L (*see* Choi et al). 1999;18:1103-10
Carboni GL (*see* Stammberger et al). 1999;18:74-75 (Abstract), 1999;18:862-67
Cardella JA (*see* Cassivi et al). 1181-88
Cardella JA (*see* Cassivi et al). 1999;18:88-89 (Abstract)
Cardella JA, Mourgeon E, Cassivi SD, Fischer S, Isowa N, Slutsky AS, Keshavjee S, Liu M. A novel cell culture model for aerobic, hypothermic lung preservation for transplantation. 1999;18:88 (Abstract)
Cardiac Transplant Research Database (*see* Lake et al). 1999;18:81 (Abstract)
Carere RG (*see* Pamboukian et al). 1999;18:367-70
Caretta Q (*see* Voci et al). 1999;18:921-23
Carey MF (*see* Morton et al). 1999;18:52 (Abstract)
Cargnoni A, Ceconi C, Bernocchi P, Parrinello G, Benigno M, Boraso A, Curello S, Ferrari R. Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies. 1999;18:478-86
Caridi JG (*see* Baz et al). 1999;18:60 (Abstract)
Carotti A (*see* Parisi et al). 1999;18:275-77
Carreño MC (*see* Planas et al). 1999;18:55 (Abstract)
Carrier M, Blaise G, Bélisle S, Perrault LP, Pellerin M, Petitclerc R, Pelletier LC. Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation. 1999;18:664-67
Carrier M, White M, Perrault LP, Pelletier BG, Pellerin M, Robitaille D, Pelletier LC. A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation. 1999;18:1218-23
Cartier R (*see* Ducharme et al). 1999;18:510-16
Cartwright MM (*see* Endres et al). 1999;18:91 (Abstract)
Cary N (*see* Trull et al). 1999;18:93 (Abstract)
Casella G, Rieber J, Mudra H, Klauss V. Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy. 1143-46
Cassem JD (*see* Kobashigawa et al). 1999;18:50 (Abstract)
Cassivi S (*see* Waddell et al). 1999;18:85 (Abstract)
Cassivi SD (*see* Cardella et al). 1999;18:88 (Abstract)
Cassivi SD, Cardella JA, Fischer S, Liu M, Slutsky AS, Keshavjee S. Transtracheal gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation. 1181-88

Cassivi SD, Cardella JA, Fischer S, Liu M, Slutsky AS, Keshavjee SH. Gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation. 1999;18:88-89 (Abstract)
Castaigne A (*see* Aptecar et al). 1999;18:64 (Abstract)
Castro-Beiras A (*see* Vazquez-Rodriguez et al). 1999;18:172
Casula R (*see* Bainbridge et al). 1999;18:407-12
Catanese KA (*see* Helman et al). 1999;18:89 (Abstract)
Catena G (*see* Parisi et al). 1999;18:275-77
Caus T (*see* Bernard et al). 1999;18:572-80
Cave M (*see* Bainbridge et al). 1999;18:407-12
Cecka JM (*see* Wang et al). 1999;18:80 (Abstract)
Ceconi C (*see* Cargnoni et al). 1999;18:478-86
Cerene A (*see* Dambrin et al). 1999;18:524-30
Chada S (*see* Trainini et al). 1999;18:1120-25
Chai P (*see* Lau et al). 1999;18:65-66 (Abstract)
Chait J (*see* Eisenring et al). 1999;18:58-59 (Abstract)
Chait J, Kobashigawa J, Chuang J, Moriguchi J, Kawata N, Laks H. Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients. 1999;18:58 (Abstract)
Chan CKN (*see* Chaparro et al). 1999;18:46 (Abstract)
Chang J (*see* Briffa et al). 1999;18:66 (Abstract)
Chang S (*see* Zeevi et al). 1999;18:81-82 (Abstract)
Chang T (*see* Goldstein et al). 1999;18:69 (Abstract)
Chan KM (*see* Uppal et al). 1999;18:54 (Abstract)
Chan KM, Veeraraghavan S, Barbers RG, Yung RW, Barr ML, Schenkel FA, Cohen RG, Starnes VA. Effects of oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients. 1999;18:85 (Abstract)
Chan M (*see* Kato et al). 1999;18:50 (Abstract)
Chaparro C, Gutierrez CA, Kesten S, Hutcheon M, Winton T, Snell G, Chan CKN, Keshavjee SH, Maurer J. Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant. 1999;18:46 (Abstract)
Charbonneau M (*see* Lands et al). 1999;18:113-19 (Abstract)
Chartier R (*see* Cantarovich et al). 1999;18:78 (Abstract)
Chatterjee K (*see* Schwitter et al). 1999;18:1003-13
Chaudhry FA (*see* Pahl et al). 1999;18:725-32
Chen EP (*see* Bittner et al). 1999;18:87 (Abstract)
Chen EP (*see* Lau et al). 1999;18:65-66 (Abstract)
Chen JM (*see* Argenziano et al). 1999;18:814-17
Chen JM, Spanier TB, Gonzalez JJ, Marelli D, Flannery MA, Tector KA, Cullinane S, Oz MC. Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance. 1999;18:351-57
Chen JS (*see* Luh et al). 1999;18:62 (Abstract)
Chen K (*see* Asfour B et al). 1999;18:927-36
Chen R (*see* Iwata et al). 1999;18:37 (Abstract)
Chevtchik O (*see* Laufer et al). 1999;18:94 (Abstract)
Chevtchik O (*see* Mallinger et al). 1999;18:77 (Abstract)
Chevtchik O (*see* Moidl et al). 1999;18:194-200
Chiera A (*see* Voci et al). 1999;18:921-23
Chin C (*see* Dubin et al). 1999;18:781-84
Chinnock R (*see* Boucek et al). 1999;18:460-69
Chinnock RE (*see* Dearani et al). 1999;18:70 (Abstract)
Choi L, Choudhri AF, Pillarisetty VG, Sampath LA, Caraos L, Brunnert SR, Oz MC, Modak SM. Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections. 1999;18:1103-10
Chott A (*see* Mallinger et al). 1999;18:77 (Abstract)
Choudhri AF (*see* Argenziano et al). 1999;18:814-17
Choudhri AF (*see* Choi et al). 1999;18:1103-10
Christen A (*see* Trainini et al). 1999;18:42-43 (Abstract)
Christen AI (*see* Trainini et al). 1999;18:1120-25
Christiansen FT (*see* Ketheesan et al). 1999;18:226-29
Christians U (*see* Hausen et al). 1999;18:73 (Abstract), 1999;18:150-58, 1999;18:714-24
Christians U (*see* Ikonen et al). 1999;18:72 (Abstract)
Chuang J (*see* Chait et al). 1999;18:58 (Abstract)
Chuang J (*see* Wang et al). 1999;18:80 (Abstract)
Cicini MP (*see* Parisi et al). 1999;18:275-77
Cipriani L (*see* Webber et al). 1999;18:69 (Abstract)
Claas F (*see* Welters et al). 1999;18:53 (Abstract)
Clark SC (*see* Sudarshan et al). 1999;18:78 (Abstract)
Clark SC, Sudarshan CD, Dark JH. Summary measures: a superior method of data analysis in lung preservation studies. 1999;18:172-73
Cleeland AD (*see* Kormos et al). 1999;18:63 (Abstract)
Cobelli F (*see* Raczak et al). 1999;18:399-405
Coffman TM (*see* Mannon et al). 1999;18:819-26
Cohen AH (*see* Hunstad et al). 1999;18:801-4
Cohen RG (*see* Chan et al). 1999;18:85 (Abstract)
Cohen RG (*see* Uppal et al). 1999;18:54 (Abstract)
Colina F (*see* Delgado et al). 1999;18:607-10
Collins BJ (*see* Blair et al). 1999;18:54 (Abstract)
Colvino-Santos R (*see* Vazquez-Rodriguez et al). 1999;18:172
Comerio G (*see* Oliva et al). 1999;18:75 (Abstract)
Connors JM (*see* Cook et al). 1999;18:84-85 (Abstract)
Connors JM (*see* Partovi et al). 1999;18:85 (Abstract)
Conrad N (*see* Wildhirt et al). 1999;18:40 (Abstract), 1999;18:64-65 (Abstract)
Conte JV, Orens JB. Lung transplantation in a Jehovah's witness. 1999;18:796-99
Conte JV Jr (*see* Song et al). 1999;18:744-48
Cook DJ, Bishay E, Raspovic S, McCarthy JF, Starling RC, Young JB, Smedira N, McCarthy PM. The impact of HLA sensitization and donor cause of death in heart transplantation. 1999;18:38 (Abstract)
Cook RC (*see* Pamboukian et al). 1999;18:367-70
Cook RC, Connors JM, Gascoyne RD, Fradet G, Levy RD. Effective treatment of lymphoproliferative disease following lung transplantation using a monoclonal anti-CD20 B-cell antibody. 1999;18:84-85 (Abstract)
Cook RC, Tupper JK, Parker S, Kingsbury K, Frohlich JJ, Abel JG, Gao M, Ignaszewski AP. Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation. 1999;18:420-24
Cooper A (*see* Densem et al). 1999;18:52 (Abstract)
Cooper JD (*see* Reznik et al). 1999;18:68 (Abstract)

Cooper JD (*see* Smith et al). 1999;18:51 (Abstract)
Cooper LT (*see* Brilakis et al). 1999;18:43–44 (Abstract)
Copeland JG (*see* Arabia et al). 1999;18:89 (Abstract)
Cornelius JF (*see* Wittwer et al). 1999;18:684–91
Cornwell RD (*see* Love et al). 1999;18:87 (Abstract)
Corris PA (*see* De Soyza et al). 1999;18:45 (Abstract)
Corris PA (*see* Fisher et al). 1999;18:88 (Abstract)
Costanzo M (*see* Keogh et al). 1999;18:53 (Abstract)
Costanzo MR (*see* Grady et al). 1999;18:750–60
Costanzo MR (*see* Jaski et al). 1999;18:37 (Abstract)
Cotler SJ, Jensen DM, Kesten S. Hepatitis C virus infection and lung transplantation: a survey of practices. 1999;18:456–58
Cottman MJ (*see* Atkines et al). 1999;18:1173–80
Courval J-F (*see* Ducharme et al). 1999;18:510–16 (Abstract)
Cozzone PJ (*see* Bernard et al). 1999;18:572–80
Crawford SE (*see* Pahl et al). 1999;18:725–32
Crawford SE (*see* Ringewald et al). 1999;18:70 (Abstract)
Crawford SE, Huang L, Hsueh W, Takami H, Gonzalez-Crussi F, Backer CL, Mu Y, Liu H, Mavroudis C. Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds. 1999;18:470–76
Creaser J (*see* Drazner et al). 1999;18:1126–32
Crespo-Leiro MG (*see* Vazquez-Rodriguez et al). 1999;18:172
Criner GJ (*see* O'Brien et al). 1999;18:255–63
Cullinane S (*see* Argenziano et al). 1999;18:814–17
Cullinane S (*see* Chen et al). 1999;18:351–57
Curello S (*see* Cargnoni et al). 1999;18:478–86
Custer DA (*see* Gibson et al). 1999;18:185–88
Czernin J (*see* Allen-Auerbach et al). 1999;18:211–18

D

Daggett WC (*see* Lau et al). 1999;18:65–66 (Abstract)
Dagum P (*see* Hausen et al). 1999;18:714–24
Daily OP (*see* Kauffman et al). 1999;18:414–19
Dalmasso AP (*see* Kulick et al). 1999;18:65 (Abstract)
Daly RC (*see* Brilakis et al). 1999;18:43–44 (Abstract)
Dambrin C, Calise D, Pieraggi MT, Thiers J-C, Thomsen M. Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis. 1999;18:946–51
Dambrin C, El Feghaly M, Abbal M, Glock Y, Durand D, Fournial G, Ohayon E, Cerene A. A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dt_{max}. 1999;18:524–30
D'Amico TA (*see* Palmer et al). 1999;18:51 (Abstract)
Dandel M (*see* Müller et al). 1999;18:70–71 (Abstract)
Dannenberg O (*see* Pethig et al). 1999;18:77–78 (Abstract)
Danto SI (*see* Kim et al). 1999;18:74 (Abstract)
Dark JH (*see* Clark et al). 1999;18:172–73
Dark JH (*see* Fisher et al). 1999;18:88 (Abstract)
Dark JH (*see* Sudarshan et al). 1999;18:78 (Abstract)
D'Armini AM (*see* Raczak et al). 1999;18:399–405
Darragh R (*see* Bando et al). 1999;18:70 (Abstract)
Darragh R (*see* Flaspohler et al). 1999;18:91 (Abstract)
Das GS (*see* Nguyen et al). 1999;18:1021–23
Dauber J (*see* Zeevi et al). 1999;18:81–1999;18:82 (Abstract)
Dauber JG (*see* Keenan et al). 1999;18:55 (Abstract)
Davis RD (*see* Bittner et al). 1999;18:87 (Abstract)
Davis RD (*see* Lau et al). 1999;18:65 (Abstract), 1999;18:65–66 (Abstract)
Davis RD (*see* Palmer et al). 1999;18:51 (Abstract)
Dawkins RL (*see* Ketheesan et al). 1999;18:226–29
Dearani JA, Razzouk AJ, Gundry SR, Chinnock RE, Larsen RL, del Rio MJ, Johnston JK, Bailey LL. Pediatric cardiac retransplantation: experience at a single institution. 1999;18:70 (Abstract)
de Boer HD, de Jonge N, de Boer WJ. Mitral valve myxoma: an unusual reason for rejecting a donor heart. 1999;18:924–25
de Boer WJ (*see* de Boer et al). 1999;18:924–25
de Boer WJ (*see* van den Berg et al). 1999;18:85 (Abstract)
de Boer WJ (*see* van Enckevort et al). 1999;18:496–97
de Bustillo EM (*see* Delgado et al). 1999;18:607–10
DeCampos KN, Keshavjee S, Slutsky AS, Liu M. Alveolar recruitment prevents rapid-perfusion-induced injury of lung transplants. 1999;18:1096–1102
Decker CJ (*see* Gummert et al). 1999;18:72 (Abstract)
De Geest S, Dunbar-Jacob J, Vanhaecke J. Diagnostic value of structured interviews in assessing noncompliance with immunosuppressive therapy in heart transplant recipients. 1999;18:91 (Abstract)
de Groot-Kruseman HA, Baan CC, Niesters HGM, Maat APWM, Balk AHMM, Weimer W. Increased intragraft expression of TGF-β mRNA in patients with graft vascular disease after clinical heart transplantation. 1999;18:52 (Abstract)
de Groot MCH (*see* Bruinsma et al). 1999;18:1189–97
deGruiter H (*see* Mehra et al). 1999;18:76 (Abstract)
Deiraniya A (*see* Aziz et al). 1999;18:1253–54 (Letter)
Deiraniya A (*see* El-Gamel et al). 1999;18:828–35
Deiraniya AK (*see* Aziz et al). 1999;18:37 (Abstract)
Deiraniya AK (*see* Burgess et al). 1999;18:44–45 (Abstract)
Deiraniya AK (*see* El-Gamel et al). 1999;18:517–22
de Jonge N (*see* de Boer et al). 1999;18:924–25
Dekan G (*see* Zuckermann et al). 1999;18:432–39
Delcourt A (*see* Salim Roussouliéres et al). 1999;18:1147–50 (Letter)
Delcroix M (*see* Verleden et al). 1999;18:1139–46
de Leval M (*see* Gassas et al). 1999;18:83 (Abstract)
Delgado J, de Bustillo EM, Ibarrola C, Colina F, Morales JM, Rodriguez E, Aguado JM, Fuertes A, Gomez MA. Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor?. 1999;18:607–10
del Nido PJ (*see* Yoshida et al). 1999;18:1054–64
del Rio MJ (*see* Dearani et al). 1999;18:70 (Abstract)
Del Rizzo DF, Menkis AH, Pflugfelder PW, Novick RJ, McKenzie FN, Boyd WD, Kostuk WJ. The role of donor age and ischemic time on survival following orthotopic heart transplantation. 1999;18:310–19
DeMarco T (*see* Schwitter et al). 1999;18:1003–13
Dembitsky WP (*see* Jaski et al). 1999;18:1031–40

Demedts M (*see* Verleden et al). 1999;18:1139-46
De Meester J, Smits JMA, Persijn GG, Haverich A. Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration. 1999; 18:563-71
Demers P (*see* Ducharme et al). 1999;18:510-16
Dengler T (*see* Kallinowski et al). 1999;18:190-93
Dengler TJ, Raftery MJ, Werle M, Zimmermann R, Schönrich G. Increased or de novo expression of ICAM-1, V-CAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release. 1999;18:61 (Abstract)
Deng MC (*see* Baba et al). 1999;18:57 (Abstract), 1999;18: 963-71
Deng MC (*see* Plenz et al). 1999;18:923-24 (Letter)
DeNofrio D, Loh E, Kao A, Korecka M, Acker MA, Shaw LM. Mycophenolic acid concentrations are associated with cardiac allograft rejection. 1999;18:46 (Abstract)
Densem CG, Hutchinson IV, Cooper A, Roberts T, Yonan N, Brooks NH. Low producers of TGF beta are protected from cardiac transplant vasculopathy. 1999;18: 52 (Abstract)
Densem CG, Hutchinson IV, Fynn S, Yonan N, Brooks NH. TGF beta polymorphism does not influence the rise in creatinine following cardiac transplantation. 1999;18: 77 (Abstract)
de Paz J (*see* Trainini et al). 1999;18:42-43 (Abstract)
DeRose JJ Jr (*see* Williams et al). 1999;18:44 (Abstract)
De Somer F, Van Belleghem Y, Foubert L, Caes F, François K, Dubrulle F, Van Nooten G. Feasibility of a pumpless extracorporeal respiratory assist device. 1999; 18:1014-17
De Somer F, Van Belleghem Y, Foubert L, Dubrulle F, Van Nooten G. Feasibility of a pumpless extracorporeal respiratory assist device. 1999;18:41-42 (Abstract)
De Soyza A, Small T, Fisher AJ, Corris PA. The effect of inhaled steroids on exhaled nitric oxide in lung transplant recipients with lymphocytic bronchitis. 1999; 18:45 (Abstract)
Détruit H (*see* Xiong et al). 1999;18:320-26
de Varennes B (*see* Cantarovich et al). 1999;18:78 (Abstract)
Deviatko E (*see* Wisser et al). 1999;18:67 (Abstract)
De Vita C (*see* Gronda et al). 1999;18:654-61
Dew MA, Kormos RL, Roth LH, Murali S, DiMartini A, Griffith BP. Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation. 1999;18:549-59
Diamond LE (*see* Lau et al). 1999;18:65-66 (Abstract)
DiIulio NA, DiPaola NR, Smedira NG, McCarthy PM, Moravec CS. Reversal of the heart failure phenotype by mechanical unloading. 1999;18:89-90 (Abstract)
DiMartini A (*see* Dew et al). 1999;18:549-59
DiPaola NR (*see* DiIulio et al). 1999;18:89-90 (Abstract)
Dipchand AI, Benson L, McCrindle BW, West L. Mycophenolate mofetil in paediatric heart transplant recipients: a single center experience. 1999;18:83-84 (Abstract)
DiSano S (*see* Boucek et al). 1999;18:460-69
Di Tullio M (*see* Maybaum et al). 1999;18:44 (Abstract)
Dodd SJ (*see* Yoshida et al). 1999;18:1054-64
Dong C (*see* Wang et al). 1999;18:48 (Abstract), 1999;18: 48-49 (Abstract)
Donnelly SC (*see* Fisher et al). 1999;18:88 (Abstract)
Donofrio MT, Kakavand B, Schieken RM, Gullquist SD, Moskowitz WB. Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography. 1999;18:84 (Abstract)
Donovan M (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Dorent R (*see* Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
Dosanjh A (*see* Wan et al). 1999;18:90 (Abstract)
Dosanjh AK (*see* Wan et al). 1999;18:90 (Abstract)
Downing SW (*see* Seta et al). 1999;18:61 (Abstract)
Doyle R, Brazelton T, Wong R, Newmark R, Bush C, Poirier C, Altinger J, Hausen H, Theodore J, Reitz B, Morris R, International Lung Transplant Database Group. The International Lung Transplant Database: demographics and outcomes in 826 lung transplant recipients. 1999;18:86 (Abstract)
Doyle RL (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59-60 (Abstract)
Doyle RL (*see* Faul et al). 1999;18:384-87
Doyle RL (*see* Valantine et al). 1999;18:81 (Abstract)
Dracup K (*see* Westlake et al). 1999;18:1133-38
Drazner MH, Hamilton MA, Fonarow G, Creaser J, Flavell C, Stevenson LW. Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure. 1999;18:1126-32
Drescher J (*see* Fraund et al). 1999;18:220-24
Dubin AM, Rosenthal DN, Chin C, Bernstein D. QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation. 1999;18:781-84
Dubois-Randé JL (*see* Aptecar et al). 1999;18:64 (Abstract)
Dubrulle F (*see* De Somer et al). 1999;18:41-42 (Abstract), 1999;18:1014-17
Ducharme A, Demers P, Elkouri S, Courval J-F, Cartier R, Tardif J-C. Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography. 1999;18:510-16
Duffy CE (*see* Pahl et al). 1999;18:725-32
Dummer JS (*see* Ely et al). 1999;18:55-56 (Abstract)
Dunbar-Jacob J (*see* De Geest et al). 1999;18:91 (Abstract)
Dunitz J (*see* Park et al). 1999;18:60 (Abstract)
Dunning J (*see* Ongcharit et al). 1999;18:37 (Abstract)
Dupouy P (*see* Aptecar et al). 1999;18:64 (Abstract)
Duquesnoy R (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
Durand D (*see* Dambrin et al). 1999;18:524-30
Dureau G (*see* Keogh et al). 1999;18:53 (Abstract)
Dusek LK (*see* Lawless et al). 1999;18:38 (Abstract)
D'yachkova Y (*see* Pamboukian et al). 1999;18:367-70

E

Ebrahimi K (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Eccleshall SC, Beer SA, Wilson IC, Bonser RS. Factors affecting outcome in patients "too well" for heart transplantation at initial assessment. 1999;18:46 (Abstract)
Edinburgh KJ (*see* Jonosono et al). 1999;18:972-85
Edwards JA (*see* Iannettoni et al). 1999;18:86-87 (Abstract)
Edwards N (*see* Ankersmit et al). 1999;18:56 (Abstract)
Edwards N (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Edwards N (*see* Lietz et al). 1999;18:80 (Abstract)
Edwards NM (*see* Argenziano et al). 1999;18:814-17
Edwards NM (*see* Helman et al). 1999;18:89 (Abstract)
Egan J (*see* El-Gamel et al). 1999;18:828-35
Ehtisham S (*see* Gassas et al). 1999;18:83 (Abstract)
Einhorn K (*see* Allen-Auerbach et al). 1999;18:211-18
Eisen H (*see* Keogh et al). 1999;18:53 (Abstract)
Eisen HJ (*see* Belland et al). 1999;18:54 (Abstract)
Eisen HJ (*see* Jaski et al). 1999;18:37 (Abstract)
Eisen HJ (*see* McGurl et al). 1999;18:93 (Abstract)
Eisen HJ, Mueller EA, Turkin D, Mellein B, Hobbs RE. Multicenter, double-blind, randomized study of neoral vs sandimmune in heart transplantation: one year results. 1999;18:93 (Abstract)
Eisenring EM, Canobbio MM, Chait J, Kobashigawa J, Aleos JC, Rapkin A, Laks H. Does cardiac transplantation affect gynecologic and reproductive outcomes?. 1999; 18:58-59 (Abstract)
Eiskjaer H (*see* Ongcharit et al). 1999;18:37 (Abstract)
Elencwajg B (*see* Trainini et al). 1999;18:42-43 (Abstract)
Elencwajg B (*see* Trainini et al). 1999;18:1120-25
El Feghaly M. (*see* Dambrin et al). 1999;18:524-30
El-Gamel A (*see* Burgess et al). 1999;18:44-45 (Abstract)
El-Gamel A, Awad MR, Hasleton PS, Yonan NA, Hutchinson JA, Campbell CS, Rahman AH, Deiraniya AK, Sinnott PJ, Hutchinson IV. Transforming growth factor-beta (TGF-β1) genotype and lung allograft fibrosis. 1999;18: 517-22
El-Gamel A, Sim E, Hasleton P, Hutchinson J, Yonan N, Egan J, Campbell C, Rahman A, Sheldon S, Deiraniya A, Huchinson IV. Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation. 1999;18:828-35
Elki S (*see* Wittwer et al). 1999;18:684-91
Elki S (*see* Wittwer et al). 1999;18:1198-1201
Elkouri S (*see* Ducharme et al). 1999;18:510-16
Elliot MJ (*see* Gassas et al). 1999;18:83 (Abstract)
Elpern E (*see* Kesten et al). 1999;18:266-68
Elstein E (*see* Cantarovich et al). 1999;18:78 (Abstract)
Ely EW, Milstone AP, Loyd JE, Roberts JR, Dummer JS, Pierson RN III. A nation-wide list would cause major redistribution of cadaveric lungs. 1999;18:55-56 (Abstract)
Emery RW Jr (*see* Wright et al). 1999;18:913-15
Enders G (*see* Weis et al). 1999;18:64 (Abstract)
Enders G (*see* Weis et al). 1999;18:1071-79
Endres NL, Welter DL, Lorenz BL, Cartwright MM, Love RB. Maintaining or improving nutritional parameters for patients awaiting lung transplantation. 1999;18:91 (Abstract)
Ennen MP, Poston RS, Feeley BT, Hoyt G, Robbins RC. Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae. 1999;18:49 (Abstract)
Epilly E (*see* Zoll et al). 1999;18:71 (Abstract)
Epstein S (*see* Maybaum et al). 1999;18:62 (Abstract)
Erren M (*see* Baba et al). 1999;18:963-71
Erren M (*see* Plenz et al). 1999;18:923-24 (Letter)
Esmore DS (*see* Griffiths et al). 1999;18:86 (Abstract)
Esmore DS (*see* Morton et al). 1999;18:52 (Abstract)
Espejo M (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Esu F (*see* Parisi et al). 1999;18:275-77
Ewert R (*see* Waurick et al). 1999;18:1243-45

F

Fabri R (*see* Verleden et al). 1999;18:1139-46
Fang KC (*see* Jonosono et al). 1999;18:972-85
Faro A (*see* Boucek et al). 1999;18:1151-72 (Registry)
Farrar DJ, Holman WR, McBride LR, Kormos RL, Narrod JA, Icenogle TB, Hendry PJ, Moore CH. Long-term follow-up of thoratec ventricular assist device bridge-to-recovery patients after resolution of non-ischemic heart failure. 1999;18:62-63 (Abstract)
Fastenau DR, Laberrere CA, Hormuth DA, McIntyre JA. Immunohistochemical analysis of vascular prostheses implanted with the left ventricular assist system. 1999; 18:916-20
Faul JL, Akindipe OA, Berry GJ, Doyle RL, Theodore J. Recurrent *Pneumocystic carinii* colonization in a heart-lung transplantation recipient on long-term trimethoprin-sulfamethoxazole prophylaxis. 1999;18:384-87
Favaloro RR (*see* Moscoloni et al). 1999;18:58 (Abstract)
Favrot LK (*see* Jaski et al). 1999;18:1031-40
Fazekas L (*see* Szabó et al). 1999;18:54 (Abstract)
Fazio D (*see* Marelli et al). 1999;18:87 (Abstract)
Fecchia M (*see* Ongcharit et al). 1999;18:37 (Abstract)
Feccia M (*see* Tsui et al). 1999;18:78-79 (Abstract)
Fedalen P (*see* McGurl et al). 1999;18:93 (Abstract)
Fedalen PA, Fisher CA, Furukawa S, Bibidakis A, Ramasamy D, Vattikuti R, Jeevanandam V. Profile of soluble coagulant and inflammatory markers during long-term left ventricular assist device support. 1999;18:56-57 (Abstract)
Feeley BT (*see* Ennen et al). 1999;18:49 (Abstract)
Feeley BT, Park A, Hoyt EG, Robbins RC. Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts. 1999;18:48 (Abstract)
Feeley BT, Park AK, Hoyt G, Robbins RC. Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants. 1999;18:1088-95
Fehrenbach A (*see* Wittwer et al). 1999;18:684-91
Fehrenbach A (*see* Wittwer et al). 1999;18:1198-1201
Fehrenbach H (*see* Wittwer et al). 1999;18:684-91

Felix R (*see* Hummel et al). 1999;18:49 (Abstract)
Ferrari R (*see* Cargnoni et al). 1999;18:478-86
Feucht HE (*see* Behr et al). 1999;18:904-11
Feussner M (*see* Braun-Dullaeus et al). 1999;18:328-34
Fiane AE, Videm V, Lambris JD, Geiran OR, Svennevig JL, Mollnes TE. Inhibition of hyperacute pig-to-human xenograft rejection by modulating the fluid-phase complement activation. 1999;18:66 (Abstract)
Filella X (*see* Roig et al). 1999;18:91 (Abstract)
Finkbeiner WE (*see* Jonosono et al). 1999;18:972-85
Fiol B (*see* Boucek et al). 1999;18:1151-72 (Registry)
Fiol B (*see* Hosenpud et al). 1999;18:611-26 (Abstract)
Fiore AC (*see* Balfour et al). 1999;18:1027-29
Fischbein MP, Yun JJ, Laks H, Fishbein MC, Espejo M, Ebrahimi K, Bonavida B, Ardehali A. Temporal pattern of T lymphocyte and macrophage infiltration in a non-immunosuppressed model of CAV. 1999;18:40-41 (Abstract)
Fischer S (*see* Cardella et al). 1999;18:88 (Abstract)
Fischer S (*see* Cassivi et al). 1181-88
Fischer S (*see* Cassivi et al). 1999;18:88-89 (Abstract)
Fishbein MC (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Fisher AJ (*see* De Soyza et al). 1999;18:45 (Abstract)
Fisher AJ, Donnelly SC, Burdick M, Strieter RM, Dark JH, Corris PA. The effect of intra-pulmonary CXC-chemokines in the donor lung on early graft function after lung transplantation. 1999;18:88 (Abstract)
Fisher CA (*see* Fedalen et al). 1999;18:56-57 (Abstract)
Fitzsimmons A (*see* Webber et al). 1999;18:83 (Abstract)
FitzSimmons S (*see* Cahill et al). 1999;18:86 (Abstract)
Flannery MA (*see* Chen et al). 1999;18:351-57
Flannery MA (*see* Helman et al). 1999;18:89 (Abstract)
Flaspohler T (*see* Bando et al). 1999;18:70 (Abstract)
Flaspohler T, Bando K, Caldwell R, Darragh R, Sharp T, Okada Y, Turrentine M, Park H-J, Brown J. Risk factor analysis for inappropriate growth after pediatric heart transplantation (HTX). 1999;18:91 (Abstract)
Flavell C (*see* Drazner et al). 1999;18:1126-32
Flecknell P (*see* Sudarshan et al). 1999;18:78 (Abstract)
Flemming P (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Foegh ML (*see* Saito et al). 1999;18:937-45
Fonarow G (*see* Drazner et al). 1999;18:1126-32
Fonarow G (*see* Westlake et al). 1999;18:1133-38
Foster AH (*see* Song et al). 1999;18:744-48
Foubert L (*see* De Somer et al). 1999;18:41-42 (Abstract), 1999;18:1014-17
Fournial G (*see* Dambrin et al). 1999;18:524-30
Fradet G (*see* Cook et al). 1999;18:84-85 (Abstract)
Fradet G (*see* Partovi et al). 1999;18:85 (Abstract)
François K (*see* De Somer et al). 1999;18:1014-17
Franke U (*see* Harringer et al). 1999;18:56 (Abstract)
Franke U (*see* Strüber et al). 1999;18:87 (Abstract)
Fraser SF (*see* Morton et al). 1999;18:52 (Abstract)
Fraunberger P (*see* Weis et al). 1999;18:64 (Abstract)
Fraund S, Wagner D, Pethig K, Drescher J, Girgsdies OE, Haverich A. Influenza vaccination in heart transplant recipients. 1999;18:220-24
Frazier EA, Naftel DC, Canter CE, Boucek MM, Kirklin JK, Morrow WR, Pediatric Heart Transplant Study. Death after heart transplantation in children: who dies when and why. 1999;18:69-70 (Abstract)
Frazier OH (*see* Kerman et al). 1999;18:38 (Abstract)
Frazier OH (*see* Radovancevic et al). 1999;18:63 (Abstract)
Frazier OH (*see* Taylor et al). 1999;18:336-45
Freeman R (*see* Gould et al). 1999;18:173-74
Freudenberger R, Alexis J, Gass A, Fuster V, Badimon J. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy. 1999;18:1228-31
Frey B (*see* Berger et al). 1999;18:47 (Abstract), 1999;18:75 (Abstract)
Frey B (*see* Stanek et al). 1999;18:358-65
Fricker FJ (*see* Pahl et al). 1999;18:725-32
Fricker FJ (*see* Penson et al). 1999;18:707-12
Frigerio M (*see* Gronda et al). 1999;18:654-61
Frigerio M (*see* Oliva et al). 1999;18:75 (Abstract)
Friskel ED (*see* Baz et al). 1999;18:60 (Abstract)
Frohlich JJ (*see* Cook et al). 1999;18:420-24
Fuertes A (*see* Delgado et al). 1999;18:607-10
Fukano AK (*see* Jonosono et al). 1999;18:972-85
Fukushima N (*see* Kobayashi et al). 1999;18:66 (Abstract)
Fukushima N (*see* Nishimura et al). 1999;18:57 (Abstract)
Fuller CB (*see* Uppal et al). 1999;18:54 (Abstract)
Fuller TC (*see* Stringham et al). 1999;18:160-65
Fung J (*see* McCurry et al). 1999;18:72 (Abstract)
Fürst H (*see* Müller et al). 1999;18:40 (Abstract)
Furukawa S (*see* Fedalen et al). 1999;18:56-57 (Abstract)
Furukawa S (*see* McGurl et al). 1999;18:93 (Abstract)
Furukawa S (*see* Slachta et al). 1999;18:41 (Abstract)
Fuster V (*see* Freudenberger et al). 1999;18:1228-31
Fynn S (*see* Densem et al). 1999;18:77 (Abstract)

G

Gabbay E (*see* Griffiths et al). 1999;18:86 (Abstract)
Gabbay E, Orsida B, Taylor J, Ward C, Whitford H, Kotsimbos T, Snell GI, Walters EH, Williams TJ. Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS. 1999;18:51 (Abstract)
Gadiraju S (*see* Koglin et al). 1999;18:71 (Abstract)
Galantowicz ME (*see* Helman et al). 1999;18:89 (Abstract)
Galbraith AJ, McCarthy J, Tesar PJ, McGiffin DC. Cardiac transplantation for prosthetic valve endocarditis in a previously transplanted heart. 1999;18:805-6
Gamberg PL (*see* Bernstein et al). 1999;18:69 (Abstract)
Gamburg E (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Gandjbakhch I (*see* Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
Gangemi JJ (*see* Ross et al). 1999;18:72 (Abstract), 1999;18:994-1002
Gao F (*see* McLean et al). 1999;18:68 (Abstract)
Gao M (*see* Cook et al). 1999;18:420-24
Gao S-Z (*see* Kato et al). 1999;18:50 (Abstract)

Garascia A (*see* Gronda et al). 1999;18:654-61
Garcia B (*see* Parry et al). 1999;18:441-46
Garot P (*see* Aptecar et al). 1999;18:64 (Abstract)
Garrity ER (*see* Bhorade et al). 1999;18:79 (Abstract)
Garrity ER Jr, Hertz MI, Trulock EP, Keenan R, Love R. Suggested Guidelines for the use of Tacrolimus in lung-transplant recipients. 1999;18:175-76
Gascoyne RD (*see* Cook et al). 1999;18:84-85 (Abstract)
Gaspert A (*see* Stammberger et al). 1999;18:79 (Abstract)
Gass A (*see* Freudenberger et al). 1999;18:1228-31
Gassas A, Ehtisham S, Aurora P, Whitehead B, Whitmore P, Rees PG, Tsang VT, Elliot MJ, de Leval M. The effect of pre lung transplant clinical status on post transplant outcome for children with cystic fibrosis: a ten year experience. 1999;18:83 (Abstract)
Gaughan JP (*see* McGurl et al). 1999;18:93 (Abstract)
Gauthier R (*see* Lands et al). 1999;18:113-19 (Abstract)
Geertsma A (*see* van Enckevort et al). 1999;18:496-97
Geiran OR (*see* Fiane et al). 1999;18:66 (Abstract)
Gelman AE (*see* Krasinskas et al). 1999;18:88 (Abstract)
Genton RE (*see* Borkon et al). 1999;18:668-73
George JF (*see* Goldstein et al). 1999;18:69 (Abstract)
Ghossoub J-J (*see* Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
Giannetti N (*see* Kato et al). 1999;18:50 (Abstract)
Gibbons RJ (*see* Rayburn et al). 1999;18:47 (Abstract)
Gibson SW, Valente JF, Alexander JW, Custer DA, Babcock GF, Ogle CK. The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion. 1999;18:185-88
Gidding SS (*see* Ringewald et al). 1999;18:70 (Abstract)
Gidding SS (*see* Shaddy et al). 1999;18:269-74
Gilbert EM (*see* Shaddy et al). 1999;18:269-74
Gillinov AM (*see* Kaplon et al). 1999;18:346-50
Gill RG (*see* Pietra et al). 1999;18:48 (Abstract)
Ginsberg M (*see* Schulman et al). 1999;18:107-12
Giordano R (*see* Trainini et al). 1999;18:42-43 (Abstract)
Girgsdies OE (*see* Fraund et al). 1999;18:220-24
Globits S (*see* Schwitter et al). 1999;18:1003-13
Glock Y (*see* Dambrin et al). 1999;18:524-30
Glower DD (*see* Atkins et al). 1999;18:43 (Abstract)
Glysing-Jensen T (*see* Räisänen-Sokolowski et al). 1999;18:61 (Abstract), 1999;18:735-43
Goddard MJ (*see* Bardsley et al). 1999;18:41 (Abstract)
Golden JA (*see* Jonosono et al). 1999;18:972-85
Goldman B (*see* Agelan et al). 1999;18:40 (Abstract)
Goldman B (*see* Slachta et al). 1999;18:60 (Abstract)
Goldman BI (*see* McGurl et al). 1999;18:93 (Abstract)
Goldman BI (*see* Xu et al). 1999;18:90 (Abstract)
Goldschmidt-Clermont PJ (*see* Wang et al). 1999;18:48 (Abstract), 1999;18:48-49 (Abstract)
Goldsmith R (*see* Jaski et al). 1999;18:1031-40
Goldstein DR, Chang T, Sweeney SD, Kirklin JK, Thomas JM, George JF. Donor specific spleen cells mediate allograft survival by a different mechanism than bone marrow. 1999;18:69 (Abstract)
Gold WM (*see* Jonosono et al). 1999;18:972-85
Golino A (*see* Radovancevic et al). 1999;18:63 (Abstract)
Gomez MA (*see* Delgado et al). 1999;18:607-10
Gómez-Nieto J (*see* Planas et al). 1999;18:55 (Abstract)
Gonzalez-Crussi F (*see* Crawford et al). 1999;18:470-76
Gonzalez-Cuesta M (*see* Vazquez-Rodriguez et al). 1999;18:172
Gonzalez JJ (*see* Chen et al). 1999;18:351-57
Gonzalez-Stawinski G (*see* Lau et al). 1999;18:65 (Abstract)
Goodman M (*see* Williams et al). 1999;18:44 (Abstract)
Goormastic M (*see* Kaplon et al). 1999;18:63 (Abstract), 1999;18:346-50
Goormastic M (*see* Sheffield et al). 1999;18:39 (Abstract)
Goormastic M (*see* Smedira et al). 1999;18:44 (Abstract)
Goormastic M (*see* Yu et al). 1999;18:764-68
Gordon SM (*see* Sandur et al). 1999;18:810-13
Gorton ME (*see* Borkon et al). 1999;18:668-73
Gould K, Kearns A, Freeman R. Diphtheria by donation. 1999;18:173-74
Grabellus F (*see* Baba et al). 1999;18:963-71
Gradaus R (*see* Baba et al). 1999;18:963-71
Gradinac S, Jovanovič I, &Dhyphen;ukič M, Hercog &Dhyphen;, Jovovič L, Kokai G, Stajevič M, Simeunovič S. Partial left ventriculectomy in a two-year old girl with dilated cardiomyopathy. 1999;18:381-83
Grady KL, Jalowiec A, White-Williams C. Predictors of quality of life in patients at one year after heart transplantation. 1999;18:202-10
Grady KL, White-Williams C, Naftel D, Costanzo MR, Pitts D, Rayburn B, VanBakel A, Jaski B, Bourge R, Kirklin J. Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multiinstitutional study of preoperative weight-height indices. 1999;18:750-60
Grasser B, Iberer F, Schreier G, Kastner P, Schaffellner S, Hipmair G, Prenner G, Wasler A, Petutschnigg P, Müller H, Hutten H, Schaldach M, Tscheliessnigg KH. Noninvasive cardiac graft monitoring: the Graz experience. 1999;18:80 (Abstract)
Grauhan O, Krabatsch T, Tambeur L, Lieback E, Hetzer R. Transmyocardial laser revascularization (TMR) in ischemic cardiomyopathy. 1999;18:66 (Abstract)
Gray JJ (*see* Wreghitt et al). 1999;18:82 (Abstract)
Green M (*see* Webber et al). 1999;18:83 (Abstract)
Grehan J (*see* Kulick et al). 1999;18:65 (Abstract)
Griffin KE (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Griffith B (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
Griffith BP (*see* Dew et al). 1999;18:549-59
Griffith BP (*see* Keenan et al). 1999;18:55 (Abstract)
Griffith BP (*see* McCurry et al). 1999;18:72 (Abstract)
Griffith BP (*see* Robinson et al). 1999;18:786-90
Griffith BP (*see* Stanford et al). 1999;18:58 (Abstract)
Griffith BP (*see* Tagusari et al). 1999;18:1111-19
Griffith BP (*see* Webber et al). 1999;18:83 (Abstract)

Griffiths AP, Macfarlane LM, Gabbay E, Shirashi T, Williams TJ, Esmore DS, Snell GI. Maximizing thoracic organ transplant (TOTX) opportunities - the importance of efficient co-ordination. 1999;18:86 (Abstract)
Grimminger F (*see* Braun-Dullaeus et al). 1999;18:328-34
Grimm M (*see* Berger et al). 1999;18:75 (Abstract)
Grimm M (*see* Laufer et al). 1999;18:94 (Abstract)
Grimm M (*see* Mallinger et al). 1999;18:77 (Abstract)
Grimm M (*see* Moidl et al). 1999;18:194-200
Grimm M (*see* Stanek et al). 1999;18:358-65
Grimm M (*see* Zuckermann et al). 1999;18:93 (Abstract)
Grollier G (*see* Agostini et al). 1999;18:47 (Abstract)
Gronda E (*see* Oliva et al). 1999;18:75 (Abstract)
Gronda EG, Barbieri P, Frigerio M, Mangiavacchi M, Oliva F, Quaini E, Andreuzzi B, Garascia A, De Vita C, Pellegrin A. Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmocologic circulatory support. 1999; 18:654-61
Gross TG (*see* Balfour et al). 1999;18:492-94
Grove R (*see* Iwata et al). 1999;18:37 (Abstract)
Grubbs BC (*see* Nguyen et al). 1999;18:1021-23
Guevara MS (*see* Baz et al). 1999;18:60 (Abstract)
Gullquist SD (*see* Donofrio et al). 1999;18:84 (Abstract)
Gummert J (*see* Hausen et al). 1999;18:73 (Abstract)
Gummert JF (*see* Ikonen et al). 1999;18:72 (Abstract)
Gummert JF, Barten MJ, Boeke K, Leon EJ, Decker CJ, Nimmesgern E, Billingham ME, Morris RE. VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival. 1999;18:72 (Abstract)
Gummert JF, Barten MJ, Wang Y, Billingham ME, Morris RE. Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection. 1999;18:53-54 (Abstract)
Gundry SR (*see* Dearani et al). 1999;18:70 (Abstract)
Gutierrez CA (*see* Chaparro et al). 1999;18:46 (Abstract)
Gutiérrez-Carretero E, Bello-Puentes R, Borrego-Domínguez JM, Hernández-Fernández A, Muñoz-Garcia J, Ordóñez-Fernández A. Alteration in diastolic function following cardiac cryopreservation at subzero temperatures. 1999;18:372-75
Guzman-Paz M (*see* Kulick et al). 1999;18:65 (Abstract)

H

Haberbosch W (*see* Braun-Dullaeus et al). 1999;18:328-34
Haberstroh J (*see* Martin et al). 1999;18:597-605
Hachida M, Zhang X, Lu H, Hoshi H, Koyanagi H. Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation. 1999;18:248-53
Hackert T (*see* Szabó et al). 1999;18:39 (Abstract)
Hadama T (*see* Wada et al). 1999;18:499-508
Hage A (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)
Hage A (*see* Moriguchi et al). 1999;18:76 (Abstract)
Hagel J (*see* Kallinowski et al). 1999;18:190-93
Hagen JA (*see* Uppal et al). 1999;18:54 (Abstract)
Hagl S (*see* Szabó et al). 1999;18:54 (Abstract)
Hague LK (*see* Yu et al). 1999;18:764-68
Hallgren R (*see* Johnsson et al). 1999;18:1238-42
Hall TS (*see* Jonosono et al). 1999;18:972-85
Hamilton MA (*see* Drazner et al). 1999;18:1126-32
Hamilton MA (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)
Hamilton MA (*see* Moriguchi et al). 1999;18:76 (Abstract)
Hammel D (*see* Asfour B et al). 1999;18:927-36
Hammel D (*see* Baba et al). 1999;18:57 (Abstract)
Hammer C (*see* Brenner et al). 1999;18:59 (Abstract)
Hammer C (*see* Brenner et al). 1999;18:1211-17
Hamon M (*see* Agostini et al). 1999;18:47 (Abstract)
Hancock WW (*see* Wilhelm et al). 1999;18:68 (Abstract)
Han WR (*see* Mottram et al). 1999;18:94 (Abstract)
Hare JM (*see* Asfour B et al). 1999;18:927-36
Harker K (*see* Penson et al). 1999;18:707-12
Harland JA (*see* McCaffrey et al). 1999;18:76 (Abstract)
Harringer W (*see* Strüber et al). 1999;18:87 (Abstract)
Harringer W (*see* Teebken et al). 1999;18:807-9
Harringer W, Wiebe K, Strüber M, Franke U, Niedermeyer J, Wahlers T, Haverich A. Improved results for retransplantation in acute and late pulmonary graft failure. 1999;18:56 (Abstract)
Harrison PC, Madwed JB. Anti-LFA-1[uni]945α[/uni] reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats. 1999;18:279-84
Hasegawa T, Iacono A, Yousem SA. The significance of bronchial associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection?. 1999;18:41 (Abstract)
Hasegawa Y (*see* Oshima et al). 1999;18:852-61
Hasegawa Y (*see* Takahashi et al). 1999;18:285-91
Hasleton P (*see* Aziz et al). 1999;18:37 (Abstract)
Hasleton P (*see* El-Gamel et al). 1999;18:828-35
Hasleton PS (*see* El-Gamel et al). 1999;18:517-22
Hattler BG (*see* Tagusari et al). 1999;18:1111-19
Hatton PS (*see* Wang et al). 1999;18:48 (Abstract)
Haug MT III (*see* Yu et al). 1999;18:764-68
Hausen B (*see* Ikonen et al). 1999;18:72 (Abstract)
Hausen B, Berry GJ, Dagum P, Ikonen T, Christians U, Briffa N, Hook L, Morris RE. The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant models. 1999;18:714-24
Hausen B, Boeke K, Berry GJ, Morris RE. Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat. 1999;18: 79-80 (Abstract)
Hausen B, Boeke K, Berry GJ, Segarra IT, Christians U, Morris RE. Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in

combination with a microemulsion formulation of cyclosporine. 1999;18:150-58
Hausen B, Gummert J, Berry GJ, Christians U, Hook L, Ikonen T, Legay F, Morris RE. Basiliximab ([uni]945α[/uni]IL2R Mab) induction therapy combined with subtherapeutic doses of neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model. 1999;18:73 (Abstract)
Hausen H (*see* Brazelton et al). 1999;18:59 (Abstract)
Hausen H (*see* Doyle et al). 1999;18:86 (Abstract)
Haverich A (*see* De Meester et al). 1999;18:563-71
Haverich A (*see* Fraund et al). 1999;18:220-24
Haverich A (*see* Harringer et al). 1999;18:56 (Abstract)
Haverich A (*see* Klauss et al). 1999;18:50 (Abstract)
Haverich A (*see* Pethig et al). 1999;18:52 (Abstract), 1999;18:77-78 (Abstract)
Haverich A (*see* Strüber et al). 1999;18:87 (Abstract)
Haverich A (*see* Teebken et al). 1999;18:807-9
Haverich A (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Haverich A (*see* Wittwer et al). 1999;18:684-91
Haverich A (*see* Wittwer et al). 1999;18:1198-1201
Hawkins RC (*see* Keogh et al). 1999;18:67 (Abstract)
Hawkins RC (*see* Spratt et al). 1999;18:42 (Abstract)
Hayase M (*see* Ikonen et al). 1999;18:72 (Abstract)
Häyry PJ (*see* Kallio et al). 1999;18:52-53 (Abstract)
Heilman JK (*see* Lake et al). 1999;18:81 (Abstract)
Heilmann C (*see* Svendsen et al). 1999;18:388-89
Helman DN, Addonizio LJ, Morales DLS, Catanese KA, Flannery MA, Quagebeur J, Edwards NM, Galantowicz ME, Oz MC. Implantable left ventricular assist devices can successfully bridge pediatric patients to transplant. 1999;18:89 (Abstract)
Hendry PJ (*see* Farrar et al). 1999;18:62-63 (Abstract)
Hendry PJ (*see* Mussivand et al). 1999;18:166-71
Hepkema BG (*see* van den Berg et al). 1999;18:85 (Abstract)
Heras M (*see* Roig et al). 1999;18:91 (Abstract)
Hercog &Dhyphen; (*see* Gradinac et al). 1999;18:381-83
Hernández-Fernández A (*see* Gutiérrez-Carretero et al). 1999;18:372-75
Hertz M (*see* Park et al). 1999;18:60 (Abstract)
Hertz MI (*see* Garrity et al). 1999;18:175-76
Hetzer R (*see* Grauhan et al). 1999;18:66 (Abstract)
Hetzer R (*see* Hummel et al). 1999;18:49 (Abstract), 1999;18:77 (Abstract)
Hetzer R (*see* Müller et al). 1999;18:70-71 (Abstract)
Hetzer R (*see* Wagner et al). 1999;18:89 (Abstract)
Hetzer R (*see* Waurick et al). 1999;18:1243-45
Heublein B (*see* Klauss et al). 1999;18:50 (Abstract)
Heublein B (*see* Pethig et al). 1999;18:52 (Abstract), 1999;18:77-78 (Abstract)
Higgins CB (*see* Schwitter et al). 1999;18:1003-13
Higgins R (*see* Parry et al). 1999;18:121-25
Hillinger S (*see* Stammberger et al). 1999;18:74-75 (Abstract), 1999;18:79 (Abstract), 1999;18:862-67
Hillinger S, Sandera P, Stammberger U, Weder W, Schmid RA. 8-BR-cyclic GMP given during reperfusion improves posttransplant lung edema and free radical injury. 1999;18:74 (Abstract)
Hinkamp T (*see* Bhorade et al). 1999;18:79 (Abstract)
Hink M (*see* Brenner et al). 1999;18:1211-17
Hinz M (*see* Brenner et al). 1999;18:59 (Abstract)
Hipmair G (*see* Grasser et al). 1999;18:80 (Abstract)
Hirt SW, You XM, Möller F, Boeke K, Starke M, Spranger U, Wottge HU. Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment. 1999;18:542-48
Hisamochi K (*see* Cable et al). 1999;18:177-83
Hittinger L (*see* Aptecar et al). 1999;18:64 (Abstract)
Hobbs RE (*see* Eisen et al). 1999;18:93 (Abstract)
Ho C (*see* Yoshida et al). 1999;18:1054-64
Hodges N (*see* Weill et al). 1999;18:1080-87
Hodges TN (*see* Weill et al). 1999;18:55 (Abstract)
Hodges TN (*see* Zamora et al). 1999;18:81 (Abstract)
Hoercher K (*see* Matsumiya et al). 1999;18:79 (Abstract)
Hoercher K (*see* Sheffield et al). 1999;18:39 (Abstract)
Hoercher K (*see* Smedira et al). 1999;18:44 (Abstract)
Hoercher K, Young JB, Starling RC, Price LL, Banbury M, Smedira NS, McCarthy PM. Should advanced recipient age be contraindicated in cardiac transplantation? Continued analysis of a single center experience. 1999;18:45 (Abstract)
Hoffman AM (*see* Onsager et al). 1999;18:448-54
Hoffmann A (*see* Pethig et al). 1999;18:52 (Abstract)
Hoffmann H (*see* Müller et al). 1999;18:40 (Abstract)
Hoidal JR (*see* Cahill et al). 1999;18:86 (Abstract)
Holman WR (*see* Farrar et al). 1999;18:62-63 (Abstract)
Honda Y (*see* Ikonen et al). 1999;18:72 (Abstract)
Hong RA (*see* Kaufman et al). 1999;18:1018-20
Hook L (*see* Hausen et al). 1999;18:73 (Abstract), 1999;18:714-24
Hopmann H (*see* Braun-Dullaeus et al). 1999;18:328-34
Hormuth DA (*see* Fastenau et al). 1999;18:916-20
Horn MV (*see* Woo et al). 1999;18:86 (Abstract)
Hosenpud JD (*see* Boucek et al). 1999;18:1151-72 (Registry)
Hosenpud JD (*see* Khanna et al). 1999;18:49 (Abstract)
Hosenpud JD (*see* Novick et al). 1999;18:425-31
Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ. The registry of the International Society for Heart and Lung Transplantation: sixteenth official report-1999. 1999;18:611-26
Hoshi H (*see* Hachida et al). 1999;18:248-53
Howden B (*see* Baxter et al). 1999;18:769-73
Hoyt EG (*see* Feeley et al). 1999;18:48 (Abstract)
Hoyt G (*see* Ennen et al). 1999;18:49 (Abstract)
Hoyt G (*see* Feeley et al). 1999;18:1088-95
Hruban RH (*see* Asfour B et al). 1999;18:927-36
Hruban RH (*see* McLean et al). 1999;18:68 (Abstract)
Hsu DT (*see* Bernstein et al). 1999;18:69 (Abstract)
Hsueh W (*see* Crawford et al). 1999;18:470-76
Huang L (*see* Crawford et al). 1999;18:470-76
Huber H (*see* Brenner et al). 1999;18:59 (Abstract)

Huber H (*see* Brenner et al). 1999;18:1211-17
Huddleston CB (*see* Sweet et al). 1999;18:82-83 (Abstract)
Hueman MT (*see* Atkines et al). 1999;18:1173-80
Hull AR. Public and professional attitudes toward xenotransplantation and other options to increase organ availability. 1999;18:92 (Abstract)
Hülsmann M (*see* Stanek et al). 1999;18:358-65
Hummel M (*see* Müller et al). 1999;18:70-71 (Abstract)
Hummel M (*see* Waurick et al). 1999;18:1243-45
Hummel M, Knollmann FD, Spiegelsberger S, Boksch W, Wellnhofer E, Felix R, Hetzer R. Noninvasive cost-effective detection of cardiac allograft vasculopathy by electron beam computed tomography (EBCT). 1999; 18:49 (Abstract)
Hummel M, Kurzuk M, Hetzer R. Prophylactic and pre-emptive strategies for control of Legionnaires' disease in heart transplant recipients. A single center 10-years survey in a high-risk environment. 1999;18:77 (Abstract)
Hunstad DA, Cohen AH, St. Geme JW III. Successful eradication of mucormycosis occurring in a pulmonary allograft. 1999;18:801-4
Hunt BJ, Parmar K, Jansen PGM, Wheeldon DR, Portner PM. A Prospective study of haemostatic changes after implantation of the novacor LVAS. 1999;18:43 (Abstract)
Hunt SA (*see* Kato et al). 1999;18:50 (Abstract)
Hunt SA (*see* Valantine et al). 1999;18:81 (Abstract)
Hutcheon M (*see* Chaparro et al). 1999;18:46 (Abstract)
Hutcheson BS (*see* Atkines et al). 1999;18:1173-80
Hutchinson IV (*see* Aziz et al). 1999;18:37 (Abstract)
Hutchinson IV (*see* Densem et al). 1999;18:52 (Abstract), 1999;18:77 (Abstract)
Hutchinson IV (*see* El-Gamel et al). 1999;18:517-22, 1999; 18:828-35
Hutchinson J (*see* El-Gamel et al). 1999;18:828-35
Hutchinson JA (*see* El-Gamel et al). 1999;18:517-22
Hutten H (*see* Grasser et al). 1999;18:80 (Abstract)

I

Iacono A (*see* Hasegawa et al). 1999;18:41 (Abstract)
Iacono A (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
Iacono AT (*see* Keenan et al). 1999;18:55 (Abstract)
Iannettoni MD, Mulligan MS, Zaremba LM, Edwards JA, Orringer MB. Cooperative procurement for lung transplantation improves organ utilization without increasing complications. 1999;18:86-87 (Abstract)
Ibarrola C (*see* Delgado et al). 1999;18:607-10 (Abstract)
Iberer F (*see* Grasser et al). 1999;18:80 (Abstract)
Ibrahim J, Blume E, Phelan D, Lublin D, Canter CE. Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results. 1999;18:83 (Abstract)
Icenogle TB (*see* Farrar et al). 1999;18:62-63 (Abstract)
Icenogle TB (*see* Jaski et al). 1999;18:1031-40
Ignaszewski AP (*see* Cook et al). 1999;18:420-24
Ignaszewski AP (*see* Pamboukian et al). 1999;18:367-70
Ikonen T (*see* Hausen et al). 1999;18:73 (Abstract), 1999; 18:714-24
Ikonen T (*see* Wan et al). 1999;18:90 (Abstract)
Ikonen TS, Adams B, Lange E, Berry GJ, Morris RE. A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats. 1999; 18:73 (Abstract)
Ikonen TS, Gummert JF, Honda Y, Hayase M, Christians U, Serkova N, Hausen B, Yock PG, Morris RE. Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound. 1999; 18:72 (Abstract)
Ikonen TS, Shorthouse RS, Berry GJ, Morris RE. Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute rejection and proliferation of [uni]945α[/uni]-actin positive cells. 1999;18:60 (Abstract)
Ikonomidis JS (*see* Wittnich et al). 1999;18:675-83
Imaizumi M (*see* Teranishi et al). 1999;18:73 (Abstract)
Imhof M (*see* Laufer et al). 1999;18:94 (Abstract)
Ingemansson R (*see* Bolys et al). 1999;18:582-86
Ingenito EP (*see* Moy et al). 1999;18:986-93
International Lung Transplant Database Group (*see* Doyle et al). 1999;18:86 (Abstract)
Ishibashi-Ueda H (*see* Kawaguchi et al). 1999;18:67 (Abstract)
Ishikawa S (*see* Mohara et al). 1999;18:39 (Abstract)
Ishikawa S (*see* Oshima et al). 1999;18:852-61
Isowa N (*see* Cardella et al). 1999;18:88 (Abstract)
Itescu S (*see* Ankersmit et al). 1999;18:56 (Abstract)
Itescu S (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Itescu S (*see* Lietz et al). 1999;18:80 (Abstract)
Iwata A, Sai S, Chen M, Thomas R, Rothnie C, Grove R, Allen MD. Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts. 1999; 18:37 (Abstract)

J

Jablonski P (*see* Baxter et al). 1999;18:769-73
Jacobsen N (*see* Svendsen et al). 1999;18:388-89
Jäger U (*see* Mallinger et al). 1999;18:77 (Abstract)
Jahania MS (*see* Onsager et al). 1999;18:448-54
Jalowiec A (*see* Grady et al). 1999;18:202-10
Janicki M (*see* Kallinowski et al). 1999;18:190-93
Jansen PGM (*see* Hunt et al). 1999;18:43 (Abstract)
Jansen PGM, Wheeldon DR, Portner PM. Long term home discharge support with Novacor LVAS. 1999;18:67-68 (Abstract)
Jántsch-Watzinger V (*see* Wisser et al). 1999;18:42 (Abstract)
Jaramillo A (*see* Reznik et al). 1999;18:68 (Abstract)
Jaramillo A (*see* Smith et al). 1999;18:51 (Abstract)
Jarcho J (*see* Jaski et al). 1999;18:37 (Abstract)
Jarecki N (*see* Lawless et al). 1999;18:38 (Abstract)
Jaski B (*see* Grady et al). 1999;18:750-60

Jaski BE, Kim J, Naftel DC, Lingle RJ, Brozen SC, Jarcho J, Costanzo MR, Eisen HJ, Kirklin JK, Bourge RC. Cardiac transplant outcome between patients supported on a left ventricular assist device versus intravenous inotropic therapy. 1999;18:37 (Abstract)

Jaski BE, Lingle RJ, Kim J, Branch KR, Goldsmith R, Johnson MR, Lahpor JR, Icenogle TB, Piña I, Adamson R, Favrot LK, Dembitsky WP. Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial. 1999;18:1031-40

Jassawala JS (*see* Kormos et al). 1999;18:63 (Abstract)

Jeevanandam V (*see* Belland et al). 1999;18:54 (Abstract)

Jeevanandam V (*see* Fedalen et al). 1999;18:56-57 (Abstract)

Jeevanandam V (*see* McGurl et al). 1999;18:93 (Abstract)

Jeevanandam V (*see* Slachta et al). 1999;18:41 (Abstract), 1999;18:60 (Abstract)

Jeevanandam V (*see* Xu et al). 1999;18:90 (Abstract)

Jensen DM (*see* Cotler et al). 1999;18:456-58

Jia C-X (*see* Rabkin et al). 1999;18:775-80

Johnson J (*see* Allen-Auerbach et al). 1999;18:211-18

Johnson MR (*see* Jaski et al). 1999;18:1031-40

Johnsson C, Hallgren R, Lindbom L-O, Tufveson G. Edema treatment during cardiac allograft. 1999;18:1238-42

Johnston JK (*see* Dearani et al). 1999;18:70 (Abstract)

Jones PG (*see* Borkon et al). 1999;18:668-73

Jonosono M, Fang KC, Keith FM, Turck CW, Blanc PD, Hall TS, Fukano AK, Rifkin CJ, Gold MW, Webb WR, Edinburgh KJ, Finkbeiner WE, Golden JA. Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients. 1999;18:972-85

Jordan SC (*see* Ross et al). 1999;18:627-35

Joseph KJ (*see* Blair et al). 1999;18:54 (Abstract)

Jovanovič I (*see* Gradinac et al). 1999;18:381-83

Jovovič L (*see* Gradinac et al). 1999;18:381-83

Jucewicz M (*see* Mallinger et al). 1999;18:77 (Abstract)

Juffe-Stein A (*see* Vazquez-Rodriguez et al). 1999;18:172

Jureidini SB (*see* Balfour et al). 1999;18:1027-29

K

Kahan BD (*see* Kerman et al). 1999;18:38 (Abstract)

Kahan BD (*see* Perez et al). 1999;18:68 (Abstract)

Kahler DA (*see* Penson et al). 1999;18:707-12

Kakavand B (*see* Donofrio et al). 1999;18:84 (Abstract)

Kalies H (*see* Klauss et al). 1999;18:50 (Abstract)

Kallinowski B, Janicki M, Seelig R, Seipp S, Hagel J, Dengler T, Schnitzler P, Theilmann L, Stremmel W. Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients. 1999;18:190-93

Kallio EA (*see* Tikkanen et al). 1999;18:62 (Abstract)

Kallio EA, Lemström KB, Tikkanen JM, Ryan US, Häyry PJ, Koskinen PK. Effect of soluble complement receptor type 1 (sCR1) on experimental obliterative bronchiolitis (OB). 1999;18:52-53 (Abstract)

Kao A (*see* DeNofrio et al). 1999;18:46 (Abstract)

Kapadia SR (*see* Kaplon et al). 1999;18:63 (Abstract)

Kaplon RJ, Gillinov AM, Smedira NG, Kottke-Marchant K, Wang I-W, Goormastic M, McCarthy PM. Vitamin K reduces bleeding in left ventricular assist device recipients. 1999;18:346-50

Kaplon RJ, Kapadia SR, Smedira NG, Buda T, Goormastic M, Tuzcu EM, McCarthy PM. Does LVAD bridging-to-transplantation increase graft vasculopathy?. 1999;18:63 (Abstract)

Kapoor C (*see* Mehra et al). 1999;18:76 (Abstract)

Karck M (*see* Strüber et al). 1999;18:87 (Abstract)

Karwande SV (*see* Stringham et al). 1999;18:160-65

Kass DA (*see* Asfour B et al). 1999;18:927-36

Kass RM (*see* Ross et al). 1999;18:627-35

Kastner P (*see* Grasser et al). 1999;18:80 (Abstract)

Kato T, Maehara A, Chan M, Giannetti N, Gao S-Z, Schroeder J, Hunt SA, Valantine HA. Hemoglobin A1C predicts of transplant coronary artery disease incidence and severity. 1999;18:50 (Abstract)

Katsetos CD (*see* Agelan et al). 1999;18:40 (Abstract)

Katz SM (*see* Kerman et al). 1999;18:38 (Abstract)

Kauffman HM, McBride MA, Shield CF, Daily OP, Wolf JS, Kirklin JK. Determinants of waiting time for heart transplants in the United States. 1999;18:414-19

Kaufman LJ, Kofalvi AE, Hong RA, Moreno-Cabral CE, Low LL. Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient. 1999;18:1018-20

Kavanagh T, Yacoub MH, Kennedy J, Austin PC. Return to work after heart transplantation: 12-year follow-up. 1999;18:846-50

Kawaguchi AT, Ishibashi-Ueda H, Ujiie T, Shimura S, Koide S, Batista RJV. Histopathology of resected myocardium is correlated with survival after partial left ventriculectomy - a clue to indication for PLV versus transplantation. 1999;18:67 (Abstract)

Kawaharada N, Shears LL, Li S, Pham SM. Mixed Hematopoietic chimerism prevents allograft vasculopathy. 1999;18:532-40

Kawai A (*see* Tagusari et al). 1999;18:1111-19

Kawashima Y (*see* Tomizawa et al). 1999;18:637-44

Kawata N (*see* Chait et al). 1999;18:58 (Abstract)

Kawata N (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)

Kawata N (*see* Moriguchi et al). 1999;18:76 (Abstract)

Kearns A (*see* Gould et al). 1999;18:173-74

Keck BM (*see* Boucek et al). 1999;18:1151-72 (Registry)

Keck BM (*see* Hosenpud et al). 1999;18:611-26 (Abstract)

Keenan R (*see* Garrity et al). 1999;18:175-76

Keenan R (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)

Keenan RJ (*see* McCurry et al). 1999;18:72 (Abstract)

Keenan RJ, Levy R, Dauber JH, Iacono AT, McCurry KR, Manzetti J, Aquilino T, Vensak J, Griffith BP. Predictors of survival to transplant in cystic fibrosis: impact of international listing guidelines. 1999;18:55 (Abstract)

Keith FM (*see* Jonosono et al). 1999;18:972-85

Kennedy AS (*see* Sonett et al). 1999;18:84 (Abstract)
Kennedy J (*see* Kavanagh et al). 1999;18:846-50
Kenzora JL (*see* Kirklin et al). 1999;18:47 (Abstract)
Keogh A, Bourge R, Costanzo M, Dureau G, Eisen H, Kobashigawa J, Mehra M, Mentzer R, Miller L, Renlund D, Smart F, Valantine H. Three year results of the double-blind randomized multicenter trial of mycophenolate mofetil in heart transplant patients. 1999;18:53 (Abstract)
Keogh AM (*see* McCaffrey et al). 1999;18:76 (Abstract)
Keogh AM (*see* Spratt et al). 1999;18:42 (Abstract)
Keogh AM, Spratt PM, Macdonald PS, Mundy JA, Hawkins RC, Amor R. Randomised trial of cardiomyoplasty against optimal medical therapy in class III heart failure. 1999;18:67 (Abstract)
Keon WJ (*see* Mussivand et al). 1999;18:166-71
Kepron W (*see* Partovi et al). 1999;18:85 (Abstract)
Kerman RH, Przybylowski P, Bologna M, Susskind B, Van Buren CT, Katz SM, Radovancevic B, Frazier OH, Kahan BD. The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients. 1999;18:38 (Abstract)
Keshavjee S (*see* Cardella et al). 1999;18:88 (Abstract)
Keshavjee S (*see* Cassivi et al). 1181-88
Keshavjee S (*see* DeCampos et al). 1999;18:1096-1102
Keshavjee SH (*see* Cassivi et al). 1999;18:88-89 (Abstract)
Keshavjee SH (*see* Chaparro et al). 1999;18:46 (Abstract)
Keshavjee SH (*see* Waddell et al). 1999;18:85 (Abstract)
Kesten S (*see* Chaparro et al). 1999;18:46 (Abstract)
Kesten S (*see* Cotler et al). 1999;18:456-58
Kesten S (*see* Minai et al). 1999;18:891-900
Kesten S, Elpern E, Warren W, Szidon P. Loss of pulmonary function gains after lung volume reduction surgery. 1999;18:266-68
Ketheesan N, Tay GK, Witt CS, Christiansen FT, Taylor RR, Dawkins RL. The significance of HLA matching in cardiac transplantation. 1999;18:226-29
Kevelaitis E, Nyborg NCB, Menasché P. Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors. 1999;18:239-46
Kfoury AG (*see* Renlund et al). 1999;18:1065-70
Kfoury AG (*see* Stringham et al). 1999;18:160-65
Khaghani A (*see* Radley-Smith et al). 1999;18:84 (Abstract)
Khanna AK, Plummer M, Hosenpud JD. p21 overexpression inhibits cell proliferation and enhances cyclosporine's antiproliferative effects: a novel strategy for immunosuppression. 1999;18:49 (Abstract)
Khan SU (*see* Yu et al). 1999;18:764-68
Khayat A (*see* Agostini et al). 1999;18:47 (Abstract)
Kim J (*see* Jaski et al). 1999;18:37 (Abstract)
Kim J (*see* Jaski et al). 1999;18:1031-40
Kim JD, Barr ML, Baker CJ, Roberts RF, Danto SI. Modulation of pulmonary Na^+ pump gene expression during cold storage and reperfusion. 1999;18:74 (Abstract)
Kingsbury K (*see* Cook et al). 1999;18:420-24
Kirklin J (*see* Grady et al). 1999;18:750-60
Kirklin JK (*see* Bernstein et al). 1999;18:69 (Abstract)
Kirklin JK (*see* Frazier et al). 1999;18:69-70 (Abstract)
Kirklin JK (*see* Goldstein et al). 1999;18:69 (Abstract)
Kirklin JK (*see* Jaski et al). 1999;18:37 (Abstract)
Kirklin JK (*see* Kauffman et al). 1999;18:414-19
Kirklin JK (*see* Lake et al). 1999;18:81 (Abstract)
Kirklin JK (*see* Rayburn et al). 1999;18:47 (Abstract)
Kirklin JK (*see* Webber et al). 1999;18:69 (Abstract)
Kirklin JK, Naftel DC, Boehmer JP, Kobashigawa JA, Kenzora JL, Mehra MR, Miller LW, Kubo SH, Stevenson LW, Bourge RC. Refining the criteria for heart transplant listing and status: a multi-institutional risk factor analysis for rehospitalization following listing. 1999;18:47 (Abstract)
Klapdor R (*see* Nägele et al). 1999;18:957-62
Klauss V (*see* Casella et al). 1143-46
Klauss V (*see* Meiser et al). 1999;18:78 (Abstract)
Klauss V (*see* Rieber et al). 1999;18:65 (Abstract)
Klauss V (*see* Spes et al). 1999;18:391-97
Klauss V, Pethig K, Kalies H, Pichlmayer E, Heublein B, Rieber J, Spes CH, Reichart B, Siebert U, Haverich A, Mudra H. Intravascular ultrasound has prognostic impact after heart transplantation: a multivariable analysis in a large patient cohort. 1999;18:50 (Abstract)
Kleber FX (*see* Waurick et al). 1999;18:1243-45
Kleber FX (*see* Wensel et al). 1999;18:877-82
Klepetko W (*see* Takahashi et al). 1999;18:304-9
Klepetko W (*see* Wisser et al). 1999;18:42 (Abstract), 1999;18:67 (Abstract)
Klepetko W (*see* Zuckermann et al). 1999;18:432-39
Klepetko W, Reichenspurner H, Zuckermann A, Meiser B, Birsnan T, Treede H, Kupilik N, Kur F, Wisser W. Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. Tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX). 1999;18:45-46 (Abstract)
Klinski C (*see* Schwitter et al). 1999;18:1003-13
Knollmann FD (*see* Hummel et al). 1999;18:49 (Abstract)
Knoop C (*see* Welters et al). 1999;18:53 (Abstract)
Kobashigawa J (*see* Allen-Auerbach et al). 1999;18:211-18
Kobashigawa J (*see* Chait et al). 1999;18:58 (Abstract)
Kobashigawa J (*see* Eisenring et al). 1999;18:58-59 (Abstract)
Kobashigawa J (*see* Keogh et al). 1999;18:53 (Abstract)
Kobashigawa J (*see* Wang et al). 1999;18:80 (Abstract)
Kobashigawa JA (*see* Kirklin et al). 1999;18:47 (Abstract)
Kobashigawa JA (*see* Moriguchi et al). 1999;18:76 (Abstract)
Kobashigawa JA (*see* Skotzko et al). 1999;18:952-56
Kobashigawa JA, Moriguchi JD, Laks H, Ro TK, Hamilton MA, Hage A, Wener L, Kawata N. Five-year follow-up of a randomized trial of pravastatin in heart transplant patients. 1999;18:71 (Abstract)
Kobashigawa JA, Ro TK, Moriguchi JD, Lee R, Cassem JD, Hamilton MA, Hage A, Kawata N, Laks H. Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients. 1999;18:50 (Abstract)

Kobayashi Y, Fukushima N, Ohtake S, Sawa Y, Nishimura M, Sakaguchi T, Miyagawa S, Matsuda H. Prevention of endothelial cell activation in hamster-to-rat cardiac xenografts by gene transfection of Bcl-2. 1999;18:66 (Abstract)
Koch C (*see* Svendsen et al). 1999;18:388-89 (Abstract)
Kocher A (*see* Ankersmit et al). 1999;18:56 (Abstract)
Kocher A (*see* Laufer et al). 1999;18:94 (Abstract)
Kocher A (*see* Mallinger et al). 1999;18:77 (Abstract)
Koelling T (*see* Aaronson et al). 1999;18:80 (Abstract)
Koëter GH (*see* van den Berg et al). 1999;18:85 (Abstract)
Kofalvi AE (*see* Kaufman et al). 1999;18:1018-20
Kofoed K (*see* Allen-Auerbach et al). 1999;18:211-18
Koglin J, Gadiraju S, Russell ME. Stat4-mediated Th1 responses promote the development of graft arteriosclerosis. 1999;18:71 (Abstract)
Kohl T (*see* Asfour B et al). 1999;18:927-36
Koide S (*see* Kawaguchi et al). 1999;18:67 (Abstract)
Kokai G (*see* Gradinac et al). 1999;18:381-83
Korecka M (*see* DeNofrio et al). 1999;18:46 (Abstract)
Kormos RL (*see* Dew et al). 1999;18:549-59
Kormos RL (*see* Farrar et al). 1999;18:62-63 (Abstract)
Kormos RL (*see* Stanford et al). 1999;18:58 (Abstract)
Kormos RL (*see* Tagusari et al). 1999;18:1111-19
Kormos RL, Ramasamy N, Sit S, Cleeland AD, Jassawala JS, Portner PM. Bridge-to-transplant (BTT) experience with the Novacor left ventricular assist system (LVAS): results of a multicenter US study. 1999;18:63 (Abstract)
Koskinen PK (*see* Kallio et al). 1999;18:52-53 (Abstract)
Koskinen PK (*see* Sihvola et al). 1999;18:61-62 (Abstract)
Koskinen PK (*see* Tikkanen et al). 1999;18:62 (Abstract)
Kostuk WJ (*see* Del Rizzo et al). 1999;18:310-19
Kotsimbos T (*see* Gabbay et al). 1999;18:51 (Abstract)
Kottke-Marchant K (*see* Kaplon et al). 1999;18:346-50
Koyanagi H (*see* Hachida et al). 1999;18:248-53
Koyano T (*see* Mohara et al). 1999;18:39 (Abstract)
Koyano T (*see* Takahashi et al). 1999;18:285-91
Krabatsch T (*see* Grauhan et al). 1999;18:66 (Abstract)
Kraemer H-J (*see* Braun-Dullaeus et al). 1999;18:328-34
Kranz A (*see* Birsan et al). 1999;18:304-9
Krasinskas AM (*see* McLean et al). 1999;18:68 (Abstract)
Krasinskas AM, Gelman AE, Popma SH, McLean AD, Rosengard BR. Assessment of murine bone marrow transplant chimeras. 1999;18:88 (Abstract)
Kreisel D (*see* McLean et al). 1999;18:68 (Abstract)
Kreuzer E (*see* Meiser et al). 1999;18:143-48
Krieg P (*see* Teebken et al). 1999;18:807-9
Kritzinger M (*see* Wisser et al). 1999;18:42 (Abstract)
Kron IL (*see* Ross et al). 1999;18:72 (Abstract), 1999;18:994-1002
Kruger RM, Storch GA, Shannon WD, Arens MQ, Lynch JP, Trulock EP. The impact of ganciclovir-resistant cytomegalovirus infection in lung transplantation. 1999;18:82 (Abstract)
Kubilis PS (*see* Penson et al). 1999;18:707-12
Kubo SH (*see* Kirklin et al). 1999;18:47 (Abstract)
Kuchling G (*see* Berger et al). 1999;18:75 (Abstract)
Kuehnapfel S (*see* Wildhirt et al). 1999;18:40 (Abstract)
Kulick DM (*see* Nguyen et al). 1999;18:55 (Abstract)
Kulick DM, Dalmasso AP, Salerno CT, Grehan J, Park SJ, Guzman-Paz M, Bolman RM III. Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection. 1999;18:65 (Abstract)
Kupilik N (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Kur F (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Kur F (*see* Müller et al). 1999;18:40 (Abstract)
Kur F, Meiser BM, Treede H, Reichenspurner H, v. Scheidt W, Reichart B. Does initial photopheresis have an impact on the development of graft atherosclerosis after cardiac transplantation - a 6-year follow-up. 1999;18:93 (Abstract)
Kurland G (*see* Webber et al). 1999;18:83 (Abstract)
Kurzuk M (*see* Hummel et al). 1999;18:77 (Abstract)
Kusaka M (*see* Wilhelm et al). 1999;18:68 (Abstract)

L

Laberrere CA (*see* Fastenau et al). 1999;18:916-20
Lahpor JR (*see* Jaski et al). 1999;18:1031-40
Lake KD (*see* Wright et al). 1999;18:913-15
Lake KD, Smith CI, Pritzker MR, Renlund DE, Heilman JK, Smith AL, Miller LW, Weiss LT, Kirklin JK, Bourge RC, Cardiac Transplant Research Database. Outcomes with hepatitis C following cardiac transplantation-a multi-institutional study. 1999;18:81 (Abstract)
Laks H (*see* Chait et al). 1999;18:58 (Abstract)
Laks H (*see* Eisenring et al). 1999;18:58-59 (Abstract)
Laks H (*see* Fischbein et al). 1999;18:40-41 (Abstract)
Laks H (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)
Laks H (*see* Marelli et al). 1999;18:87 (Abstract)
Laks H (*see* Moriguchi et al). 1999;18:76 (Abstract)
Laks H (*see* Skotzko et al). 1999;18:952-56
Lambris JD (*see* Fiane et al). 1999;18:66 (Abstract)
Lampert E (*see* Zoll et al). 1999;18:71 (Abstract)
Lan C (*see* Bernard et al). 1999;18:572-80
Landry DW (*see* Argenziano et al). 1999;18:814-17
Lands LC, Smountas AA, Mesiano G, Brosseau L, Shennib H, Charbonneau M, Gauthier R. Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation. 1999;18:113-19
Lange E (*see* Ikonen et al). 1999;18:73 (Abstract)
Lanpher BC (*see* Ross et al). 1999;18:72 (Abstract), 1999;18:994-1002
Large S (*see* Trull et al). 1999;18:93 (Abstract)
Large SR (*see* Bainbridge et al). 1999;18:407-12 (Abstract)
Large SR (*see* Ongcharit et al). 1999;18:37 (Abstract)
Large SR (*see* Tsui et al). 1999;18:78-79 (Abstract)
Large SR (*see* Wreghitt et al). 1999;18:82 (Abstract)
La Rovere MT (*see* Raczak et al). 1999;18:399-405
Larsen B (*see* Svendsen et al). 1999;18:388-89 (Abstract)
Larsen RL (*see* Dearani et al). 1999;18:70 (Abstract)
Laubach V (*see* Mannon et al). 1999;18:819-26

Lau CL, Daggett WC, Yeatman MF, Chai P, Lin SS, Lodge AJ, Chen EP, Diamond LE, Byrne GW, Logan JS, Parker W, Platt JL, Davis RD. The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants. 1999;18: 65-66 (Abstract)

Lau CL, Gonzalez-Stawinski G, Nichols T, Platt JL, Davis RD. Von Willebrand deficient swine lungs transplanted into baboons. 1999;18:65 (Abstract)

Laufer G (*see* Berger et al). 1999;18:75 (Abstract)

Laufer G (*see* Mallinger et al). 1999;18:77 (Abstract)

Laufer G (*see* Moidl et al). 1999;18:194-200

Laufer G (*see* Stanek et al). 1999;18:358-65

Laufer G (*see* Zuckermann et al). 1999;18:93 (Abstract)

Laufer G, Zuckermann A, Podesser B, Mallinger R, Schlechta B, Chevtchik O, Kocher A, Imhof M, Grimm M. Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients. 1999; 18:94 (Abstract)

Lavie C (*see* Mehra et al). 1999;18:76 (Abstract)

Lawless CE (*see* Mullen et al). 1999;18:92 (Abstract)

Lawless CE (*see* Pisani et al). 1999;18:701-6

Lawless CE, Dusek LK, Jarecki N, Myles M, Mozdzierz G, Maly J, Mullen GM, Malinowska K. Impact of patient noncompliance on survival in cardiac transplant recipients. 1999;18:38 (Abstract)

Lawrence CM (*see* Palmer et al). 1999;18:51 (Abstract)

Law Y (*see* Webber et al). 1999;18:83 (Abstract)

Law YM (*see* Robinson et al). 1999;18:786-90

Lazarovits AI (*see* Parry et al). 1999;18:441-46

Lee R (*see* Kobashigawa et al). 1999;18:50 (Abstract)

Lee RS (*see* Menard et al). 1999;18:71 (Abstract)

Lee YC (*see* Luh et al). 1999;18:62 (Abstract)

Legagneux J (*see* Xiong et al). 1999;18:320-26

Legay F (*see* Hausen et al). 1999;18:73 (Abstract)

Lehman A (*see* Ankersmit et al). 1999;18:56 (Abstract)

Leitz K (*see* Beniaminovitz et al). 1999;18:45 (Abstract)

Lemes V (*see* Shaddy et al). 1999;18:269-74

Lems SPM (*see* van den Berg et al). 1999;18:85 (Abstract)

Lemström KB (*see* Kallio et al). 1999;18:52-53 (Abstract)

Lemström KB (*see* Sihvola et al). 1999;18:61-62 (Abstract)

Lemström KB (*see* Tikkanen et al). 1999;18:62 (Abstract)

Leon EJ (*see* Gummert et al). 1999;18:72 (Abstract)

Lerut T (*see* Verleden et al). 1999;18:1139-46

Levine AJ (*see* Rooney et al). 1999;18:73 (Abstract)

Levy R (*see* Keenan et al). 1999;18:55 (Abstract)

Levy RD (*see* Cook et al). 1999;18:84-85 (Abstract)

Levy RD (*see* Partovi et al). 1999;18:85 (Abstract)

Lewis ME (*see* Pagano et al). 1999;18:67 (Abstract)

Lieback E (*see* Grauhan et al). 1999;18:66 (Abstract)

Lien D (*see* Partovi et al). 1999;18:85 (Abstract)

Lietz K (*see* Ankersmit et al). 1999;18:56 (Abstract)

Lietz K, Baran D, Burke E, Tung T, Ankersmit J, Mancini D, Edwards N, Suciu-Foca N, Itescu S. IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease. 1999;18:80 (Abstract)

Lindbom L-O (*see* Johnsson et al). 1999;18:1238-42

Linden J (*see* Ross et al). 1999;18:72 (Abstract), 1999;18: 994-1002

Lingle RJ (*see* Jaski et al). 1999;18:37 (Abstract)

Lingle RJ (*see* Jaski et al). 1999;18:1031-40

Lin SS (*see* Lau et al). 1999;18:65-66 (Abstract)

Liou TG (*see* Cahill et al). 1999;18:86 (Abstract)

Li S (*see* Kawaharada et al). 1999;18:532-40

Liu H (*see* Crawford et al). 1999;18:470-76

Liu M (*see* Cardella et al). 1999;18:88 (Abstract)

Liu M (*see* Cassivi et al). 1181-88

Liu M (*see* Cassivi et al). 1999;18:88-89 (Abstract)

Liu M (*see* DeCampos et al). 1999;18:1096-1102

Livi U (*see* Belloni et al). 1999;18:77 (Abstract)

LoCicero J (*see* Sasaki et al). 1999;18:127-32, 1999;18: 139-42

Locker G (*see* Stanek et al). 1999;18:358-65

Lodge AJ (*see* Lau et al). 1999;18:65-66 (Abstract)

Loebe M (*see* Wagner et al). 1999;18:89 (Abstract)

Logan JS (*see* Lau et al). 1999;18:65-66 (Abstract)

Logar A (*see* Zeevi et al). 1999;18:82 (Abstract)

Loh E (*see* DeNofrio et al). 1999;18:46 (Abstract)

Loisance D (*see* Aptecar et al). 1999;18:64 (Abstract)

Lok S. Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients. 1999;18:884-89

Lonchyna V (*see* Bhorade et al). 1999;18:79 (Abstract)

Long JW (*see* McKellar et al). 1999;18:57 (Abstract)

Long ND (*see* Borkon et al). 1999;18:668-73

Long T, Wray J, Banner N. What are the attitudes of potential heart and heart-lung patients to xenotransplantation?. 1999;18:92 (Abstract)

Lonsdorfer E (*see* Zoll et al). 1999;18:71 (Abstract)

Lorenz BL (*see* Endres et al). 1999;18:91 (Abstract)

Loring SH (*see* Moy et al). 1999;18:986-93

Lou H (*see* Saito et al). 1999;18:937-45

Love R (*see* Garrity et al). 1999;18:175-76

Love RB (*see* Endres et al). 1999;18:91 (Abstract)

Love RB (*see* Onsager et al). 1999;18:448-54

Love RB (*see* Stringham et al). 1999;18:587-95

Love RB, Cornwell RD, Welter DL, Canver CC, Meyer KC. Human lung preservation can be extended beyond eight hours using UW solution. 1999;18:87 (Abstract)

Low LL (*see* Kaufman et al). 1999;18:1018-20

Loyd JE (*see* Ely et al). 1999;18:55-56 (Abstract)

Loyola Lung Transplant Team (*see* Bhorade et al). 1999; 18:79 (Abstract)

Lublin D (*see* Ibrahim et al). 1999;18:83 (Abstract)

Lu H (*see* Hachida et al). 1999;18:248-53

Luh SP, Chen JS, Lee YC. The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors. 1999;18:62 (Abstract)

Luikart H (*see* Valantine et al). 1999;18:81 (Abstract)

Luisiri A (*see* Balfour et al). 1999;18:492-94
Luke P (*see* Parry et al). 1999;18:441-46
Lutter G (*see* Martin et al). 1999;18:597-605
Lynch JP (*see* Kruger et al). 1999;18:82 (Abstract)
Lynch JP (*see* Smith et al). 1999;18:51 (Abstract)

M

Maat APWM (*see* Baan et al). 1999;18:69 (Abstract)
Maat APWM (*see* de Groot-Kruseman et al). 1999;18:52 (Abstract)
MacDonald D (*see* Szabó et al). 1999;18:54 (Abstract)
Macdonald PS (*see* Keogh et al). 1999;18:67 (Abstract)
Macdonald PS (*see* McCaffrey et al). 1999;18:76 (Abstract)
Macdonald PS (*see* Spratt et al). 1999;18:42 (Abstract)
Macfarlane LM (*see* Griffiths et al). 1999;18:86 (Abstract)
MacLaughlin EF (*see* Woo et al). 1999;18:86 (Abstract)
Madden BP (*see* Stamenkovic et al). 1999;18:1246-50
Madsen JC (*see* Mawulawde et al). 1999;18:53 (Abstract)
Madsen JC (*see* Menard et al). 1999;18:71 (Abstract)
Madwed JB (*see* Harrison et al). 1999;18:279-84
Maehara A (*see* Kato et al). 1999;18:50 (Abstract)
Maestri R (*see* Raczak et al). 1999;18:399-405
Magalski A (*see* Borkon et al). 1999;18:668-73
Magnan C (*see* Cantarovich et al). 1999;18:78 (Abstract)
Malinowska K (*see* Lawless et al). 1999;18:38 (Abstract)
Malinowska K (*see* Mullen et al). 1999;18:92 (Abstract)
Malinowska K (*see* Pisani et al). 1999;18:701-6
Mallinger R (*see* Laufer et al). 1999;18:94 (Abstract)
Mallinger R, Chevtchik O, Zuckermann A, Jucewicz M, Moidl R, Kocher A, Chott A, Jäger U, Grimm M, Laufer G. Development and spectrum of PTLD in 691 cardiac transplant (Htx) recipients receiving induction therapy. 1999;18:77 (Abstract)
Mallory GB Jr (*see* Sweet et al). 1999;18:82-83 (Abstract)
Maly J (*see* Lawless et al). 1999;18:38 (Abstract)
Mancini D (*see* Ankersmit et al). 1999;18:56 (Abstract)
Mancini D (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Mancini D (*see* Lietz et al). 1999;18:80 (Abstract)
Mancini D (*see* Maybaum et al). 1999;18:44 (Abstract), 1999;18:62 (Abstract)
Mangiavacchi M (*see* Gronda et al). 1999;18:654-61
Mangiavacchi M (*see* Oliva et al). 1999;18:75 (Abstract)
Mannon RB, Roberts K, Ruiz P, Laubach V, Coffman TM. Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection. 1999;18:819-26
Manns MP (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Manzetti J (*see* Keenan et al). 1999;18:55 (Abstract)
Marchevsky AM (*see* Ross et al). 1999;18:627-35
Marcus FI (*see* Sharma et al). 1999;18:792-94
Marelli D (*see* Chen et al). 1999;18:351-57
Marelli D, Laks H, Moriguchi J, Moore S, Fazio D. Is the use of donor hearts with left ventricular hypertrophy acceptable?. 1999;18:87 (Abstract)
Mares P (*see* Takahashi et al). 1999;18:304-9
Marks JD (*see* McKellar et al). 1999;18:57 (Abstract)
Marshall BC (*see* Cahill et al). 1999;18:86 (Abstract)
Marshall-Neff J (*see* Wang et al). 1999;18:48-49 (Abstract)
Marsh JW (*see* Blair et al). 1999;18:54 (Abstract)
Martin J, Sarai K, Yoshitake M, Haberstroh J, Takahashi N, Lutter G, Beyersdorf F. Successful orthotopic pig heart transplantation from non-heart beating donors. 1999;18:597-605
Martin KL (*see* Bhorade et al). 1999;18:79 (Abstract)
Marullo AGM, McCarthy PM, Smedira NG, Buda T, Shiota T, Starling RC, Young JB. Left ventricular reconstruction using the Dor Procedure for ischemic aneurysm or akinetic dilatation. 1999;18:42 (Abstract)
Masciocco G (*see* Oliva et al). 1999;18:75 (Abstract)
Maseki T (*see* Teranishi et al). 1999;18:73 (Abstract)
Massetti M (*see* Agostini et al). 1999;18:47 (Abstract)
Massey JK (*see* Zander et al). 1999;18:646-52
Massimo F (*see* Sartori et al). 1999;18:693-99
Masters RG (*see* Mussivand et al). 1999;18:166-71
Matsuda H (*see* Kobayashi et al). 1999;18:66 (Abstract)
Matsuda H (*see* Nishimura et al). 1999;18:57 (Abstract)
Matsumiya G, McCarthy PM, Smedira NG, Hoercher K, Schmitt S, Starling RC, Young JB. Is it safe to utilize hearts from donors with positive blood cultures?. 1999;18:79 (Abstract)
Matsumoto K (*see* Mohara et al). 1999;18:39 (Abstract)
Matsumoto K (*see* Mohara et al). 1999;18:1202-10
Matsumoto K (*see* Oshima et al). 1999;18:852-61
Matsumoto K (*see* Takahashi et al). 1999;18:285-91
Maurer J (*see* Chaparro et al). 1999;18:46 (Abstract)
Maurer JR (*see* Minai et al). 1999;18:891-900
Maurer JR (*see* Sandur et al). 1999;18:810-13
Maurer JR (*see* Yu et al). 1999;18:764-68
Maurizio PG (*see* Sartori et al). 1999;18:693-99
Mavroudis C (*see* Crawford et al). 1999;18:470-76
Mavroudis C (*see* Pahl et al). 1999;18:725-32
Mavroudis C (*see* Ringewald et al). 1999;18:70 (Abstract)
Mawulawde K (*see* Menard et al). 1999;18:71 (Abstract)
Mawulawde K, Pins MR, Menard MT, Yamada K, Allan JS, Slisz JK, Sachs DH, Madsen JC. Effects of MHC class II antigens on the development of cardiac allograft vasculopathy in miniature swine. 1999;18:53 (Abstract)
Maybaum S, Beniaminovitz A, Oz M, Di Tullio M, Savin S, Mancini D. Resting left ventricular size predicts improved native cardiac output during exercise and the ability to exercise with the device weaned in patients with the TCI Heartmate left ventricular assist device. 1999;18:44 (Abstract)
Maybaum S, Epstein S, Beniaminovitz A, Oz M, Bergmann S, Mancini D. Resting myocardial blood flow and metabolism predicts improved native left ventricular output and the ability to exercise with weaning in patients with the TCI Heartmate left ventricular assist device. 1999;18:62 (Abstract)
McBride G (*see* Scott et al). 1999;18:39 (Abstract)
McBride LR (*see* Farrar et al). 1999;18:62-63 (Abstract)
McBride LR, Moroney DA, Braun PR, Swartz MT. Interhospital transfer of patients receiving advanced mechanical circulatory support. 1999;18:90 (Abstract)

McBride MA (*see* Kauffman et al). 1999;18:414-19
McCabe MA (*see* Bhorade et al). 1999;18:79 (Abstract)
McCaffrey DJ, Keogh AM, Macdonald PS, Harland JA. Time course of reverse left ventricular remodeling in response to carvedilol in heart failure. 1999;18:76 (Abstract)
McCarthy J (*see* Galbraith et al). 1999;18:805-6
McCarthy JF (*see* Cook et al). 1999;18:38 (Abstract)
McCarthy PM (*see* Cook et al). 1999;18:38 (Abstract)
McCarthy PM (*see* DiIulio et al). 1999;18:89-90 (Abstract)
McCarthy PM (*see* Hoercher et al). 1999;18:45 (Abstract)
McCarthy PM (*see* Kaplon et al). 1999;18:63 (Abstract), 1999;18:346-50
McCarthy PM (*see* Marullo et al). 1999;18:42 (Abstract)
McCarthy PM (*see* Matsumiya et al). 1999;18:79 (Abstract)
McCarthy PM (*see* Ogletree-Hughes et al). 1999;18:63 (Abstract)
McCarthy PM (*see* Park et al). 1999;18:1224-27
McCarthy PM (*see* Sheffield et al). 1999;18:39 (Abstract)
McCarthy PM (*see* Smedira et al). 1999;18:44 (Abstract)
McCrindle BW (*see* Dipchand et al). 1999;18:83-84 (Abstract)
McCue J (*see* Ankersmit et al). 1999;18:56 (Abstract)
McCully JD (*see* Sasaki et al). 1999;18:127-32, 1999;18:139-42
McCurry K (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
McCurry KR (*see* Keenan et al). 1999;18:55 (Abstract)
McCurry KR (*see* Stanford et al). 1999;18:58 (Abstract)
McCurry KR, Pham SI, Zeevi A, Webber S, Rao A, Ostrowski L, Salgar S, Starzl TE, Bentlejewski C, Keenan RJ, Fung J, Griffith BP. Immunomodulatory effects of donor bone marrow infusion in heart or lung transplantation: five year experience. 1999;18:72 (Abstract)
McGiffin DC (*see* Galbraith et al). 1999;18:805-6
McGregor C (*see* Schulman et al). 1999;18:107-12
McGuire A (*see* Anyanwu et al). 1999;18:51 (Abstract)
McGurl PA, Platsoucas CD, Ricordi C, Slachta CA, Goldman BI, Fedalen P, Gaughan JP, Xu B, Eisen HJ, Furukawa S, Jeevanandam V. Efficacy of donor specific bone marrow in reducing frequency of rejection following heart transplantation. 1999;18:93 (Abstract)
McIntyre JA (*see* Fastenau et al). 1999;18:916-20
McKellar SH, Marks JD, Renlund DG, Long JW. IVIg postpones alloimmunization in LVAD and artificial heart recipients. 1999;18:57 (Abstract)
McKenna MJ (*see* Morton et al). 1999;18:52 (Abstract)
McKenzie FN (*see* Del Rizzo et al). 1999;18:310-19
McLaughlin JS (*see* Seta et al). 1999;18:61 (Abstract)
McLaughlin JS (*see* Song et al). 1999;18:744-48
McLean AD (*see* Krasinskas et al). 1999;18:88 (Abstract)
McLean AD, Krasinskas AM, Popma SH, Shen XD, Gao F, Kreisel D, Hruban RH, Moore JS, Rosengard BR. Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype. 1999;18:68 (Abstract)
McNeil K (*see* Bardsley et al). 1999;18:41 (Abstract)
McNeil K (*see* Ongcharit et al). 1999;18:37 (Abstract)
McNeil K (*see* Tsui et al). 1999;18:78-79 (Abstract)
McNeil K (*see* Wreghitt et al). 1999;18:82 (Abstract)
Mehra M (*see* Keogh et al). 1999;18:53 (Abstract)
Mehra MR (*see* Kirklin et al). 1999;18:47 (Abstract)
Mehra MR (*see* Scott et al). 1999;18:39 (Abstract)
Mehra MR (*see* Uber et al). 1999;18:43 (Abstract)
Mehra MR, Prasad A, Uber PA, Park M, Scott R. The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study. 1999;18:49 (Abstract)
Mehra MR, Vivekananthan K, Uber PA, deGruiter H, Kapoor C, Solis S, Lavie C, Milani R. The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial. 1999;18:76 (Abstract)
Mehta AC (*see* Sandur et al). 1999;18:810-13
Mehta AC (*see* Yu et al). 1999;18:764-68
Meiser B (*see* Brenner et al). 1999;18:1211-17
Meiser BM (*see* Behr et al). 1999;18:904-11
Meiser BM (*see* Brenner et al). 1999;18:59 (Abstract)
Meiser BM (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Meiser BM (*see* Kur et al). 1999;18:93 (Abstract)
Meiser BM (*see* Schmidt et al). 1999;18:46 (Abstract)
Meiser BM (*see* Weis et al). 1999;18:50 (Abstract), 1999;18:64 (Abstract)
Meiser BM (*see* Weis et al). 1999;18:1071-79
Meiser BM, Pfeiffer M, Schmidt D, Ueberfuhr P, Reichenspurner H, Paulus D, Scheidt W von, Kreuzer E, Seidel D, Reichart B. Combination therapy with Tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. 1999;18:143-48
Meiser MB, Schmidt D, Pfeiffer M, Scheidt Wv, Klauss V, Wildhirt S, Überfuhr P, Reichenspurner H, Reichart B. Comparison of long-term effects between Tacrolimus and cyclosporine based immunosuppression after HTx. 1999;18:78 (Abstract)
Mellein B (*see* Eisen et al). 1999;18:93 (Abstract)
Melnitschuk S (*see* Szabó et al). 1999;18:39 (Abstract)
Menard MT (*see* Mawulawde et al). 1999;18:53 (Abstract)
Menard MT, Mawulawde K, Yamada K, Schwarze ML, Lee RS, Slisz JK, Allison KS, Sachs DH, Madsen JC. Transplantation of "thymoheart" allografts in miniature swine. 1999;18:71 (Abstract)
Menasché P (*see* Kevelaitis et al). 1999;18:239-46
Menasché P (*see* Xiong et al). 1999;18:320-26
Mendeloff EN (*see* Sweet et al). 1999;18:82-83 (Abstract)
Mendez J (*see* Pisani et al). 1999;18:701-6
Mendez JC (*see* Mullen et al). 1999;18:92 (Abstract)
Menkis AH (*see* Del Rizzo et al). 1999;18:310-19
Mentzer R (*see* Keogh et al). 1999;18:53 (Abstract)
Mentzer RM Jr (*see* Onsager et al). 1999;18:448-54
Mentzer RM Jr (*see* Stringham et al). 1999;18:587-95
Mentzer RM Jr (*see* Taylor et al). 1999;18:336-45
Mentzer SJ (*see* Moy et al). 1999;18:986-93
Mesiano G (*see* Lands et al). 1999;18:113-19 (Abstract)

Mettauer B (*see* Zoll et al). 1999;18:71 (Abstract)
Meuchal JM (*see* Atkines et al). 1999;18:1173–80
Meuchel JM (*see* Atkins et al). 1999;18:43 (Abstract)
Meyer DM (*see* Novick et al). 1999;18:425–31
Meyer KC (*see* Love et al). 1999;18:87 (Abstract)
Michaels MG (*see* Webber et al). 1999;18:83 (Abstract)
Michalski M (*see* Onsager et al). 1999;18:448–54
Milani R (*see* Mehra et al). 1999;18:76 (Abstract)
Miller L (*see* Keogh et al). 1999;18:53 (Abstract)
Miller LW (*see* Kirklin et al). 1999;18:47 (Abstract)
Miller LW (*see* Lake et al). 1999;18:81 (Abstract)
Miller SA (*see* Robinson et al). 1999;18:786–90
Miller SA (*see* Webber et al). 1999;18:83 (Abstract)
Milstone AP (*see* Ely et al). 1999;18:55–56 (Abstract)
Minai OA, Maurer JR, Kesten S. Comorbidities in end-stage lung disease. 1999;18:891–900
Miralles AP (*see* Palmer et al). 1999;18:51 (Abstract)
Mist BA (*see* Bainbridge et al). 1999;18:407–12
Mittlböck M (*see* Moidl et al). 1999;18:194–200
Miyagawa S (*see* Kobayashi et al). 1999;18:66 (Abstract)
Modak S (*see* Ankersmit et al). 1999;18:56 (Abstract)
Modak SM (*see* Choi et al). 1999;18:1103–10
Mohanakumar T (*see* Reznik et al). 1999;18:68 (Abstract)
Mohanakumar T (*see* Smith et al). 1999;18:51 (Abstract)
Mohara J (*see* Oshima et al). 1999;18:852–61
Mohara J, Morishita Y, Takahashi T, Oshima K, Yamagishi T, Takeyoshi I, Matsumoto K. A comparative study of Celsior and University of Wisconsin solutions based on 12-Hr preservation followed by transplantation in canine solutions. 1999;18:1202–10
Mohara J, Takahashi T, Oshima K, Yamagishi T, Koyano T, Takeyoshi I, Ishikawa S, Matsumoto K, Morishita Y. A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models. 1999;18:39 (Abstract)
Moidl R (*see* Mallinger et al). 1999;18:77 (Abstract)
Moidl R, Chevtchik O, Simon P, Grimm M, Wieselthaler G, Ullrich R, Mittlböck M, Wolner E, Laufer G. Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection. 1999;18:194–200
Moldovan NI (*see* Wang et al). 1999;18:48–49 (Abstract)
Möller F (*see* Hirt et al). 1999;18:542–48
Mollnes TE (*see* Fiane et al). 1999;18:66 (Abstract)
Moore CH (*see* Farrar et al). 1999;18:62–63 (Abstract)
Moore JS (*see* McLean et al). 1999;18:68 (Abstract)
Moore S (*see* Marelli et al). 1999;18:87 (Abstract)
Morales DLS (*see* Helman et al). 1999;18:89 (Abstract)
Morales DLS (*see* Williams et al). 1999;18:44 (Abstract)
Morales JM (*see* Delgado et al). 1999;18:607–10
Moravec CS (*see* DiIulio et al). 1999;18:89–90 (Abstract)
Moravec CS (*see* Ogletree-Hughes et al). 1999;18:63 (Abstract)
Moreno-Cabral (*see* Kaufman et al). 1999;18:1018–20
Moriguchi J (*see* Chait et al). 1999;18:58 (Abstract)
Moriguchi J (*see* Marelli et al). 1999;18:87 (Abstract)
Moriguchi JD (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)
Moriguchi JD, Kobashigawa JA, Ro TK, Hamilton MA, Hage A, Kawata N, Laks H. Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients. 1999;18:76 (Abstract)
Morishita Y (*see* Mohara et al). 1999;18:39 (Abstract)
Morishita Y (*see* Mohara et al). 1999;18:1202–10
Morishita Y (*see* Oshima et al). 1999;18:852–61
Morishita Y (*see* Takahashi et al). 1999;18:285–91
Morishita Y (*see* Tomizawa et al). 1999;18:637–44
Moroney DA (*see* McBride et al). 1999;18:90 (Abstract)
Morrison K (*see* Raisky et al). 1999;18:61 (Abstract)
Morris R (*see* Doyle et al). 1999;18:86 (Abstract)
Morris RE (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59–60 (Abstract)
Morris RE (*see* Briffa et al). 1999;18:66 (Abstract)
Morris RE (*see* Gummert et al). 1999;18:53–54 (Abstract), 1999;18:72 (Abstract)
Morris RE (*see* Hausen et al). 1999;18:73 (Abstract), 1999;18:79–80 (Abstract), 1999;18:150–58, 1999;18:714–24
Morris RE (*see* Ikonen et al). 1999;18:60 (Abstract), 1999;18:72 (Abstract)–1999;18:73 (Abstract)
Morris RE (*see* Slauson et al). 1999;18:1251–52 (Letter)
Morris RE (*see* Wan et al). 1999;18:90 (Abstract)
Morrow RW (*see* Boucek et al). 1999;18:460–69
Morrow WR (*see* Bernstein et al). 1999;18:69 (Abstract)
Morrow WR (*see* Frazier et al). 1999;18:69–70 (Abstract)
Morrow WR (*see* Webber et al). 1999;18:69 (Abstract)
Mortara A (*see* Raczak et al). 1999;18:399–405
Morton JM, McKenna MJ, Carey MF, Fraser SF, Parkin JA, Snell G, Rabinov M, Smith JA, Esmore DS, Williams TJ. Reductions in type 1 fibre proportions and oxidative enzyme activity in skeletal muscle exist pre & post lung transplantation. 1999;18:52 (Abstract)
Moscoloni SE, Barmak A, Perrone SV, Favaloro RR. Psychological evaluation as a prognostic factor among patients candidates for cardiac transplantation. 1999;18:58 (Abstract)
Moskowitz WB (*see* Donofrio et al). 1999;18:84 (Abstract)
Mottram PL, Han WR, Murray-Segal LJ, Pietersz GA. Anti-CD3: F(ab′)2-idarubicin conjugates prolong mouse cardiac allografts. 1999;18:94 (Abstract)
Mouas C (*see* Xiong et al). 1999;18:320–26
Moudgil A (*see* Ross et al). 1999;18:627–35
Mouras J (*see* Trainini et al). 1999;18:42–43 (Abstract)
Mourgeon E (*see* Cardella et al). 1999;18:88 (Abstract)
Moy ML, Loring SH, Ingenito EP, Mentzer SJ, Reilly JJ Jr. Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction. 1999;18:986–93
Mozdzierz G (*see* Lawless et al). 1999;18:38 (Abstract)
Mudra H (*see* Casella et al). 1143–46
Mudra H (*see* Klauss et al). 1999;18:50 (Abstract)
Mudra H (*see* Rieber et al). 1999;18:65 (Abstract)

Mudra H (*see* Spes et al). 1999;18:391-97
Muehlebach GF (*see* Borkon et al). 1999;18:668-73
Mueller EA (*see* Eisen et al). 1999;18:93 (Abstract)
Mulla N (*see* Webber et al). 1999;18:69 (Abstract)
Mullen GM (*see* Lawless et al). 1999;18:38 (Abstract)
Mullen GM (*see* Pisani et al). 1999;18:701-6
Mullen GM (*see* Rayburn et al). 1999;18:47 (Abstract)
Mullen GM, Malinowska K, Lawless CE, Pisani BA, Mendez JC, Robinson JA. Recipient weight as an independent risk factor in heart transplantation. 1999;18:92 (Abstract)
Müller C, Hoffman H, Reichenspurner H, Kur F, Fürst H. Comparison of Euro Collinsr- and low potassium dextran (Perfadexr)-solution in clinical lung preservation. 1999;18:40 (Abstract)
Müller H (*see* Grasser et al). 1999;18:80 (Abstract)
Müller J (*see* Wagner et al). 1999;18:89 (Abstract)
Müller J, Wallukat G, Dandel M, Bieda H, Hummel M, Hetzer R. Immunoglobulin adsorption as effective treatment of severe dilated cardiomyopathy. 1999;18:70-71 (Abstract)
Mulligan MS (*see* Iannettoni et al). 1999;18:86-87 (Abstract)
Mulligan MS, Warner RL, Bolling SF, Ward PA. Regulatory roles of chemokines in delayed cardiac xenograft rejection. 1999;18:59 (Abstract)
Mulligan MS, Whyte RI, Warner RL, Ward PA. The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB). 1999;18:88 (Abstract)
Mundy JA (*see* Keogh et al). 1999;18:67 (Abstract)
Mundy JA (*see* Spratt et al). 1999;18:42 (Abstract)
Munger TM (*see* Brilakis et al). 1999;18:376-80
Muñoz-Garcia J (*see* Gutiérrez-Carretero et al). 1999;18:372-75
Murali S (*see* Dew et al). 1999;18:549-59
Murali S (*see* Stanford et al). 1999;18:58 (Abstract)
Murali S (*see* Tagusari et al). 1999;18:1111-19
Murday AJ (*see* Anyanwu et al). 1999;18:37-38 (Abstract), 1999;18:51 (Abstract)
Murday AJ (*see* Takahashi et al). 1999;18:297-303
Murphy D (*see* Bando et al). 1999;18:70 (Abstract)
Murray-Segal LJ (*see* Mottram et al). 1999;18:94 (Abstract)
Mussivand T, Hendry PJ, Masters RG, Keon WJ. Development of a ventricular assist device for out-of-hospital use. 1999;18:166-71
Mu Y (*see* Crawford et al). 1999;18:470-76
Myers JL (*see* Robinson et al). 1999;18:786-90
Myers JN, Shabshab SF, Burton NA, Nathan SD. Successful use of cyclosporine in a lung transplant recipient with Tacrolimus-associated hemolytic uremic syndrome. 1999;18:1024-26
Myles M (*see* Lawless et al). 1999;18:38 (Abstract)

N

Naftel D (*see* Boucek et al). 1999;18:460-69
Naftel D (*see* Grady et al). 1999;18:750-60
Naftel DC (*see* Bernstein et al). 1999;18:69 (Abstract)
Naftel DC (*see* Frazier et al). 1999;18:69-70 (Abstract)
Naftel DC (*see* Jaski et al). 1999;18:37 (Abstract)
Naftel DC (*see* Kirklin et al). 1999;18:47 (Abstract)
Naftel DC (*see* Webber et al). 1999;18:69 (Abstract)
Nägele H, Bahlo M, Klapdor R, Rödiger W. Tumor marker determination after orthotopic heart transplantation. 1999;18:957-62
Nägele H, Rödiger W. Sudden death and tailored medical therapy in elective candidates for heart transplantation. 1999;18:869-75
Narrod JA (*see* Farrar et al). 1999;18:62-63 (Abstract)
Nathan SD (*see* Myers et al). 1999;18:1024-26
Nederhoff MGJ (*see* Bruinsma et al). 1999;18:1189-97
Nelson DP (*see* Pietra et al). 1999;18:48 (Abstract)
Newmark R (*see* Doyle et al). 1999;18:86 (Abstract)
Newmark RD (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59-60 (Abstract)
Nguyen D (*see* Park et al). 1999;18:60 (Abstract)
Nguyen DQ, Das GS, Grubbs BC, Bolman RM III, Park SJ. Transcatheter closure of patent foramen ovale for hypoxemia during left ventricular assist device support. 1999;18:1021-23
Nguyen DQ, Kulick DM, Bolman RM III, Park SJ. Temporary ECMO support following lung and heart-lung transplantation. 1999;18:55 (Abstract)
Nichols T (*see* Lau et al). 1999;18:65 (Abstract)
Niedermeyer J (*see* Harringer et al). 1999;18:56 (Abstract)
Niesters HGM (*see* de Groot-Kruseman et al). 1999;18:52 (Abstract)
Nimmesgern E (*see* Gummert et al). 1999;18:72 (Abstract)
Nishimura M (*see* Kobayashi et al). 1999;18:66 (Abstract)
Nishimura M, Ohtake S, Sawa Y, Fukushima N, Yamaguchi T, Matsuda H. Inflammatory cytokines and hepatic sinusoid endothelial dysfunction play a role in hyperbilirubinemia in patients following implantation of an LVAS. 1999;18:57 (Abstract)
Novick RJ (*see* Boucek et al). 1999;18:1151-72 (Registry)
Novick RJ (*see* Del Rizzo et al). 1999;18:310-19
Novick RJ (*see* Hosenpud et al). 1999;18:611-26 (Abstract)
Novick RJ, Bennett LE, Meyer DM, Hosenpud JD. Influence of graft ischemic time and donor age on survival after lung transplantation. 1999;18:425-31
Novick RJ, Bennett LE, Quantz M. Influence of HLA matching on survival and development of obliterative bronchiolitis (OB) after lung transplantation. 1999;18:50-51 (Abstract)
Nozynski J (*see* Wojnicz et al). 1999;18:40 (Abstract)
Nyborg NCB (*see* Kevelaitis et al). 1999;18:239-46

O

Obadia JF (*see* Raisky et al). 1999;18:61 (Abstract)
O'Brien G, Criner GJ. Mechanical ventilation as a bridge to lung transplantation. 1999;18:255-63
Ochs M (*see* Wittwer et al). 1999;18:684-91
Odegaard P (*see* Radovancevic et al). 1999;18:63 (Abstract)

Oei F (*see* Welters et al). 1999;18:53 (Abstract)
Ofner P (*see* Zuckermann et al). 1999;18:93 (Abstract)
Ogawa T (*see* Tomizawa et al). 1999;18:637–44
Ogle CK (*see* Gibson et al). 1999;18:185–88
Ogletree-Hughes ML, Barrett-Stull L, Smedira NG, McCarthy PM, Moravec CS. Mechanical unloading restores beta-adrenergic responsiveness in the failing human heart. 1999;18:63 (Abstract)
O'Hair DP (*see* Schulman et al). 1999;18:107–12
Ohayon E (*see* Dambrin et al). 1999;18:524–30
Ohtake S (*see* Kobayashi et al). 1999;18:66 (Abstract)
Ohtake S (*see* Nishimura et al). 1999;18:57 (Abstract)
Ohwada S (*see* Tomizawa et al). 1999;18:637–44
Ohya T (*see* Tomizawa et al). 1999;18:637–44
Okada Y (*see* Bando et al). 1999;18:70 (Abstract)
Okada Y (*see* Flaspohler et al). 1999;18:91 (Abstract)
Oleszak EL (*see* Agelan et al). 1999;18:40 (Abstract)
Oleszak EL (*see* Xu et al). 1999;18:90 (Abstract)
Oliva F (*see* Gronda et al). 1999;18:654–61
Oliva F, Andreuzzi B, Comerio G, Barosi A, Masciocco G, Frigerio M, Mangiavacchi M, Gronda E. Outpatient inotropic therapy in refractory heart failure. 1999;18:75 (Abstract)
Olmos JJ (*see* Weill et al). 1999;18:55 (Abstract)
Olmos JJ (*see* Weill et al). 1999;18:1080–87
Olmos JJ (*see* Zamora et al). 1999;18:81 (Abstract)
Olson K (*see* Ankersmit et al). 1999;18:56 (Abstract)
Olson LJ (*see* Brilakis et al). 1999;18:43–44 (Abstract)
Ongcharit P (*see* Tsui et al). 1999;18:78–79 (Abstract)
Ongcharit P, Eiskjaer H, Fecchia M, Taylor G, Dunning J, Mcneil K, Parameshwar J, Wallwork J, Large SR. Domino heart transplantation: 10 years experience. 1999;18:37 (Abstract)
Ono K (*see* Wada et al). 1999;18:499–508
Onsager DR, Canver CC, Jahania MS, Welter D, Michalski M, Hoffman AM, Mentzer RM Jr, Love RB. Efficacy of Tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. 1999;18:448–54
Onwu N, Watson CJ, Roberts IS, Roberts TE, Brenchley PEC. Early mediators of lung ischaemia-reperfusion injury. 1999;18:74 (Abstract)
Opitz CF (*see* Wensel et al). 1999;18:877–82
Oppelt P (*see* Pethig et al). 1999;18:77–78 (Abstract)
Ordóñez-Fernández A (*see* Gutiérrez-Carretero et al). 1999;18:372–75
Orens J (*see* Sonett et al). 1999;18:84 (Abstract)
Orens JB (*see* Conte et al). 1999;18:796–99
Orr H (*see* Sudarshan et al). 1999;18:78 (Abstract)
Orringer MB (*see* Iannettoni et al). 1999;18:86–87 (Abstract)
Orsida B (*see* Gabbay et al). 1999;18:51 (Abstract)
Orsida BE (*see* Zheng et al). 1999;18:231–37
Orsmond GS (*see* Shaddy et al). 1999;18:269–74
Orús J (*see* Roig et al). 1999;18:91 (Abstract)
Oshima K (*see* Mohara et al). 1999;18:39 (Abstract)
Oshima K (*see* Mohara et al). 1999;18:1202–10
Oshima K (*see* Takahashi et al). 1999;18:285–91
Oshima K, Morishita Y, Yamagishi T, Mohara J, Takahashi T, Hasegawa Y, Ishikawa S, Matsumoto K. Long-term heart preservation using a new portable hypothermic perfusion apparatus. 1999;18:852–61
Ostrowski L (*see* McCurry et al). 1999;18:72 (Abstract)
Oubenaïssa A (*see* Xiong et al). 1999;18:320–26
Ozenci M (*see* Scott et al). 1999;18:39 (Abstract)
Oz M (*see* Ankersmit et al). 1999;18:56 (Abstract)
Oz M (*see* Maybaum et al). 1999;18:44 (Abstract), 1999;18:62 (Abstract)
Oz MC (*see* Argenziano et al). 1999;18:814–17
Oz MC (*see* Chen et al). 1999;18:351–57
Oz MC (*see* Choi et al). 1999;18:1103–10
Oz MC (*see* Helman et al). 1999;18:89 (Abstract)
Oz MC (*see* Williams et al). 1999;18:44 (Abstract)

P

Pacher R (*see* Berger et al). 1999;18:47 (Abstract), 1999;18:75 (Abstract)
Pacher R (*see* Stanek et al). 1999;18:358–65
Pagani FD (*see* Aaronson et al). 1999;18:80 (Abstract)
Pagano D, Lewis ME, Townend JN, Camici PG, Bonser RS. Revascularisation for post-ischaemic heart failure: how myocardial viability affects survival. 1999;18:67 (Abstract)
Pahl E (*see* Boucek et al). 1999;18:460–69
Pahl E (*see* Ringewald et al). 1999;18:70 (Abstract)
Pahl E (*see* Shaddy et al). 1999;18:269–74
Pahl E, Crawford SE, Swenson JM, Duffy CE, Fricker FJ, Backer CL, Mavroudis C, Chaudhry FA. Dobutamine stress echocardiography: experience in pediatric heart transplant recipients. 1999;18:725–32
Palmer SM, Steele MP, Miralles AP, Lawrence CM, Petersen A, D'Amico TA, David RD, Tapson VF. Gastroesophageal reflux is an important cause of allograft dysfunction in lung transplant recipients. 1999;18:51 (Abstract)
Pamboukian SV, Carere RG, Webb JG, Cook RC, D'yachkova Y, Abel JG, Ignaszewski AP. The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension. 1999;18:367–70
Pampin-Conde MF (*see* Vazquez-Rodriguez et al). 1999;18:172
Panagiotis T (*see* Sartori et al). 1999;18:693–99 (Abstract)
Papalia U (*see* Voci et al). 1999;18:921–23
Paramesh V (*see* Arabia et al). 1999;18:89 (Abstract)
Parameshwar J (*see* Bainbridge et al). 1999;18:407–12
Parameshwar J (*see* Ongcharit et al). 1999;18:37 (Abstract)
Parameshwar J (*see* Trull et al). 1999;18:93 (Abstract)
Parameshwar J (*see* Wreghitt et al). 1999;18:82 (Abstract)
Paré C (*see* Roig et al). 1999;18:91 (Abstract)
Parisi F, Squitieri C, Carotti A, Abbatista AD, Cicini MP, Esu F, Catena G. Ten-year follow-up after pediatric transplantation. 1999;18:275–77
Park A (*see* Feeley et al). 1999;18:48 (Abstract)
Park AK (*see* Feeley et al). 1999;18:1088–95
Parker J (*see* Webber et al). 1999;18:69 (Abstract)
Parker S (*see* Cook et al). 1999;18:420–24

Parker W (*see* Lau et al). 1999;18:65-66 (Abstract)
Parkes K (*see* Rooney et al). 1999;18:73 (Abstract)
Park H-J (*see* Flaspohler et al). 1999;18:91 (Abstract)
Park HJ (*see* Bando et al). 1999;18:70 (Abstract)
Parkin JA (*see* Morton et al). 1999;18:52 (Abstract)
Park M (*see* Mehra et al). 1999;18:49 (Abstract)
Park MH (*see* Pathak et al). 1999;18:43 (Abstract)
Park MH (*see* Scott et al). 1999;18:39 (Abstract)
Park MH, Pathak A, Starling RC, Young JB. Failure to wean from parenteral inotropes: a strong predictor for early mortality among patients with end stage heart disease. 1999;18:47-48 (Abstract)
Park MH, Starling RC, Ratliff NB, McCarthy PM, Smedira NS, Pelegrin D, Young JB. Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection. 1999;18:1224-27
Park SJ (*see* Bolman et al). 1999;18:55 (Abstract)
Park SJ (*see* Kulick et al). 1999;18:65 (Abstract)
Park SJ (*see* Nguyen et al). 1999;18:55 (Abstract), 1999; 18:1021-23
Park SJ, Nguyen D, Savik K, Dunitz J, Hertz M, Bolman RM III. Decreased survival associated with size mis-matching in lung transplantation. 1999;18:60 (Abstract)
Parmar K (*see* Hunt et al). 1999;18:43 (Abstract)
Parmley WW (*see* Schwitter et al). 1999;18:1003-13
Parrinello G (*see* Cargnoni et al). 1999;18:478-86
Parry A, Higgins R, Wheeldon D, Bethune D, Wallwork J. The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function. 1999;18:121-25
Parry N, Lazarovits AI, Wang J, Garcia B, Luke P, Poppema S, Zhong R. Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB. 1999;18:441-46
Partovi N, Fradet G, Connors JM, Ahmed D, Kepron W, Lien D, Poirier C, Shennib H, Levy RD. Post-transplant lymphoproliferative disease (PTLD) following lung transplantation in Canadian transplant centers. 1999; 18:85 (Abstract)
Pathak A (*see* Park et al). 1999;18:47-48 (Abstract)
Pathak A, Park MH, Starling RC, Young JB. Hemodynamic guided inotropic tailoring does not appear to impact long term survival among patients requiring chronic home inotropic therapy. 1999;18:43 (Abstract)
Patterson GA (*see* Reznik et al). 1999;18:68 (Abstract)
Patterson GA (*see* Smith et al). 1999;18:51 (Abstract)
Paulus D (*see* Meiser et al). 1999;18:143-48
Paulus D (*see* Schmidt et al). 1999;18:46 (Abstract)
Pavlakis M (*see* Zeevi et al). 1999;18:81-82 (Abstract)
Peacock WF, Albert NM. Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU). 1999;18:92 (Abstract)
Pediatric Heart Transplant Study (*see* Frazier et al). 1999; 18:69-70 (Abstract)
Pediatric Heart Transplant Study (*see* Webber et al). 1999;18:69 (Abstract)
Pediatric Heart Transplant Study Group (*see* Bernstein et al). 1999;18:69 (Abstract)
Pehlivanli S (*see* Weis et al). 1999;18:50 (Abstract), 1999; 18:64 (Abstract)
Pehlivanli S (*see* Wildhirt et al). 1999;18:64-65 (Abstract)
Pelegrin D (*see* Park et al). 1999;18:1224-27
Pellegrin A (*see* Gronda et al). 1999;18:654-61
Pellerin M (*see* Carrier et al). 1999;18:664-67
Pellerin M (*see* Carrier et al). 1999;18:1218-23
Pelletier GB (*see* Carrier et al). 1999;18:1218-23
Pelletier LC (*see* Carrier et al). 1999;18:664-67
Pelletier LC (*see* Carrier et al). 1999;18:1218-23
Pennington JJ, Wright L. Evaluation of a mentorship programme for heart transplant patients. 1999;18:91 (Abstract)
Penson MG, Winter WE, Fricker FJ, Harker K, Kahler DA, Kubilis PS, Schowengerdt KO. Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients. 1999;18: 707-12
Perez J, Yu J, Song P, Stepkowski S, Kahan BD. Soluble rat class I MHC proteins induce prolonged survival of rat cardiac allografts. 1999;18:68 (Abstract)
Pérez-Villa F (*see* Roig et al). 1999;18:91 (Abstract)
Pernes JM (*see* Aptecar et al). 1999;18:64 (Abstract)
Perrault LP (*see* Carrier et al). 1999;18:664-67
Perrault LP (*see* Carrier et al). 1999;18:1218-23
Perrone SV (*see* Moscoloni et al). 1999;18:58 (Abstract)
Persijn GG (*see* De Meester et al). 1999;18:563-71
Peserico A (*see* Belloni et al). 1999;18:77 (Abstract)
Peteiro-Cartelle J (*see* Vazquez-Rodriguez et al). 1999;18: 172
Petersen A (*see* Palmer et al). 1999;18:51 (Abstract)
Pethig K (*see* Fraund et al). 1999;18:220-24
Pethig K (*see* Klauss et al). 1999;18:50 (Abstract)
Pethig K (*see* Teebken et al). 1999;18:807-9
Pethig K (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Pethig K, Hoffmann A, Heublein B, Haverich A. Genetic polymorphism of transforming growth factor-β (CODON 25) and development of cardiac allograft vascular disease. 1999;18:52 (Abstract)
Pethig K, Wahlers Th, Heublein B, Dannenberg O, Oppelt P, Haverich A. Mycophenolate Mofetil for secondary prevention of allograft vasculopathy following heart transplantation: a prospective; randomized; intravascular ultrasound controlled trial. 1999;18:77-78 (Abstract)
Petitclerc R (*see* Carrier et al). 1999;18:664-67
Petterson G (*see* Svendsen et al). 1999;18:388-89
Petutschnigg P (*see* Grasser et al). 1999;18:80 (Abstract)
Petzold DR (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Pfeiffer M (*see* Meiser et al). 1999;18:78 (Abstract), 1999; 18:143-48
Pfeiffer M (*see* Schmidt et al). 1999;18:46 (Abstract)
Pfeiffer S (*see* Wagner et al). 1999;18:74 (Abstract)
Pfitzmann R (*see* Waurick et al). 1999;18:1243-45
Pflugfelder PW (*see* Del Rizzo et al). 1999;18:310-19
Pham SI (*see* McCurry et al). 1999;18:72 (Abstract)

Pham SM (*see* Kawaharada et al). 1999;18:532–40
Pham SM (*see* Tagusari et al). 1999;18:1111–19
Pham Y (*see* Wang et al). 1999;18:48 (Abstract)
Phelan D (*see* Ibrahim et al). 1999;18:83 (Abstract)
Phelan DL (*see* Smith et al). 1999;18:51 (Abstract)
Phelps ME (*see* Allen-Auerbach et al). 1999;18:211–18
Piaserico S (*see* Belloni et al). 1999;18:77 (Abstract)
Pichlmayer E (*see* Klauss et al). 1999;18:50 (Abstract)
Pieraggi MT (*see* Dambrin et al). 1999;18:946–51
Pierson RN III (*see* Blair et al). 1999;18:54 (Abstract)
Pierson RN III (*see* Ely et al). 1999;18:55–56 (Abstract)
Pietersz GA (*see* Mottram et al). 1999;18:94 (Abstract)
Pietra BA, Gill RG, Wiseman A, Rizeq M, Robbins J, Boucek MM, Nelson DP. CD4 T cell mediated rejection of cardiac allograft is FAS/FASL sensitive. 1999;18:48 (Abstract)
Pigula F (*see* Webber et al). 1999;18:83 (Abstract)
Pillarisetty VG (*see* Choi et al). 1999;18:1103–10
Piña I (*see* Jaski et al). 1999;18:1031–40
Pinchas A (*see* Ben-Gal et al). 1999;18:75–76 (Abstract)
Pinna GD (*see* Raczak et al). 1999;18:399–405
Pinski SL, Bredikis AJ, Winkel E, Trohman RG. Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus. 1999;18:292–96
Pins MR (*see* Mawulawde et al). 1999;18:53 (Abstract)
Pisani BA (*see* Mullen et al). 1999;18:92 (Abstract)
Pisani BA, Mullen GM, Malinowska K, Lawless CE, Mendez J, Silver MA, Radvany R, Robinson JA. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation. 1999;18:701–6
Pitts D (*see* Grady et al). 1999;18:750–60
Planas A, Ussetti P, Varela A, Abejón D, Gómez-Nieto J, Tejada J, Carreño MC. Inhaled nitric oxide in early severe allograft lung dysfunction. 1999;18:55 (Abstract)
Platsoucas CD (*see* Agelan et al). 1999;18:40 (Abstract)
Platsoucas CD (*see* McGurl et al). 1999;18:93 (Abstract)
Platsoucas CD (*see* Slachta et al). 1999;18:41 (Abstract), 1999;18:60 (Abstract)
Platsoucas CD (*see* Xu et al). 1999;18:90 (Abstract)
Platt JL (*see* Lau et al). 1999;18:65 (Abstract), 1999;18:65–66 (Abstract)
Plenz G (*see* Baba et al). 1999;18:57 (Abstract), 1999;18:963–71
Plenz G, Baba HA, Erren M, Scheld HH, Deng MC. Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome. 1999;18:923–24 (Letter)
Plummer M (*see* Khanna et al). 1999;18:49 (Abstract)
Podesser B (*see* Laufer et al). 1999;18:94 (Abstract)
Poirier C (*see* Brazelton et al). 1999;18:59 (Abstract)
Poirier C (*see* Doyle et al). 1999;18:86 (Abstract)
Poirier C (*see* Partovi et al). 1999;18:85 (Abstract)
Pongratz D (*see* Behr et al). 1999;18:904–11
Popma SH (*see* Krasinskas et al). 1999;18:88 (Abstract)
Popma SH (*see* McLean et al). 1999;18:68 (Abstract)
Poppema S (*see* Parry et al). 1999;18:441–46
Porter CB (*see* Borkon et al). 1999;18:668–73
Portner PM (*see* Hunt et al). 1999;18:43 (Abstract)
Portner PM (*see* Jansen et al). 1999;18:67–68 (Abstract)
Portner PM (*see* Kormos et al). 1999;18:63 (Abstract)
Postma DS (*see* van den Berg et al). 1999;18:85 (Abstract)
Poston RS (*see* Ennen et al). 1999;18:49 (Abstract)
Potier JC (*see* Agostini et al). 1999;18:47 (Abstract)
Prasad A (*see* Mehra et al). 1999;18:49 (Abstract)
Prati F (*see* Rieber et al). 1999;18:65 (Abstract)
Pratschke J (*see* Wilhelm et al). 1999;18:68 (Abstract)
Prenner G (*see* Grasser et al). 1999;18:80 (Abstract)
Price LL (*see* Hoercher et al). 1999;18:45 (Abstract)
Pritzker MR (*see* Lake et al). 1999;18:81 (Abstract)
Prpa A (*see* Raczak et al). 1999;18:399–405
Przybylowski P (*see* Kerman et al). 1999;18:38 (Abstract)
Pulkkinen VP (*see* Sihvola et al). 1999;18:61–62 (Abstract)

Q

Qian QH (*see* Blair et al). 1999;18:54 (Abstract)
Quagebeur J (*see* Helman et al). 1999;18:89 (Abstract)
Quaini E (*see* Gronda et al). 1999;18:654–61
Quantz M (*see* Novick et al). 1999;18:50–51 (Abstract)
Qu L (*see* Webber et al). 1999;18:83 (Abstract)

R

Rabinovitch M. Pulmonary hypertension: pathophysiology as a basis for clinical decision making. 1999;18:1041–53
Rabinov M (*see* Morton et al). 1999;18:52 (Abstract)
Rabkin DG, Jia C-X, Spotnitz HM. Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft. 1999;18:775–80
Raczak G, La Rovere MT, Mortara A, Assandri J, Prpa A, Pinna GD, Maestri R, D'Armini AM, Viganó M, Cobelli F. Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation. 1999;18:399–405
Radley-Smith R (*see* Wray et al). 1999;18:57 (Abstract)
Radley-Smith R, Khaghani A, Yacoub M. Medium term results of children with two hearts. 1999;18:84 (Abstract)
Radovancevic B (*see* Kerman et al). 1999;18:38 (Abstract)
Radovancevic B (*see* Taylor et al). 1999;18:336–45
Radovancevic B, Golino A, Thomas C, Odegaard P, Radovancevic R, Frazier OH. Is the use of left ventricular assist device as a bridge to heart transplantation a risk factor for development of transplant coronary artery disease?. 1999;18:63 (Abstract)
Radovancevic R (*see* Radovancevic et al). 1999;18:63 (Abstract)
Radvany R (*see* Pisani et al). 1999;18:701–6
Raftery MJ (*see* Dengler et al). 1999;18:61 (Abstract)
Rahman A (*see* Aziz et al). 1999;18:37 (Abstract)
Rahman A (*see* El-Gamel et al). 1999;18:828–35
Rahman AH (*see* El-Gamel et al). 1999;18:517–22
Rahman AN (*see* Burgess et al). 1999;18:44–45 (Abstract)
Räisänen-Sokolowski A, Glysing-Jensen T, Russell ME. Donor and recipient contribution of ICAM-1 and P-selectin

in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice. 1999;18:735-43
Räisänen-Sokolowski AK, Glysing-Jensen T, Russell ME. Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice. 1999;18:61 (Abstract)
Raisky O, Morrison K, Obadia JF, Yacoub MH, Rose ML. Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin. 1999;18:61 (Abstract)
Ramasamy D (*see* Fedalen et al). 1999;18:56-57 (Abstract)
Ramasamy N (*see* Kormos et al). 1999;18:63 (Abstract)
Rambusch EG (*see* Wedemeyer et al). 1999;18:81 (Abstract)
Ramwell PW (*see* Saito et al). 1999;18:937-45
Rao A (*see* McCurry et al). 1999;18:72 (Abstract)
Rapkin A (*see* Eisenring et al). 1999;18:58-59 (Abstract)
Raspovic S (*see* Cook et al). 1999;18:38 (Abstract)
Ratliff NB (*see* Park et al). 1999;18:1224-27
Rayburn B (*see* Grady et al). 1999;18:750-60
Rayburn BK, Rodeheffer RJ, Young JB, Mullen GM, Torre G, Tolman DE, Gibbons RJ, Brown RN, Bourge RC, Kirklin JK. Prognostic value of the relative lymphocyte concentration and white blood cell count in heart failure. 1999;18:47 (Abstract)
Ray SG (*see* Burgess et al). 1999;18:44-45 (Abstract)
Razzouk AJ (*see* Dearani et al). 1999;18:70 (Abstract)
Reed WA (*see* Borkon et al). 1999;18:668-73
Rees PG (*see* Gassas et al). 1999;18:83 (Abstract)
Reichart B (*see* Brenner et al). 1999;18:59 (Abstract)
Reichart B (*see* Brenner et al). 1999;18:1211-17
Reichart B (*see* Klauss et al). 1999;18:50 (Abstract)
Reichart B (*see* Kur et al). 1999;18:93 (Abstract)
Reichart B (*see* Meiser et al). 1999;18:78 (Abstract), 1999;18:143-48
Reichart B (*see* Rieber et al). 1999;18:65 (Abstract)
Reichart B (*see* Schmidt et al). 1999;18:46 (Abstract)
Reichart B (*see* Schwaiblmair et al). 1999;18:838-44
Reichart B (*see* Spes et al). 1999;18:391-97
Reichart B (*see* Wildhirt et al). 1999;18:40 (Abstract), 1999;18:64-65 (Abstract)
Reichenspurner H (*see* Brenner et al). 1999;18:59 (Abstract)
Reichenspurner H (*see* Brenner et al). 1999;18:1211-17
Reichenspurner H (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Reichenspurner H (*see* Kur et al). 1999;18:93 (Abstract)
Reichenspurner H (*see* Meiser et al). 1999;18:78 (Abstract), 1999;18:143-48
Reichenspurner H (*see* Müller et al). 1999;18:40 (Abstract)
Reichenspurner H (*see* Schmidt et al). 1999;18:46 (Abstract)
Reichenspurner H (*see* Wildhirt et al). 1999;18:64-65 (Abstract)
Reilly JJ Jr. (*see* Moy et al). 1999;18:986-93
Reiter C (*see* Behr et al). 1999;18:904-11
Reitz B (*see* Doyle et al). 1999;18:86 (Abstract)
Reitz BA (*see* Brazelton et al). 1999;18:59 (Abstract)
Reitz BA (*see* Valantine et al). 1999;18:81 (Abstract)
Renlund D (*see* Keogh et al). 1999;18:53 (Abstract)
Renlund DE (*see* Lake et al). 1999;18:81 (Abstract)
Renlund DG (*see* McKellar et al). 1999;18:57 (Abstract)
Renlund DG (*see* Stringham et al). 1999;18:160-65
Renlund DG (*see* Taylor et al). 1999;18:336-45
Renlund DG, Taylor DO, Kfoury AG, Shaddy RS. New UNOS rules: historical background and implications for transplantation management. 1999;18:1065-70
Revell M (*see* Rooney et al). 1999;18:73 (Abstract)
Reznik SI, Jaramillo A, Patterson GA, Cooper JD, Mohanakumar T. Indirect allorecognition of HLA class II allopeptides in lung allograft recipients. 1999;18:68 (Abstract)
Rice P (*see* Stamenkovic et al). 1999;18:1246-50
Richter J (*see* Wittwer et al). 1999;18:684-91
Richter K (*see* Behr et al). 1999;18:904-11
Ricordi C (*see* McGurl et al). 1999;18:93 (Abstract)
Rieber J (*see* Casella et al). 1143-46
Rieber J (*see* Klauss et al). 1999;18:50 (Abstract)
Rieber J (*see* Spes et al). 1999;18:391-97
Rieber J, Klauss V, Weber C, Prati F, Spes CH, Angermann CE, Reichart B, Theisen K, Mudra H. Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction. 1999;18:65 (Abstract)
Rieder G (*see* Weis et al). 1999;18:64 (Abstract)
Rieder G (*see* Weis et al). 1999;18:1071-79
Rifkin CJ (*see* Jonosono et al). 1999;18:972-85
Ringewald JM, Gidding SS, Wax DF, Crawford SE, Rodgers S, Shah SR, Pahl E, Backer CL, Mavroudis C. Non compliance causing late acute rejection in pediatric heart transplantation. 1999;18:70 (Abstract)
Rizeq M (*see* Pietra et al). 1999;18:48 (Abstract)
Robbins J (*see* Pietra et al). 1999;18:48 (Abstract)
Robbins RC (*see* Ennen et al). 1999;18:49 (Abstract)
Robbins RC (*see* Feeley et al). 1999;18:48 (Abstract)
Robbins RC (*see* Feeley et al). 1999;18:1088-95
Robbins RC (*see* Valantine et al). 1999;18:81 (Abstract)
Robert K (*see* Mannon et al). 1999;18:819-26
Roberts IS (*see* Onwu et al). 1999;18:74 (Abstract)
Roberts JR (*see* Ely et al). 1999;18:55-56 (Abstract)
Roberts M (*see* Bainbridge et al). 1999;18:407-12
Roberts RF (*see* Kim et al). 1999;18:74 (Abstract)
Roberts T (*see* Densem et al). 1999;18:52 (Abstract)
Roberts TE (*see* Onwu et al). 1999;18:74 (Abstract)
Robinson BV, Boyle GJ, Miller SA, Law YM, Myers JL, Griffith BP, Webber SA. Optimal dosing of intravenous Tacrolimus following pediatric heart transplantation. 1999;18:786-90
Robinson JA (*see* Mullen et al). 1999;18:92 (Abstract)
Robinson JA (*see* Pisani et al). 1999;18:701-6
Robitaille D (*see* Carrier et al). 1999;18:1218-23
Rodeheffer RJ (*see* Rayburn et al). 1999;18:47 (Abstract)
Rodgers S (*see* Ringewald et al). 1999;18:70 (Abstract)
Rodgers S, Rubovits S, Weil C, Stapleton P. Pediatric heart transplant school re-entry. 1999;18:58 (Abstract)
Rödiger W (*see* Nägele et al). 1999;18:869-75, 1999;18:957-62
Rödler S (*see* Stanek et al). 1999;18:358-65

Rodriguez E (*see* Delgado et al). 1999;18:607-10
Rogers CA (*see* Anyanwu et al). 1999;18:37-38 (Abstract), 1999;18:51 (Abstract), 1999;18:297-303
Rohit SA (*see* Saito et al). 1999;18:937-45
Roig E, Pérez-Villa F, Orús J, Paré C, Azqueta M, Filella X, Heras M, Sanz G. Prognostic value of circulating levels of interleukin-6 in patients with congestive heart failure. 1999;18:91 (Abstract)
Rooney SJ, Levine AJ, Parkes K, Revell M, Shimada I, Bonser RS. Differential time scale of fluid and solute permeability following hypothermic lung preservation. 1999;18:73 (Abstract)
Ro PS, Spray TL, Bridges ND. Outcome of infants listed for lung and heart/lung transplantation. 1999;18:1232-37
Ro PS, Spray TL, Bridges ND. Outcome of infants listed for lung or heart/lung transplantation. 1999;18:83 (Abstract)
Rose D (*see* Scott et al). 1999;18:39 (Abstract)
Rose EA (*see* Argenziano et al). 1999;18:814-17
Rose EA (*see* Williams et al). 1999;18:44 (Abstract)
Rose ML (*see* Raisky et al). 1999;18:61 (Abstract)
Rosengard BR (*see* Krasinskas et al). 1999;18:88 (Abstract)
Rosengard BR (*see* McLean et al). 1999;18:68 (Abstract)
Rosenthal DN (*see* Dubin et al). 1999;18:781-84
Ross DJ, Moudgil A, Bagga A, Toyoda M, Marchevsky AM, Kass RM, Jordan SC. Lung allograft dysfunction correlates with γ-interferon gene expression in bronchoalveolar lavage. 1999;18:627-35
Ross SD, Tribble CG, Linden J, Gangemi JJ, Lanpher BC, Wang AY, Kron IL. Selective adenosine-A_{2A} activation reduces lung reperfusion injury following transplantation. 1999;18:72 (Abstract), 1999;18:994-1002
Rostron AJ (*see* Wreghitt et al). 1999;18:82 (Abstract)
Roth LH (*see* Dew et al). 1999;18:549-59
Rothnie C (*see* Iwata et al). 1999;18:37 (Abstract)
Ro TK (*see* Kobashigawa et al). 1999;18:50 (Abstract), 1999;18:71 (Abstract)
Ro TK (*see* Moriguchi et al). 1999;18:76 (Abstract)
Roughan J (*see* Sudarshan et al). 1999;18:78 (Abstract)
Rowe D (*see* Webber et al). 1999;18:83 (Abstract)
Rowe SK (*see* Borkon et al). 1999;18:668-73
Rozek MM (*see* Wojnicz et al). 1999;18:40 (Abstract)
Rubovits S (*see* Rodgers et al). 1999;18:58 (Abstract)
Rudis R (*see* Skotzko et al). 1999;18:952-56
Ruigrok TJC (*see* Bruinsma et al). 1999;18:1189-97
Ruiz P (*see* Mannon et al). 1999;18:819-26
Russell ME (*see* Koglin et al). 1999;18:71 (Abstract)
Russell ME (*see* Räisänen-Sokolowski et al). 1999;18:61 (Abstract), 1999;18:735-43
Russman PL (*see* Aaronson et al). 1999;18:80 (Abstract)
Rutten FFH (*see* van Enckevort et al). 1999;18:496-97
Ryan US (*see* Kallio et al). 1999;18:52-53 (Abstract)

S

Sabouret P (*see* Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
Sachs DH (*see* Mawulawde et al). 1999;18:53 (Abstract)
Sachs DH (*see* Menard et al). 1999;18:71 (Abstract)
Sahar G (*see* Ben-Gal et al). 1999;18:75-76 (Abstract)
St. Geme JW III (*see* Hunstad et al). 1999;18:801-4
Sai S (*see* Iwata et al). 1999;18:37 (Abstract)
Saito S, Rohit SA, Lou H, Ramwell PW, Foegh ML. Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells. 1999;18:937-45
Sakaguchi T (*see* Kobayashi et al). 1999;18:66 (Abstract)
Sakkas LI (*see* Agelan et al). 1999;18:40 (Abstract)
Sakkas LI (*see* Xu et al). 1999;18:90 (Abstract)
Sakuma H (*see* Schwitter et al). 1999;18:1003-13
Salerno CT (*see* Kulick et al). 1999;18:65 (Abstract)
Salgar S (*see* McCurry et al). 1999;18:72 (Abstract)
Salim Roussouliéres A-L, Schnetzler B, Sabouret P, Delcourt A, Ghossoub J-J, Dorent R, Beigelman C, Gandjbakhch I. Hematoma of the interventricular septum following right ventricular endomyocardial biopsy for the detection of allograft rejection after heart transplantation. 1999;18:1147-50 (Letter)
Sampath LA (*see* Choi et al). 1999;18:1103-10
Sanchez H (*see* Zoll et al). 1999;18:71 (Abstract)
Sandera P (*see* Hillinger et al). 1999;18:74 (Abstract)
Sandur S, Gordon SM, Mehta AC, Maurer JR. Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation. 1999;18:810-13
Sangrigoli R (*see* Belland et al). 1999;18:54 (Abstract)
Sanz G (*see* Roig et al). 1999;18:91 (Abstract)
Sarai K (*see* Martin et al). 1999;18:597-605
Sara P (*see* Sartori et al). 1999;18:693-99
Sartori TM, Maurizio PG, Sara P, Ugolino L, Massimo F, Antonio G, Annalisa A, Panagiotis T. Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation. 1999;18:693-99
Sasaki S, Yasuda K, McCully JD, LoCicero J. Calcium channel blocker enhances lung preservation. 1999;18:127-32
Sasaki S, Yasuda K, McCully JD, LoCicero J. Does PGE_1 attenuate potassium-induced vasoconstriction in initial pulmonary artery flush on lung preservation?. 1999;18:139-42
Saunder A (*see* Baxter et al). 1999;18:769-73
Savik K (*see* Park et al). 1999;18:60 (Abstract)
Savin S (*see* Maybaum et al). 1999;18:44 (Abstract)
Sawa Y (*see* Kobayashi et al). 1999;18:66 (Abstract)
Sawa Y (*see* Nishimura et al). 1999;18:57 (Abstract)
Sayin T (*see* Scott et al). 1999;18:39 (Abstract)
Schaffellner S (*see* Grasser et al). 1999;18:80 (Abstract)
Schaff HV (*see* Cable et al). 1999;18:177-83
Schaldach M (*see* Grasser et al). 1999;18:80 (Abstract)
Scheld HH (*see* Asfour B et al). 1999;18:927-36
Scheld HH (*see* Baba et al). 1999;18:57 (Abstract)
Scheld HH (*see* Plenz et al). 1999;18:923-24 (Letter)
Schenkel FA (*see* Chan et al). 1999;18:85 (Abstract)
Schenkel FA (*see* Uppal et al). 1999;18:54 (Abstract)
Schieken RM (*see* Donofrio et al). 1999;18:84 (Abstract)
Schirmer J (*see* Schmidt et al). 1999;18:46 (Abstract)
Schlechta B (*see* Laufer et al). 1999;18:94 (Abstract)

Schmid C (*see* Baba et al). 1999;18:57 (Abstract)
Schmid KW (*see* Baba et al). 1999;18:57 (Abstract), 1999; 18:963-71
Schmid RA (*see* Hillinger et al). 1999;18:74 (Abstract)
Schmid RA (*see* Stammberger et al). 1999;18:74-75 (Abstract), 1999;18:79 (Abstract), 1999;18:862-67
Schmidt D (*see* Meiser et al). 1999;18:78 (Abstract), 1999;18:143-48
Schmidt D, Meiser BM, Pfeiffer M, Schirmer J, Reichanspurner H, Paulus D, Seidel D, Reichart B. MPA-dose adjustment based on trough levels-high and low dose pharmocokinetics in heart transplanted patients. 1999; 18:46 (Abstract)
Schmitt S (*see* Matsumiya et al). 1999;18:79 (Abstract)
Schmoeckel M (*see* Brenner et al). 1999;18:59 (Abstract)
Schmoekel M (*see* Brenner et al). 1999;18:1211-17
Schnaack SD (*see* Spes et al). 1999;18:391-97
Schneiter D (*see* Stammberger et al). 1999;18:862-67
Schnetzler B (*see* Salim Roussouliéres et al). 1999;18: 1147-50 (Letter)
Schnitzler P (*see* Kallinowski et al). 1999;18:190-93
Schöder H (*see* Allen-Auerbach et al). 1999;18:211-18
Schönrich G (*see* Dengler et al). 1999;18:61 (Abstract)
Schowengerdt KO (*see* Penson et al). 1999;18:707-12
Schreier G (*see* Grasser et al). 1999;18:80 (Abstract)
Schroeder J (*see* Kato et al). 1999;18:50 (Abstract)
Schubert F (*see* Wagner et al). 1999;18:74 (Abstract)
Schueler S (*see* Wagner et al). 1999;18:74 (Abstract)
Schulman LL, O'Hair DP, Cantu E, McGregor C, Ginsberg ME. Salvage by volume reduction of chronic allograft rejection in emphysema. 1999;18:107-12
Schulze C (*see* Weis et al). 1999;18:64 (Abstract)
Schulze C (*see* Weis et al). 1999;18:1071-79
Schulze C (*see* Wildhirt et al). 1999;18:40 (Abstract), 1999;18:64-65 (Abstract)
Schuster M (*see* Ankersmit et al). 1999;18:56 (Abstract)
Schuster N (*see* Williams et al). 1999;18:44 (Abstract)
Schwaiblmair M, von Scheidt W, Überfuhr P, Ziegler S, Schwaiger M, Reichart B, Vogelmeier C. Functional significance of cardiac reinnervation in heart transplant recipients. 1999;18:838-44
Schwaiger M (*see* Schwaiblmair et al). 1999;18:838-44
Schwarze ML (*see* Menard et al). 1999;18:71 (Abstract)
Schwitter J, DeMarco T, Globits S, Sakuma H, Klinski C, Chatterjee K, Parmley WW, Higgins CB. Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication. 1999; 18:1003-13
Sciaky M (*see* Bernard et al). 1999;18:572-80
Scott R (*see* Mehra et al). 1999;18:49 (Abstract)
Scott RL, Sayin T, Srigiri K, Rose D, McBride G, Ozenci M, Park MH, Mehra MR. Does time to harvest determine outcome in heart transplantation with older allografts?. 1999;18:39 (Abstract)
Sebening C (*see* Szabó et al). 1999;18:39 (Abstract)
Seelig R (*see* Kallinowski et al). 1999;18:190-93
Segarra IT (*see* Hausen et al). 1999;18:150-58
Seidel D (*see* Meiser et al). 1999;18:143-48
Seidel D (*see* Schmidt et al). 1999;18:46 (Abstract)
Seipp S (*see* Kallinowski et al). 1999;18:190-93
Senbaclavaci Ö (*see* Wisser et al). 1999;18:42 (Abstract), 1999;18:67 (Abstract)
Serkova N (*see* Ikonen et al). 1999;18:72 (Abstract)
Seta K, Song H, Downing SW, McLaughlin JS, Wei C. The actions of cyclosporine-A on apoptosis and p53 expression in human vascular smooth muscle cells. 1999;18:61 (Abstract)
Sethi GK (*see* Arabia et al). 1999;18:89 (Abstract)
Shabshab SF (*see* Myers et al). 1999;18:1024-26
Shaddy RE, Tani LY, Gidding SS, Pahl E, Orsmond GS, Gilbert EM, Lemes V. Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience. 1999;18:269-74
Shaddy RS (*see* Renlund et al). 1999;18:1065-70
Shah S (*see* Ankersmit et al). 1999;18:56 (Abstract)
Shah SR (*see* Ringewald et al). 1999;18:70 (Abstract)
Shannon WD (*see* Kruger et al). 1999;18:82 (Abstract)
Sharma PP, Marcus FI. Radiofrequency ablation of a concealed accessory pathway years after heart transplant: a case report. 1999;18:792-94
Sharples L (*see* Trull et al). 1999;18:93 (Abstract)
Sharp T (*see* Bando et al). 1999;18:70 (Abstract)
Sharp T (*see* Flaspohler et al). 1999;18:91 (Abstract)
Shaw LM (*see* DeNofrio et al). 1999;18:46 (Abstract)
Shears LL (*see* Kawaharada et al). 1999;18:532-40
Sheffield CD (*see* Smedira et al). 1999;18:44 (Abstract)
Sheffield CD, Smedira NG, Hoercher K, Goormastic M, McCarthy PM, Starling RC, Young JB, Barnes D. Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality. 1999;18:39 (Abstract)
Sheldon S (*see* El-Gamel et al). 1999;18:828-35
Shennib H (*see* Lands et al). 1999;18:113-19 (Abstract)
Shennib H (*see* Partovi et al). 1999;18:85 (Abstract)
Shen XD (*see* McLean et al). 1999;18:68 (Abstract)
Sherman D (*see* Zamora et al). 1999;18:81 (Abstract)
Shield CF (*see* Kauffman et al). 1999;18:414-19
Shimada I (*see* Rooney et al). 1999;18:73 (Abstract)
Shimada T (*see* Wada et al). 1999;18:499-508
Shimura S (*see* Kawaguchi et al). 1999;18:67 (Abstract)
Shiota T (*see* Marullo et al). 1999;18:42 (Abstract)
Shirashi T (*see* Griffiths et al). 1999;18:86 (Abstract)
Shorthouse R (*see* Briffa et al). 1999;18:66 (Abstract)
Shorthouse RS (*see* Ikonen et al). 1999;18:60 (Abstract)
Shroff AR (*see* Aaronson et al). 1999;18:80 (Abstract)
Siebert U (*see* Klauss et al). 1999;18:50 (Abstract)
Sihvola RK, Tikkanen JM, Pulkkinen VP, Koskinen PK, Lemström KB. Prevention of chronic rejection by nonselective endothelin receptor antagonist. 1999;18:61-62 (Abstract)
Silva HT (*see* Slauson et al). 1999;18:1251-52 (Letter)
Silver MA (*see* Pisani et al). 1999;18:701-6
Sim E (*see* El-Gamel et al). 1999;18:828-35
Simeunovič S (*see* Gradinac et al). 1999;18:381-83

Simon-Kupilik N (*see* Wisser et al). 1999;18:67 (Abstract)
Simon P (*see* Moidl et al). 1999;18:194-200
Singh G (*see* Balfour et al). 1999;18:1027-29
Siniawski H (*see* Wagner et al). 1999;18:89 (Abstract)
Sinnott PJ (*see* El-Gamel et al). 1999;18:517-22
Sit S (*see* Kormos et al). 1999;18:63 (Abstract)
Sjöberg T (*see* Bolys et al). 1999;18:582-86
Skotzko CE, Rudis R, Kobashigawa JA, Laks H. Psychiatric disorders and outcome following cardiac transplantation. 1999;18:952-56
Slachta CA (*see* McGurl et al). 1999;18:93 (Abstract)
Slachta CA (*see* Xu et al). 1999;18:90 (Abstract)
Slachta CA, Jeevanandam V, Furukawa S, Platsoucas CD. Cytokine transcripts in coronary arteries and coronary artery-derived T-cell lines from patients with chronic rejection. 1999;18:41 (Abstract)
Slachta CA, Jeevanandam V, Goldman B, Platsoucas CD. Coronary arteries of human cardiac allografts with transplant coronary artery disease contain oligoclonal populations of T lymphocytes. 1999;18:60 (Abstract)
Slauson S, Billingham ME, Silva HT, Wang Y, Morris RE. Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats. 1999;18:1251-52 (Letter)
Slisz JK (*see* Mawulawde et al). 1999;18:53 (Abstract)
Slisz JK (*see* Menard et al). 1999;18:71 (Abstract)
Slootweg PJ (*see* Bruinsma et al). 1999;18:1189-97
Slutsky AS (*see* Cardella et al). 1999;18:88 (Abstract)
Slutsky AS (*see* Cassivi et al). 1181-88
Slutsky AS (*see* Cassivi et al). 1999;18:88-89 (Abstract)
Slutsky AS (*see* DeCampos et al). 1999;18:1096-1102
Small T (*see* De Soyza et al). 1999;18:45 (Abstract)
Smart F (*see* Keogh et al). 1999;18:53 (Abstract)
Smart FW (*see* Taylor et al). 1999;18:336-45
Smedira N (*see* Cook et al). 1999;18:38 (Abstract)
Smedira NG (*see* Dilulio et al). 1999;18:89-90 (Abstract)
Sedira NG (*see* Kaplon et al). 1999;18:63 (Abstract), 1999;18:346-50
Smedira NG (*see* Marullo et al). 1999;18:42 (Abstract)
Smedira NG (*see* Matsumiya et al). 1999;18:79 (Abstract)
Smedira NG (*see* Ogletree-Hughes et al). 1999;18:63 (Abstract)
Smedira NG (*see* Sheffield et al). 1999;18:39 (Abstract)
Smedira NG, Sheffield CD, Hoercher K, Goormastic M, McCarthy PM, Starling RC, Young JB. Gender mismatch is not associated with reduced survival after heart transplantation. 1999;18:44 (Abstract)
Smedira NS (*see* Hoercher et al). 1999;18:45 (Abstract)
Smedira NS (*see* Park et al). 1999;18:1224-27
Smith AL (*see* Lake et al). 1999;18:81 (Abstract)
Smith CI (*see* Lake et al). 1999;18:81 (Abstract)
Smith CR (*see* Argenziano et al). 1999;18:814-17
Smith JA (*see* Morton et al). 1999;18:52 (Abstract)
Smith MA, Jaramillo A, Sundaresan RS, Trulock EP, Lynch JP, Phelan DL, Cooper JD, Patterson GA, Mohanakumar T. Impact of antibodies to HLA class I molecules on the development of BOS. 1999;18:51 (Abstract)
Smith RG (*see* Arabia et al). 1999;18:89 (Abstract)
Smits JMA (*see* De Meester et al). 1999;18:563-71
Smountas AA (*see* Lands et al). 1999;18:113-19 (Abstract)
Snell G (*see* Chaparro et al). 1999;18:46 (Abstract)
Snell G (*see* Morton et al). 1999;18:52 (Abstract)
Snell GI (*see* Gabbay et al). 1999;18:51 (Abstract)
Snell GI (*see* Griffiths et al). 1999;18:86 (Abstract)
Snell GI (*see* Zheng et al). 1999;18:231-37
Solis S (*see* Mehra et al). 1999;18:76 (Abstract)
Sonett JR, Orens J, Kennedy AS. High dose brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi; theoretical and clinical applications. 1999;18:84 (Abstract)
Song H (*see* Seta et al). 1999;18:61 (Abstract)
Song H, Conte JV Jr, Foster AH, McLaughlin JS, Wei C. Increased p53 protein expression in human failing myocardium. 1999;18:744-48
Song P (*see* Perez et al). 1999;18:68 (Abstract)
Sotelo C (*see* Balfour et al). 1999;18:492-94
Spanier TB (*see* Chen et al). 1999;18:351-57
Spear BT (*see* Albert et al). 1999;18:75 (Abstract)-1999; 18:76 (Abstract)
Speroni F (*see* Wagner et al). 1999;18:89 (Abstract)
Spes CH (*see* Behr et al). 1999;18:904-11
Spes CH (*see* Klauss et al). 1999;18:50 (Abstract)
Spes CH (*see* Rieber et al). 1999;18:65 (Abstract)
Spes CH, Klauss V, Rieber J, Schnaack SD, Tammen AR, Überfuhr P, Reichart B, Theisen K, Angermann CE, Mudra H. Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary doppler and intravascular ultrasound. 1999;18:391-97
Spichty K (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
Spiegelsberger S (*see* Hummel et al). 1999;18:49 (Abstract)
Spotnitz HM (*see* Rabkin et al). 1999;18:775-80
Spranger U (*see* Hirt et al). 1999;18:542-48
Spratt PM (*see* Keogh et al). 1999;18:67 (Abstract)
Spratt PM, Keogh AM, Macdonald PS, Hawkins RC, Mundy JA. Transmyocardial laser revascularisation in class IV angina - a randomized trial. 1999;18:42 (Abstract)
Spray TL (*see* Ro et al). 1999;18:83 (Abstract)
Spray TL (*see* Ro et al). 1999;18:1232-37
Squitieri C (*see* Parisi et al). 1999;18:275-77
Srigiri K (*see* Scott et al). 1999;18:39 (Abstract)
Stajevič M (*see* Gradinac et al). 1999;18:381-83
Stamenkovic SA, Alphonso N, Rice P, Madden BP. Recurrence of hepatitis B after single lung transplantation. 1999;18:1246-50
Stammberger U (*see* Hillinger et al). 1999;18:74 (Abstract)
Stammberger U, Carboni GL, Hillinger S, Schneiter D, Weder W, Schmid RA. Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury. 1999;18:862-67
Stammberger U, Carboni GL, Hillinger S, Weder W, Schmid RA. Synergistic effect of endothelin- and PAF antagonists on posttransplant lung ischemia/reperfusion injury. 1999;18:74-75 (Abstract)

Stammberger U, Gaspert A, Hillinger S, Vogt P, Weder W, Schmid RA. Apoptosis induced by ischemia and reperfusion in experimental lung transplantation. 1999;18:79 (Abstract)
Stanek B (*see* Berger et al). 1999;18:47 (Abstract), 1999; 18:75 (Abstract)
Stanek B, Sturm B, Frey B, Hülsmann M, Bojic A, Berger R, Rödler S, Locker G, Grimm M, Laufer G, Pacher R. Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine. 1999;18:358-65
Stanford EA, Murali S, McCurry KR, Winowich S, Griffith BP, Kormos RL. Hypertension during support with ventricular assist devices: incidence, risk factors and management. 1999;18:58 (Abstract)
Staples ED (*see* Baz et al). 1999;18:60 (Abstract)
Stapleton P (*see* Rodgers et al). 1999;18:58 (Abstract)
Starke M (*see* Hirt et al). 1999;18:542-48
Starling RC (*see* Cook et al). 1999;18:38 (Abstract)
Starling RC (*see* Hoercher et al). 1999;18:45 (Abstract)
Starling RC (*see* Marullo et al). 1999;18:42 (Abstract)
Starling RC (*see* Matsumiya et al). 1999;18:79 (Abstract)
Starling RC (*see* Park et al). 1999;18:47-48 (Abstract)
Starling RC (*see* Park et al). 1999;18:1224-27
Starling RC (*see* Pathak et al). 1999;18:43 (Abstract)
Starling RC (*see* Sheffield et al). 1999;18:39 (Abstract)
Starling RC (*see* Smedira et al). 1999;18:44 (Abstract)
Starnes VA (*see* Chan et al). 1999;18:85 (Abstract)
Starnes VA (*see* Uppal et al). 1999;18:54 (Abstract)
Starnes VA (*see* Woo et al). 1999;18:86 (Abstract)
Starzl TE (*see* McCurry et al). 1999;18:72 (Abstract)
Steele MP (*see* Palmer et al). 1999;18:51 (Abstract)
Steel LA (*see* Trull et al). 1999;18:93 (Abstract)
Steen S (*see* Bolys et al). 1999;18:582-86
Steen S (*see* Wierup et al). 1999;18:127-32
Stepkowski S (*see* Perez et al). 1999;18:68 (Abstract)
Stevenson LW (*see* Drazner et al). 1999;18:1126-32
Stevenson LW (*see* Kirklin et al). 1999;18:47 (Abstract)
Stevenson SC (*see* Wang et al). 1999;18:48 (Abstract), 1999;18:48-49 (Abstract)
Stewart S (*see* Bardsley et al). 1999;18:41 (Abstract)
Storch GA (*see* Kruger et al). 1999;18:82 (Abstract)
Stremmel W (*see* Kallinowski et al). 1999;18:190-93
Strieter RM (*see* Fisher et al). 1999;18:88 (Abstract)
Stringham JC, Bull DA, Fuller TC, Kfoury AG, Taylor DO, Renlund DG, Karwande SV. Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization. 1999;18:160-65
Stringham JC, Love RB, Welter D, Canver CC, Mentzer RM Jr. Does University of Wisconsin solution harm the transplanted heart?. 1999;18:587-95
Strüber M (*see* Harringer et al). 1999;18:56 (Abstract)
Strüber M, Harringer W, Wirsing M, Teebken OE, Franke U, Wiebe K, Karck M, Haverich A. LPD solution in clinical lung transplantation. 1999;18:87 (Abstract)
Sturm B (*see* Stanek et al). 1999;18:358-65
Suciu-Foca N (*see* Lietz et al). 1999;18:80 (Abstract)
Sudarshan CD (*see* Clark et al). 1999;18:172-73
Sudarshan CD, Orr H, Clark SC, Roughan J, Flecknell P, Dark JH. Donor pre-treatment with inhaled nitric oxide attenuates acute lung injury following single lung transplantation. 1999;18:78 (Abstract)
Sundaresan RS (*see* Smith et al). 1999;18:51 (Abstract)
Susskind B (*see* Kerman et al). 1999;18:38 (Abstract)
Svejgaard A (*see* Svendsen et al). 1999;18:388-89 (Abstract)
Svendsen UG, Aggestrup S, Heilmann C, Jacobsen N, Koch C, Larsen B, Svejgaard A, Thisted B, Petterson G. Transplantation of a lobe of a lung from mother to child after previous transplantation with bone marrow. 1999; 18:388-89
Svennevig JL (*see* Fiane et al). 1999;18:66 (Abstract)
Swartz MT (*see* McBride et al). 1999;18:90 (Abstract)
Sweeney SD (*see* Goldstein et al). 1999;18:69 (Abstract)
Sweet SC, Berlinski A, Mendeloff EN, Mallory GB Jr, Huddleston CB. Early graft dysfunction in pediatric lung transplant recipients. 1999;18:82-83 (Abstract)
Swenson JM (*see* Pahl et al). 1999;18:725-32
Szabó G, Fazekas L, Bährle S, MacDonald D, Vahl CF, Hagl S. Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation. 1999;18:54 (Abstract)
Szabó G, Sebening C, Hackert T, Melnitschuk S, Vahl CF, Hagl S. Role of neural and humoral factors in cardiac dysfunction in the potential organ donor. 1999;18:39 (Abstract)
Szidon P (*see* Kesten et al). 1999;18:266-68

T

Taghavi S (*see* Takahashi et al). 1999;18:304-9
Taghavi S (*see* Wisser et al). 1999;18:67 (Abstract)
Taghavi S (*see* Zuckermann et al). 1999;18:432-39
Tagusari O, Kormos RL, Kawai A, Yamazaki K, Pham SM, Hattler BG, Murali S, Griffith BP. Native heart complications after heterotropic heart transplantation: insight into the potential risk of left ventricular assist device. 1999;18:1111-19
Takahashi N (*see* Martin et al). 1999;18:597-605
Takahashi T (*see* Mohara et al). 1999;18:39 (Abstract), 1999;18:1202-10
Takahashi T (*see* Oshima et al). 1999;18:852-61
Takahashi T, Takeyoshi I, Hasegawa Y, Koyano T, Yamagishi T, Oshima K, Matsumoto K, Morishita Y. Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts. 1999;18:285-91
Takami H (*see* Crawford et al). 1999;18:470-76
Takeda A (*see* Baba et al). 1999;18:963-71
Takemoto SK (*see* Wang et al). 1999;18:80 (Abstract)
Takeyoshi I (*see* Mohara et al). 1999;18:39 (Abstract), 1999;18:1202-10
Takeyoshi I (*see* Takahashi et al). 1999;18:285-91
Takeyoshi I (*see* Tomizawa et al). 1999;18:637-44
Tambeur L (*see* Grauhan et al). 1999;18:66 (Abstract)
Tammen AR (*see* Spes et al). 1999;18:391-97
Tani LY (*see* Shaddy et al). 1999;18:269-74
Tapson VF (*see* Palmer et al). 1999;18:51 (Abstract)

Tardif J-C (*see* Ducharme et al). 1999;18:510-16
Tay GK (*see* Ketheesan et al). 1999;18:226-29
Taylor DA (*see* Atkines et al). 1999;18:1173-80
Taylor DA (*see* Atkins et al). 1999;18:43 (Abstract)
Taylor DO (*see* Renlund et al). 1999;18:1065-70
Taylor DO (*see* Stringham et al). 1999;18:160-65
Taylor DO, Barr ML, Radovancevic B, Renlund DG, Mentzer RM Jr, Smart FW, Tolman DE, Frazier OH, Young JB, VanVeldhuisen P. A randomized, multicenter comparison of Tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with Tacrolimus. 1999; 18:336-45
Taylor G (*see* Ongcharit et al). 1999;18:37 (Abstract)
Taylor J (*see* Gabbay et al). 1999;18:51 (Abstract)
Taylor RR (*see* Ketheesan et al). 1999;18:226-29
Tector KA (*see* Chen et al). 1999;18:351-57
Teebken OE (*see* Strüber et al). 1999;18:87 (Abstract)
Teebken OE, Pethig K, Krieg P, Haverich A, Harringer W. Valve-sparing repair after aortic root dissection following heart transplantation. 1999;18:807-9
Teiger E (*see* Aptecar et al). 1999;18:64 (Abstract)
Tejada J (*see* Planas et al). 1999;18:55 (Abstract)
TenVergert EM (*see* van Enckevort et al). 1999;18:496-97
Teranishi K, Usui A, Maseki T, Watanabe T, Yasuura K, Imaizumi M. Dose and time relationship of Cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model. 1999;18:73 (Abstract)
Terasaki PI (*see* Wang et al). 1999;18:80 (Abstract)
Tesar PJ (*see* Galbraith et al). 1999;18:805-6
Thacker L (*see* Thompson et al). 1999;18:38-39 (Abstract)
Theilmann L (*see* Kallinowski et al). 1999;18:190-93
Theisen K (*see* Behr et al). 1999;18:904-11
Theisen K (*see* Rieber et al). 1999;18:65 (Abstract)
Theisen K (*see* Spes et al). 1999;18:391-97
Theodore J (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59-60 (Abstract)
Theodore J (*see* Doyle et al). 1999;18:86 (Abstract)
Theodore J (*see* Faul et al). 1999;18:384-87
Theodore J (*see* Valantine et al). 1999;18:81 (Abstract)
Thiers J-C (*see* Dambrin et al). 1999;18:946-51
Thiery J (*see* Weis et al). 1999;18:50 (Abstract)
Thisted B (*see* Svendsen et al). 1999;18:388-89
Thomas C (*see* Radovancevic et al). 1999;18:63 (Abstract)
Thomas JM (*see* Goldstein et al). 1999;18:69 (Abstract)
Thomas R (*see* Iwata et al). 1999;18:37 (Abstract)
Thompson GB (*see* Brilakis et al). 1999;18:376-80
Thompson JS, Thacker L. Effect of histocompatibility, sensitization and other risk factors on the outcome of 14,535 cardiac transplants (TNX) reported to the UNOS scientific registry. 1999;18:38-39 (Abstract)
Thomsen M (*see* Dambrin et al). 1999;18:946-51
Tikkanen JM (*see* Kallio et al). 1999;18:52-53 (Abstract)
Tikkanen JM (*see* Sihvola et al). 1999;18:61-62 (Abstract)
Tikkanen JM, Kallio EA, Bruggeman CA, Koskinen PK, Lemström KB. Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat. 1999;18:62 (Abstract)
Tillmanns H (*see* Braun-Dullaeus et al). 1999;18:328-34
Tilney NL (*see* Wilhelm et al). 1999;18:68 (Abstract)
Tinker K (*see* Balfour et al). 1999;18:1027-29
Tjan TDT (*see* Asfour B et al). 1999;18:927-36
Tjan TDT (*see* Baba et al). 1999;18:57 (Abstract), 1999;18: 963-71
Tolman DE (*see* Rayburn et al). 1999;18:47 (Abstract)
Tolman DE (*see* Taylor et al). 1999;18:336-45
Tomizawa N, Ohwada S, Ohya T, Takeyoshi I, Ogawa T, Kawashima Y, Adachi M, Morishita Y. The effects of a neutrophil elastase inhibitor (ONO-5046 [uni]8729[/uni] Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs. 1999; 18:637-44
Toporoff B (*see* Arabia et al). 1999;18:89 (Abstract)
Torre G (*see* Rayburn et al). 1999;18:47 (Abstract)
Torres F (*see* Weill et al). 1999;18:55 (Abstract)
Torres F (*see* Weill et al). 1999;18:1080-87
Torres F (*see* Zamora et al). 1999;18:81 (Abstract)
Townend JN (*see* Pagano et al). 1999;18:67 (Abstract)
Toyoda M (*see* Ross et al). 1999;18:627-35
Trainini J, Barisani J, Christen A, Elencwajg B, Giordano R, de Paz J, Mouras J, Cabrera Fischer E. Dynamic aortomyoplasty with latissimus dorsi: clinical follow-up. 1999;18:42-43 (Abstract)
Trainini J, Barisani JC, Cabrera Fischer EI, Chada S, Christen AI, Elencwajg B. Chronic aortic counterpulsation with latissimus dorsi in heart failure: clinical follow-up. 1999;18:1120-25
Treede H (*see* Klepetko et al). 1999;18:45-46 (Abstract)
Treede H (*see* Kur et al). 1999;18:93 (Abstract)
Tribble CG (*see* Ross et al). 1999;18:72 (Abstract), 1999; 18:994-1002
Trohman RG (*see* Pinski et al). 1999;18:292-96
Trull AK, Steel LA, Sharples L, Parameshwar J, Cary N, Wallwork J, Large S. Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection. 1999;18:93 (Abstract)
Trulock EP (*see* Garrity et al). 1999;18:175-76
Trulock EP (*see* Kruger et al). 1999;18:82 (Abstract)
Trulock EP (*see* Smith et al). 1999;18:51 (Abstract)
Tsang VT (*see* Gassas et al). 1999;18:83 (Abstract)
Tscheliessnigg KH (*see* Grasser et al). 1999;18:80 (Abstract)
Tsui SSL, Feccia M, Ongcharit P, Large SR, McNeil K, Wallwork J. Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience. 1999;18:78-79 (Abstract)
Tufveson G (*see* Johnsson et al). 1999;18:1238-42
Tung T (*see* Lietz et al). 1999;18:80 (Abstract)
Tupper JK (*see* Cook et al). 1999;18:420-24
Turck CW (*see* Jonosono et al). 1999;18:972-85
Turkin D (*see* Eisen et al). 1999;18:93 (Abstract)
Turrentine M (*see* Bando et al). 1999;18:70 (Abstract)

Turrentine M (*see* Flaspohler et al). 1999;18:91 (Abstract)
Tuzcu EM (*see* Kaplon et al). 1999;18:63 (Abstract)

U

Überfuhr P (*see* Behr et al). 1999;18:904-11
Überfuhr P (*see* Meiser et al). 1999;18:78 (Abstract), 1999;18:143-48
Überfuhr P (*see* Schwaiblmair et al). 1999;18:838-44
Überfuhr P (*see* Spes et al). 1999;18:391-97
Uber PA (*see* Mehra et al). 1999;18:49 (Abstract), 1999;18:76 (Abstract)
Uber PA, Mehra MR. Hypersensitivity eosinophilia: a unique cause of cardiac decompensation in inotropic dependent heart failure?. 1999;18:43 (Abstract)
Uchida Y (*see* Wada et al). 1999;18:499-508
Ugolino L (*see* Sartori et al). 1999;18:693-99
Ujiie T (*see* Kawaguchi et al). 1999;18:67 (Abstract)
&Dhyphen;ukič M (*see* Gradinac et al). 1999;18:381-83
Ullrich R (*see* Moidl et al). 1999;18:194-200
Ullrich R (*see* Zuckermann et al). 1999;18:93 (Abstract)
Uppal KM, Barr ML, Schenkel FA, Hagen JA, Fuller CB, Wells WJ, Chan KM, Barbers RG, Starnes VA, Cohen RG. Five years of living lobar donation for bilateral lung transplantation: long term results in 137 donors. 1999;18:54 (Abstract)
Ussetti P (*see* Planas et al). 1999;18:55 (Abstract)
Usui A (*see* Teranishi et al). 1999;18:73 (Abstract)

V

Vaessen L (*see* Welters et al). 1999;18:53 (Abstract)
Vahl CF (*see* Szabó et al). 1999;18:39 (Abstract), 1999;18:54 (Abstract)
Valantine H (*see* Keogh et al). 1999;18:53 (Abstract)
Valantine HA (*see* Kato et al). 1999;18:50 (Abstract)
Valantine HA, Luikart H, Doyle RL, Theodore J, Hunt SA, Robbins RC, Reitz BA. CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation. 1999;18:81 (Abstract)
Valente JF (*see* Gibson et al). 1999;18:185-88
VanBakel A (*see* Grady et al). 1999;18:750-60
Van Belleghem Y (*see* De Somer et al). 1999;18:41-42 (Abstract), 1999;18:1014-17
Van Buren CT (*see* Kerman et al). 1999;18:38 (Abstract)
Van de Kolk CWA (*see* Bruinsma et al). 1999;18:1189-97
van den Berg JWK, Hepkema BG, Koëter GH, Postma DS, de Boer WJ, Lems SPM, van der Bij W. HLA class II matching: significant impact on long term outcome of lung transplantation. 1999;18:85 (Abstract)
van der Bij W (*see* van den Berg et al). 1999;18:85 (Abstract)
van der Bij W (*see* van Enckevort et al). 1999;18:496-97
Van Echteld CJA (*see* Bruinsma et al). 1999;18:1189-97
van Enckevort PJ, TenVergert EM, Geertsma A, van der Bij W, de Boer WJ, Rutten FFH. Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. 1999;18:496-97
van Gelder T (*see* Baan et al). 1999;18:69 (Abstract)
Vanhaecke J (*see* De Geest et al). 1999;18:91 (Abstract)
Vanhaecke J (*see* Verleden et al). 1999;18:1139-46
Van Nooten G (*see* De Somer et al). 1999;18:41-42 (Abstract), 1999;18:1014-17
Van Raemdonck D (*see* Verleden et al). 1999;18:1139-46
Van Trigt P (*see* Bittner et al). 1999;18:87 (Abstract)
VanVeldhuisen P (*see* Taylor et al). 1999;18:336-45
Varela A (*see* Planas et al). 1999;18:55 (Abstract)
Vattikuti R (*see* Fedalen et al). 1999;18:56-57 (Abstract)
Vazquez-Rodriguez JM, Crespo-Leiro MG, Pampin-Conde MF, Colvino-Santos R, Peteiro-Cartelle J, Gonzalez-Cuesta M, Juffe-Stein A, Castro-Beiras A. Cardiac troponin T is not a marker of biopsy proven cellular rejection. 1999;18:172
Veeraraghavan S (*see* Chan et al). 1999;18:85 (Abstract)
Veksler V (*see* Zoll et al). 1999;18:71 (Abstract)
Vensak J (*see* Keenan et al). 1999;18:55 (Abstract)
Ventura-Clapier R (*see* Zoll et al). 1999;18:71 (Abstract)
Verleden GM, Buyse B, Delcroix M, Fabri R, Vanhaecke J, Van Raemdonck D, Lerut T, Demedts M. Cyclophosphamide rescue therapy for chronic rejection after lung transplantation. 1999;18:1139-46
Videm V (*see* Fiane et al). 1999;18:66 (Abstract)
Viganó M (*see* Raczak et al). 1999;18:399-405
Vivekananthan K (*see* Mehra et al). 1999;18:76 (Abstract)
Voci P, Chiera A, Caretta Q, Papalia U. Acquired atrial septal defect after heart transplantation. 1999;18:921-23
Vogelmeier C (*see* Schwaiblmair et al). 1999;18:838-44
Vogt P (*see* Stammberger et al). 1999;18:79 (Abstract)
Vollmar J (*see* Wedemeyer et al). 1999;18:81 (Abstract)
von Scheidt W (*see* Kur et al). 1999;18:93 (Abstract)
von Scheidt W (*see* Meiser et al). 1999;18:78 (Abstract), 1999;18:143-48
von Scheidt W (*see* Schwaiblmair et al). 1999;18:838-44
von Scheidt W (*see* Weis et al). 1999;18:50 (Abstract), 1999;18:64 (Abstract)
von Scheidt W (*see* Weis et al). 1999;18:1071-79
von Scheidt W (*see* Wildhirt et al). 1999;18:64-65 (Abstract)

W

Wada T, Ono K, Hadama T, Uchida Y, Shimada T, Arita M. Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats. 1999;18:499-508
Waddell TK, Cassivi S, Keshavjee SH. Effect of donor age on young and older lung transplant recipients. 1999;18:85 (Abstract)
Wagner D (*see* Fraund et al). 1999;18:220-24
Wagner F, Speroni F, Müller J, Loebe M, Siniawski H, Hetzer R. Comprehensive concept to support right ventricular function following left ventricular assist device implantation. 1999;18:89 (Abstract)
Wagner FM, Schubert F, Weber A, Pfeiffer S, Albrecht S, Zimmermann T, Schueler S. In-vivo measurement of oxygen free radical production correlates with pulmonary reperfusion injury. 1999;18:74 (Abstract)

Wahlers T (*see* Harringer et al). 1999;18:56 (Abstract)
Wahlers T (*see* Wittwer et al). 1999;18:684-91
Wahlers T (*see* Wittwer et al). 1999;18:1198-1201
Wahlers Th (*see* Pethig et al). 1999;18:77-78 (Abstract)
Walden A (*see* Westlake et al). 1999;18:1133-38
Walker G (*see* Braun-Dullaeus et al). 1999;18:328-34
Wall D (*see* Balfour et al). 1999;18:492-94
Wallen WJ (*see* Wittnich et al). 1999;18:675-83
Wallukat G (*see* Müller et al). 1999;18:70-71 (Abstract)
Wallwork J (*see* Bainbridge et al). 1999;18:407-12
Wallwork J (*see* Bardsley et al). 1999;18:41 (Abstract)
Wallwork J (*see* Ongcharit et al). 1999;18:37 (Abstract)
Wallwork J (*see* Parry et al). 1999;18:121-25
Wallwork J (*see* Trull et al). 1999;18:93 (Abstract)
Wallwork J (*see* Tsui et al). 1999;18:78-79 (Abstract)
Wallwork J (*see* Wreghitt et al). 1999;18:82 (Abstract)
Walters EH (*see* Gabbay et al). 1999;18:51 (Abstract)
Walters EH (*see* Zheng et al). 1999;18:231-37
Wan B, Ikonen T, Morris RE, Dosanjh A. Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection. 1999;18:90 (Abstract)
Wan B, Ikonen T, Morris RE, Dosanjh AK. IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection. 1999;18:90 (Abstract)
Wang AY (*see* Ross et al). 1999;18:72 (Abstract), 1999;18:994-1002
Wang I-W (*see* Kaplon et al). 1999;18:346-50
Wang J (*see* Parry et al). 1999;18:441-46
Wang T, Dong C, Hatton PS, Stevenson SC, Pham Y, Binkley PF, Goldschmidt-Clermont PJ. RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat. 1999;18:48 (Abstract)
Wang T, Dong C, Moldovan NI, Marshall-Neff J, Stevenson SC, Goldschmidt-Clermont PJ. Gene therapy with soluble FAS decreases AGA in a rat aortic allograft model. 1999;18:48-49 (Abstract)
Wang XM, Zhong HP, Takemoto SK, Chuang J, Kobashigawa J, Terasaki PI, Cecka JM. Immunologic assessment of risk for rejections after heart transplantation. 1999;18:80 (Abstract)
Wang Y (*see* Gummert et al). 1999;18:53-54 (Abstract)
Wang Y (*see* Slauson et al). 1999;18:1251-52 (Letter)
Ward C (*see* Gabbay et al). 1999;18:51 (Abstract)
Ward C (*see* Zheng et al). 1999;18:231-37
Ward PA (*see* Mulligan et al). 1999;18:59 (Abstract), 1999;18:88 (Abstract)
Warner RL (*see* Mulligan et al). 1999;18:59 (Abstract), 1999;18:88 (Abstract)
Warren W (*see* Kesten et al). 1999;18:266-68
Wasler A (*see* Grasser et al). 1999;18:80 (Abstract)
Wassef M (*see* Xiong et al). 1999;18:320-26
Wassenaar C (*see* Welters et al). 1999;18:53 (Abstract)
Watanabe T (*see* Teranishi et al). 1999;18:73 (Abstract)
Watson CJ (*see* Onwu et al). 1999;18:74 (Abstract)
Waurick PE, Kleber FX, Ewert R, Pfitzmann R, Bruch L, Hummel M, Hetzer R. Pulmonary artery stenosis 5 years after single lung transplantation in primary pulmonary hypertension. 1999;18:1243-45
Wax DF (*see* Ringewald et al). 1999;18:70 (Abstract)
Webber S (*see* McCurry et al). 1999;18:72 (Abstract)
Webber SA (*see* Robinson et al). 1999;18:786-90
Webber SA, Fitzsimmons A, Qu L, Boyle GJ, Law Y, Miller SA, Michaels MG, Green M, Kurland G, Pigula F, Griffith BP, Zeevi A, Rowe D. Evaluation of circulating Epstein-Barr virus (EBV) viral load in pediatric thoracic recipients: implications for diagnosis of posttransplant lymphoproliferative disorders (PTLD). 1999;18:83 (Abstract)
Webber SA, Naftel DC, Parker J, Mulla N, Balfour I, Cipriani L, Kirklin JK, Morrow WR, Pediatric Heart Transplant Study. Late rejection greater than 1 year after pediatric heart transplantation: an ominous finding. 1999;18:69 (Abstract)
Webb J (*see* Beniaminovitz et al). 1999;18:45 (Abstract)
Webb JG (*see* Pamboukian et al). 1999;18:367-70
Webb WR (*see* Jonosono et al). 1999;18:972-85
Weber A (*see* Wagner et al). 1999;18:74 (Abstract)
Weber C (*see* Rieber et al). 1999;18:65 (Abstract)
Wedemeyer H, Böker KHW, Pethig K, Petzold DR, Flemming P, Rambusch EG, Bastürk M, Gamburg E, Vollmar J, Griffin KE, Haverich A, Manns MP. Famciclovir treatment of chronic hepatitis B in heart transplant recipients. 1999;18:81 (Abstract)
Weder W (*see* Hillinger et al). 1999;18:74 (Abstract)
Weder W (*see* Stammberger et al). 1999;18:74-75 (Abstract), 1999;18:79 (Abstract), 1999;18:862-67
Wei C (*see* Seta et al). 1999;18:61 (Abstract)
Wei C (*see* Song et al). 1999;18:744-48
Weil C (*see* Rodgers et al). 1999;18:58 (Abstract)
Weill D, Torres F, Hodges TN, Olmos JJ, Zamora MR. Acute native lung hyperinflation (ANLH) is not associated with poor outcome after single lung transplant (SLT) for emphysema. 1999;18:55 (Abstract)
Weill D, Torres F, Hodges TN, Olmos JJ, Zamora MR. Acute native lung hyperinflation is not associated with poor outcomes after single lung transplant for emphysema. 1999;18:1080-87
Weimar W (*see* Baan et al). 1999;18:69 (Abstract)
Weimar W (*see* de Groot-Kruseman et al). 1999;18:52 (Abstract)
Weimar W (*see* Welters et al). 1999;18:53 (Abstract)
Weis M (*see* Wildhirt et al). 1999;18:64-65 (Abstract)
Weis M, Pehlivanli S, Meiser BM, Thiery J, von Scheidt W. The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation. 1999;18:50 (Abstract)
Weis M, Pehlivanli S, Wildhirt SM, Schulze C, Fraunberger P, Meiser BM, von Scheidt W. Induction of cardiac allograft endothelial dysfunction by cytokines in humans. 1999;18:64 (Abstract)
Weis M, Wildhirt SM, Schulze C, Rieder G, Wilbert-Lampen U, Wolf WP, Arendt RM, Enders G, Meiser BM, von Scheidt W. Endothelin in coronary endothelial

dysfunction early after human heart transplantation. 1999;18:1071-79

Weis M, Wildhirt SM, Schulze C, Wolf WP, Rieder G, Wilbert-Lampen U, Arerndt RM, Enders G, Meiser BM, von Scheidt W. The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients. 1999;18:64 (Abstract)

Weiss LT (*see* Lake et al). 1999;18:81 (Abstract)

Wellnhofer E (*see* Hummel et al). 1999;18:49 (Abstract)

Wells WJ (*see* Uppal et al). 1999;18:54 (Abstract)

Welter D (*see* Onsager et al). 1999;18:448-54

Welter D (*see* Stringham et al). 1999;18:587-95

Welter DL (*see* Endres et al). 1999;18:91 (Abstract)

Welter DL (*see* Love et al). 1999;18:87 (Abstract)

Welters M, Oei F, Knoop C, Vaessen L, Wassenaar C, Claas F, Bogers A, Weimar W. Donor-specific high avidity cytotoxic T-lymhocytes induced by implantation of cryopreserved human cardiac valves. 1999;18:53 (Abstract)

Wener L (*see* Kobashigawa et al). 1999;18:71 (Abstract)

Wensel R, Opitz CF, Kleber FX. Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure. 1999;18:877-82

Werle M (*see* Dengler et al). 1999;18:61 (Abstract)

West L (*see* Dipchand et al). 1999;18:83-84 (Abstract)

Westlake C, Dracup K, Walden A, Fonarow G. Sexuality of patients with advanced heart failure and their spouses or partners. 1999;18:1133-38

Weyand M (*see* Asfour B et al). 1999;18:927-36

Weyand M (*see* Baba et al). 1999;18:57 (Abstract)

Wheeldon D (*see* Parry et al). 1999;18:121-25

Wheeldon DR (*see* Hunt et al). 1999;18:43 (Abstract)

Wheeldon DR (*see* Jansen et al). 1999;18:67-68 (Abstract)

Whitehead B (*see* Gassas et al). 1999;18:83 (Abstract)

White M (*see* Carrier et al). 1999;18:1218-23

White-Williams C (*see* Grady et al). 1999;18:202-10, 1999; 18:750-60

Whitford H (*see* Gabbay et al). 1999;18:51 (Abstract)

Whitmore P (*see* Gassas et al). 1999;18:83 (Abstract)

Whyte RI (*see* Mulligan et al). 1999;18:88 (Abstract)

Wichter T (*see* Baba et al). 1999;18:963-71

Wiebe K (*see* Harringer et al). 1999;18:56 (Abstract)

Wiebe K (*see* Strüber et al). 1999;18:87 (Abstract)

Wierup P, Bolys R, Steen S. Gas exchange function one month after transplantation of lungs topically cooled for 2 hours in the non-heart-beating cadaver after failed resuscitation. 1999;18:133-37

Wieselthaler G (*see* Moidl et al). 1999;18:194-200

Wilbert-Lampen U (*see* Weis et al). 1999;18:64 (Abstract)

Wilbert-Lampen U (*see* Weis et al). 1999;18:1071-79

Wildhirt S (*see* Meiser et al). 1999;18:78 (Abstract)

Wildhirt SM (*see* Weis et al). 1999;18:64 (Abstract)

Wildhirt SM (*see* Weis et al). 1999;18:1071-79

Wildhirt SM, Conrad N, Kuehnapfel S, Akdemir H, Schulze C, Boehm DH, Reichart B. Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts. 1999;18:40 (Abstract)

Wildhirt SM, Weis M, Schulze C, Conrad N, Pehlivanli S, Reichenspurner H, von Scheidt W, Reichart B. Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans. 1999;18:64-65 (Abstract)

Wilhelm MJ, Pratschke J, Kusaka M, Hancock WW, Tilney NL. Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts. 1999;18:68 (Abstract)

Williams DS (*see* Yoshida et al). 1999;18:1054-64

Williams MR, Morales DLS, Goodman M, Schuster N, DeRose JJ Jr, Rose EA, Oz MC. Use of inhaled nitric oxide in cardiac transplantation. 1999;18:44 (Abstract)

Williams TJ (*see* Gabbay et al). 1999;18:51 (Abstract)

Williams TJ (*see* Griffiths et al). 1999;18:86 (Abstract)

Williams TJ (*see* Morton et al). 1999;18:52 (Abstract)

Williams TJ (*see* Zheng et al). 1999;18:231-37

Wilson IC (*see* Eccleshall et al). 1999;18:46 (Abstract)

Wilson JW (*see* Brilakis et al). 1999;18:376-80

Wilson JW (*see* Zheng et al). 1999;18:231-37

Winkel E (*see* Pinski et al). 1999;18:292-96

Winowich S (*see* Stanford et al). 1999;18:58 (Abstract)

Winter WE (*see* Penson et al). 1999;18:707-12

Winton T (*see* Chaparro et al). 1999;18:46 (Abstract)

Wirsing M (*see* Strüber et al). 1999;18:87 (Abstract)

Wiseman A (*see* Pietra et al). 1999;18:48 (Abstract)

Wisser W (*see* Klepetko et al). 1999;18:45-46 (Abstract)

Wisser W (*see* Zuckermann et al). 1999;18:432-39

Wisser W, Senbaclavaci Ö, Kritzinger M, Jántsch-Watzinger V, Klepetko W, Wolner E. Impact of morphology and ventilatory mechanics upon early functional outcome after lung volume reduction surgery. 1999;18:42 (Abstract)

Wisser W, Simon-Kupilik N, Senbaclavaci Ö, Deviatko E, Taghavi S, Klepetko W, Wolner E. Results of lung transplantation following lung volume reduction surgery. 1999;18:67 (Abstract)

Witt CS (*see* Ketheesan et al). 1999;18:226-29

Wittnich C, Wallen WJ, Belanger MB, Ikonomidis JS. Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts. 1999;18:675-83

Wittwer T, Wahlers T, Fehrenbach A, Cornelius JF, Elki S, Ochs M, Fehrenbach H, Albes J, Haverich A, Richter J. Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by celsior solution in the isolated rat lung. 1999;18:684-91

Wittwer T, Wahlers T, Fehrenbach A, Elki S, Haverich A. Improvement of pulmonary preservation with Celsior and Perfadex impact of storage time on early post-ischemic lung function. 1999;18:1198-1201

Wojnicz R, Zembala M, Zakliczynski M, Nozynski J, Rozek MM. Myocardial HLA and ICAM-1 staining pattern in

biopsies from transplanted hearts. Three years follow-up. 1999;18:40 (Abstract)
Wolf JS (*see* Kauffman et al). 1999;18:414-19
Wolf WP (*see* Weis et al). 1999;18:64 (Abstract)
Wolf WP (*see* Weis et al). 1999;18:1071-79
Wolner E (*see* Moidl et al). 1999;18:194-200
Wolner E (*see* Wisser et al). 1999;18:42 (Abstract), 1999;18:67 (Abstract)
Wolner E (*see* Zuckermann et al). 1999;18:93 (Abstract), 1999;18:432-39
Wong R (*see* Doyle et al). 1999;18:86 (Abstract)
Wong RL (*see* Brazelton et al). 1999;18:59 (Abstract), 1999;18:59-60 (Abstract)
Woo MS, MacLaughlin EF, Horn MV, Starnes VA. Pulmonary volume increases with linear growth in pediatric living donor lobar lung transplant recipients. 1999;18:86 (Abstract)
Wottge HU (*see* Hirt et al). 1999;18:542-48
Wray J (*see* Long et al). 1999;18:92 (Abstract)
Wray J, Radley-Smith R, Yacoub M. Education and the transplanted child. 1999;18:57 (Abstract)
Wreghitt TG, Rostron AJ, Gray JJ, McNeil K, Parameshwar J, Large SR, Wallwork J. Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients. 1999;18:82 (Abstract)
Wright DH, Lake KD, Bruhn PS, Emery RW Jr. Nefazodone and cyclosporine drug-drug interaction. 1999;18:913-15
Wright L (*see* Pennington et al). 1999;18:91 (Abstract)

X

Xiong L, Legagneux J, Wassef M, Oubenaïssa A, Détruit H, Mouas C, Menasché P. Protective effects of celsior in lung transplantation. 1999;18:320-26
Xu B (*see* McGurl et al). 1999;18:93 (Abstract)
Xu B, Sakkas LI, Slachta CA, Jeevanandam V, Goldman BI, Oleszak EL, Platsoucas CD. Apoptosis in human cardiac allografts with transplant coronary artery disease. 1999;18:90 (Abstract)

Y

Yacoub M (*see* Radley-Smith et al). 1999;18:84 (Abstract)
Yacoub M (*see* Wray et al). 1999;18:57 (Abstract)
Yacoub MH (*see* Kavanagh et al). 1999;18:846-50
Yacoub MH (*see* Raisky et al). 1999;18:61 (Abstract)
Yamada K (*see* Mawulawde et al). 1999;18:53 (Abstract)
Yamada K (*see* Menard et al). 1999;18:71 (Abstract)
Yamagishi T (*see* Mohara et al). 1999;18:39 (Abstract)
Yamagishi T (*see* Mohara et al). 1999;18:1202-10
Yamagishi T (*see* Oshima et al). 1999;18:852-61
Yamagishi T (*see* Takahashi et al). 1999;18:285-91
Yamaguchi T (*see* Nishimura et al). 1999;18:57 (Abstract)
Yamazaki K (*see* Tagusari et al). 1999;18:1111-19
Yasuda K (*see* Sasaki et al). 1999;18:127-32, 1999;18:139-42
Yasuura K (*see* Teranishi et al). 1999;18:73 (Abstract)
Yeatman MF (*see* Lau et al). 1999;18:65-66 (Abstract)
Yock PG (*see* Ikonen et al). 1999;18:72 (Abstract)
Yonan N (*see* Aziz et al). 1999;18:37 (Abstract)
Yonan N (*see* Aziz et al). 1999;18:1253-54 (Letter)
Yonan N (*see* Burgess et al). 1999;18:44-45 (Abstract)
Yonan N (*see* Densem et al). 1999;18:52 (Abstract), 1999;18:77 (Abstract)
Yonan N (*see* El-Gamel et al). 1999;18:828-35
Yonan NA (*see* El-Gamel et al). 1999;18:517-22
Yoshida S, Dodd, SJ, del Nido PJ, Williams DS, Ho C. Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging. 1999;18:1054-64
Yoshitake M (*see* Martin et al). 1999;18:597-605
Young JB (*see* Cook et al). 1999;18:38 (Abstract)
Young JB (*see* Hoercher et al). 1999;18:45 (Abstract)
Young JB (*see* Marullo et al). 1999;18:42 (Abstract)
Young JB (*see* Matsumiya et al). 1999;18:79 (Abstract)
Young JB (*see* Park et al). 1999;18:47-48 (Abstract)
Young JB (*see* Park et al). 1999;18:1224-27
Young JB (*see* Pathak et al). 1999;18:43 (Abstract)
Young JB (*see* Rayburn et al). 1999;18:47 (Abstract)
Young JB (*see* Sheffield et al). 1999;18:39 (Abstract)
Young JB (*see* Smedira et al). 1999;18:44 (Abstract)
Young JB (*see* Taylor et al). 1999;18:336-45
Young JB. Age before beauty: the use of "older" donor hearts for cardiac transplantation. 1999;18:488-90
Young WF Jr (*see* Brilakis et al). 1999;18:376-80
Yousem S (*see* Zeevi et al). 1999;18:81-1999;18:82 (Abstract)
Yousem SA (*see* Hasegawa et al). 1999;18:41 (Abstract)
You XM (*see* Hirt et al). 1999;18:542-48
Yu J (*see* Perez et al). 1999;18:68 (Abstract)
Yu NC, Haug MT III, Khan SU, Goormastic M, Hague LK, Mehta AC, Maurer JR. Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes?. 1999;18:764-68
Yung RW (*see* Chan et al). 1999;18:85 (Abstract)
Yun JJ (*see* Fischbein et al). 1999;18:40-41 (Abstract)

Z

Zafrir N (*see* Ben-Gal et al). 1999;18:75-76 (Abstract)
Zakliczynski M (*see* Wojnicz et al). 1999;18:40 (Abstract)
Zamora MR (*see* Weill et al). 1999;18:55 (Abstract)
Zamora MR (*see* Weill et al). 1999;18:1080-87
Zamora MR, Sherman D, Olmos JJ, Torres F, Hodges TN. Cytomegalovirus immune globulin (CMVIG) in combination with gancyclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX). 1999;18:81 (Abstract)
Zander DS, Baz MA, Massey JK. Patterns and significance of CD44 expression in lung allografts. 1999;18:646-52
Zaremba LM (*see* Iannettoni et al). 1999;18:86-87 (Abstract)
Zeevi A (*see* McCurry et al). 1999;18:72 (Abstract)
Zeevi A (*see* Webber et al). 1999;18:83 (Abstract)

Zeevi A, Banas R, Spichty K, Logar A, Iacono A, Dauber J, McCurry K, Burchart G, Duquesnoy R, Yousem S, Keenan R, Griffith B. High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection. 1999;18:82 (Abstract)

Zeevi A, Pavlakis M, Cai J, Chang S, Spichty K, Iacono A, Dauber J, Keenan R, Yousem S, Burckart G, Duquesnoy R, McCurry K, Griffith B. Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection. 1999;18:81-82 (Abstract)

Zembala M (*see* Wojnicz et al). 1999;18:40 (Abstract)

Zhang JP (*see* Blair et al). 1999;18:54 (Abstract)

Zhang X (*see* Hachida et al). 1999;18:248-53

Zheng L, Orsida BE, Ward C, Wilson JW, Williams TJ, Walters EH, Snell GI. Airway vascular changes in lung allograft recipients. 1999;18:231-37

Zhong HP (*see* Wang et al). 1999;18:80 (Abstract)

Zhong R (*see* Parry et al). 1999;18:441-46

Ziegler S (*see* Schwaiblmair et al). 1999;18:838-44

Zimmermann R (*see* Dengler et al). 1999;18:61 (Abstract)

Zimmermann T (*see* Wagner et al). 1999;18:74 (Abstract)

Zoll J, Mettauer B, Sanchez H, Epailly E, Lonsdorfer E, Lampert E, Bigard AX, Veksler V, Ventura-Clapier R. Characterization of the skeletal muscle (SM) mitochondrial respiration in severe chronic heart failure (CHF) and its relations to the ventricular oxidative capacity. 1999;18:71 (Abstract)

Zorn GL (*see* Blair et al). 1999;18:54 (Abstract)

Zuckermann A (*see* Klepetko et al). 1999;18:45-46 (Abstract)

Zuckermann A (*see* Laufer et al). 1999;18:94 (Abstract)

Zuckermann A (*see* Mallinger et al). 1999;18:77 (Abstract)

Zuckermann A (*see* Takahashi et al). 1999;18:304-9

Zuckermann A, Grimm M, Ofner P, Ullrich R, Wolner E, Laufer G. Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation. 1999;18:93 (Abstract)

Zuckermann A, Klepetko W, Birsan T, Taghavi S, Artemiou O, Wisser W, Dekan G, Wolner E. Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation. 1999;18:432-39

Subject index*

A

ABO blood groups
Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? (Yu et al). 1999;18:764-68

Acetylcholine
Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure (Wensel et al). 1999;18:877-82

Adenosine receptors
Selective adenosine-A_{2A} activation reduces lung reperfusion injury following transplantation (Ross et al). 1999;18:72 (Abstract), 1999;18:994-1002

Administration, inhalational
Donor pre-treatment with inhaled nitric oxide attenuates acute lung injury following single lung transplantation (Sudarshan et al). 1999;18:78 (Abstract)
The effect of inhaled steroids on exhaled nitric oxide in lung transplant recipients with lymphocytic bronchitis (De Soyza et al). 1999;18:45 (Abstract)
The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)
Inhaled nitric oxide in early severe allograft lung dysfunction (Planas et al). 1999;18:55 (Abstract)
Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation (Carrier et al). 1999;18:664-67
Use of inhaled nitric oxide in cardiac transplantation (Williams et al). 1999;18:44 (Abstract)

Administration, intravenous. *See Infusions, intravenous*

β-Adrenergic blockers
Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience (Shaddy et al). 1999;18:269-74

Age
Age before beauty: the use of "older" donor hearts for cardiac transplantation (Young JB). 1999;18:488-90
An analysis of the effect of age on survival after heart transplant (Borkon et al). 1999;18:668-73
Does time to harvest determine outcome in heart transplantation with older allografts? (Scott et al). 1999;18:39 (Abstract)
Effect of donor age on young and older lung transplant recipients (Waddell et al). 1999;18:85 (Abstract)
Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18:675-83
Influence of graft ischemic time and donor age on survival after lung transplantation (Novick et al). 1999;18:425-31
The role of donor age and ischemic time on survival following orthotopic heart transplantation (Del Rizzo et al). 1999;18:310-19
Should advanced recipient age be contraindicated in cardiac transplantation? Continued analysis of a single center experience (Hoercher et al). 1999;18:45 (Abstract)

Airway disease, obliterative. *See* **Bronchiolitis obliterans**

Airway obstruction
Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction (Moy et al). 1999;18:986-93

Airway stenting
Results of expandable metal stent placement in lung transplant recipients (Baz et al). 1999;18:60 (Abstract)

Airway vascularity
Airway vascular changes in lung allograft recipients (Zheng et al). 1999;18:231-37

Ambulatory care
Development of a ventricular assist device for out-of-hospital use (Mussivand et al). 1999;18:166-71
Hemodynamic guided inotropic tailoring does not appear to impact long term survival among patients requiring chronic home inotropic therapy (Pathak et al). 1999;18:43 (Abstract)

January, pp 1-106; February, pp 107-74; March, pp 175-278; April, pp 279-390; May, pp 391-498; June, pp 499-610; July, pp 611-734; August, pp 735-818; September, pp 819-926; October, pp 927-1030; November, pp 1031-1150; December, pp 1151-1354.

Long term home discharge support with Novacor LVAS (Jansen et al). 1999;18:67-68 (Abstract)
Outpatient inotropic therapy in refractory heart failure (Oliva et al). 1999;18:75 (Abstract)

Anastomosis. *See* **Complete atrioventricular transplantation**

Angina pectoris

Transmyocardial laser revascularisation in class IV angina—a randomized trial (Spratt et al). 1999;18:42 (Abstract)

Angioplasty, balloon

Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy (Casella et al). 1143-46

Angiotensin-converting enzyme inhibition/inhibitor

Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation (Berger et al). 1999;18:75 (Abstract)

Animal models

Anti-CD3:F(ab′)2-idarubicin conjugates prolong mouse cardiac allografts (Mottram et al). 1999; 18:94 (Abstract)
Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84
Apoptosis induced by ischemia and reperfusion in experimental lung transplantation (Stammberger et al). 1999;18:79 (Abstract)
Apoptosis in rat cardiac allograft is predominantly associated with cells of the immune response (Agelan et al). 1999;18:40 (Abstract)
Assessment of murine bone marrow transplant chimeras (Krasinskas et al). 1999;18:88 (Abstract)
Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80
Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999; 18:73 (Abstract)
Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97
Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32
Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999;18: 470-76
Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18: 1054-64
Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91
Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography (Ducharme et al). 1999;18:510-16
Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91
A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:1202-10
A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)
Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection (Kulick et al). 1999;18:65 (Abstract)
Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats (Wada et al). 1999;18:499-508
Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment (Hirt et al). 1999;18:542-48
Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype (McLean et al). 1999;18:68 (Abstract)
Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit myocardium (Atkins et al). 1999; 18:43 (Abstract)
Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18: 735-43
Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double

knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)
Donor specific spleen cells mediate allograft survival by a different mechanism than bone marrow (Goldstein et al). 1999;18:69 (Abstract)
Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)
Effect of soluble complement receptor type 1 (sCR1) on experimental obliterative bronchiolitis (OB) (Kallio et al). 1999;18:52-53 (Abstract)
The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18:637-44
Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)
Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45
The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)
Effects of MHC class II antigens on the development of cardiac allograft vasculopathy in miniature swine (Mawulawde et al). 1999;18:53 (Abstract)
Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)
Feasibility of a pumpless extracorporeal respiratory assist device (De Somer et al). 1999;18:1014-17
Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients (Laufer et al). 1999;18:94 (Abstract)
Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)
Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999;18:48-49 (Abstract)
The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model (Hausen et al). 1999;18:714-24
IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)
Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts (Wilhelm et al). 1999;18:68 (Abstract)
Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection (Mannon et al). 1999;18:819-26
Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption (Brenner et al). 1999;18:59 (Abstract)
Inhibition of hyperacute pig-to-human xenograft rejection by modulating the fluid-phase complement activation (Fiane et al). 1999;18:66 (Abstract)
Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999;18:79-80 (Abstract)
Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)
Mixed hematopoietic chimerism prevents allograft vasculopathy (Kawaharada et al). 1999;18:532-40
A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? (Cable et al). 1999;18:177-83
Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium (Atkines et al). 1999;18:1173-80
A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dt_{max} (Dambrin et al). 1999;18:524-30
A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats (Ikonen et al). 1999;18:73 (Abstract)
Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis (Dambrin et al). 1999;18:946-51

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

Prevention of endothelial cell activation in hamster-to-rat cardiac xenografts by gene transfection of Bcl-2 (Kobayashi et al). 1999;18:66 (Abstract)

Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats (Slauson et al). 1999;18:1251-52 (Letter)

RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)

The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB) (Mulligan et al). 1999;18:88 (Abstract)

Regulatory roles of chemokines in delayed cardiac xenograft rejection (Mulligan et al). 1999; 18:59 (Abstract)

The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants (Lau et al). 1999;18:65-66 (Abstract)

A simple new model of physiologically working heterotopic rat heart transplantation provides hemodynamic performance equivalent to that of an orthotopic heart (Asfour et al). 1999;18: 927-36

Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

Soluble rat class I MHC proteins induce prolonged survival of rat cardiac allografts (Perez et al). 1999;18:68 (Abstract)

Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

Successful orthotopic pig heart transplantation from non-heart beating donors (Martin et al). 1999;18:597-605

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58

Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV (Fischbein et al). 1999;18:40-41 (Abstract)

Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (Gummert et al). 1999;18:53-54 (Abstract)

Transplantation of "thymoheart" allografts in miniature swine (Menard et al). 1999;18:71 (Abstract)

Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae (Ennen et al). 1999;18:49 (Abstract)

Von Willebrand deficient swine lungs transplanted into baboons (Lau et al). 1999;18:65 (Abstract)

Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts (Briffa et al). 1999;18:66 (Abstract)

Antibodies

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

Impact of antibodies to HLA class I molecules on the development of BOS (Smith et al). 1999; 18:51 (Abstract)

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation (Pisani et al). 1999;18:701-6

Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients (Moriguchi et al). 1999;18:76 (Abstract)

The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants (Lau et al). 1999;18:65-66 (Abstract)

The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients (Kerman et al). 1999;18:38 (Abstract)

Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts (Briffa et al). 1999;18:66 (Abstract)

Antibodies, monoclonal

Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84

Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB (Parry et al). 1999;18:441-46

Effective treatment of lymphoproliferative disease following lung transplantation using a monoclonal anti-CD20 B-cell antibody (Cook et al). 1999;18:84-85 (Abstract)

Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients (Laufer et al). 1999;18:94 (Abstract)

Use of Daclizumab decreases the frequency of early allograft rejection in de-novo heart transplant recipients (Beniaminovitz et al). 1999; 18:45 (Abstract)

Antidepressant therapy

Nefazodone and cyclosporine drug-drug interaction (Wright et al). 1999;18:913-15

Antigens, CD3

Anti-CD3:F(ab′)2-idarubicin conjugates prolong mouse cardiac allografts (Mottram et al). 1999; 18:94 (Abstract)

Antigens, CD20

Effective treatment of lymphoproliferative disease following lung transplantation using a monoclonal anti-CD20 B-cell antibody (Cook et al). 1999;18:84-85 (Abstract)

Antigens, CD25

Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients (Laufer et al). 1999;18:94 (Abstract)

Functional responses of anti-CD25 blocked T-cells during cardiac rejection (Baan et al). 1999;18:69 (Abstract)

Antigens, CD44

Patterns and significance of CD44 expression in lung allografts (Zander et al). 1999;18:646-52

Antigens, CD45

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB (Parry et al). 1999;18:441-46

Antigens, CD95

T cell activation in left ventricular assist device (LVAD) recipients occurs via a CD95-dependent pathway, and results in loss of Th1 cells and high levels of circulating IL-10 (Ankersmit et al). 1999;18:56 (Abstract)

Antilymphocyte globulin

Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant (Chaparro et al). 1999;18:46 (Abstract)

Aortic counterpulsation

Chronic aortic counterpulsation with latissimus dorsi in heart failure: clinical follow-up (Trainini et al). 1999;18:1120-25

Dynamic aortomyoplasty with latissimus dorsi: clinical follow-up (Trainini et al). 1999;18:42-43 (Abstract)

Aortic dissection

Valve-sparing repair after aortic root dissection following heart transplantation (Teebken et al). 1999;18:807-9

Aortic transplantation

Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999; 18:48-49 (Abstract)

Mixed hematopoietic chimerism prevents allograft vasculopathy (Kawaharada et al). 1999;18: 532-40

Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis (Dambrin et al). 1999;18:946-51

RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)

Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

Valve-sparing repair after aortic root dissection following heart transplantation (Teebken et al). 1999;18:807-9

Aortomyoplasty

Dynamic aortomyoplasty with latissimus dorsi: clinical follow-up (Trainini et al). 1999;18:42-43 (Abstract)

Apoptosis

The actions of cyclosporine-A on apoptosis and p53 expression in human vascular smooth muscle cells (Seta et al). 1999;18:61 (Abstract)

Apoptosis induced by ischemia and reperfusion in experimental lung transplantation (Stammberger et al). 1999;18:79 (Abstract)

Apoptosis in human cardiac allografts with transplant coronary artery disease (Xu et al). 1999; 18:90 (Abstract)
Apoptosis in rat cardiac allograft is predominantly associated with cells of the immune response (Agelan et al). 1999;18:40 (Abstract)
CD4 T cell mediated rejection of cardiac allograft is Fas/FasL sensitive (Pietra et al). 1999;18:48 (Abstract)
Donor specific spleen cells mediate allograft survival by a different mechanism than bone marrow (Goldstein et al). 1999;18:69 (Abstract)
Increased p53 protein expression in human failing myocardium (Song et al). 1999;18:744-48
T cell apoptosis and defects in cellular immunity induced by exposure to biomaterials: implications for left ventricular assist device (LVAD) implantation (Ankersmit et al). 1999;18:56 (Abstract)

Arginine vasopressin

Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation (Argenziano et al). 1999;18:814-17

Arrhythmias

Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient (Kaufman et al). 1999;18:1018-20
QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation (Dubin et al). 1999;18: 781-84
Radiofrequency ablation of a concealed accessory pathway years after heart transplant: a case report (Sharma et al). 1999;18:792-94
Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus (Pinski et al). 1999;18:292-96

Arteriopathy, transplant

Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy (Freudenberger et al). 1999;18:1228-31

Arteriosclerosis

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43
Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)
Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45
Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999; 18:48-49 (Abstract)
Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation (Zuckermann et al). 1999;18:93 (Abstract)
Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18: 248-53
Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis (Dambrin et al). 1999;18:946-51
RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)
Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

Artificial heart

Criteria for selecting type of bridge to heart transplantation: the University of Arizona experience (Arabia et al). 1999;18:89 (Abstract)
IVIG postpones alloimmunization in LVAD and artificial heart recipients (McKellar et al). 1999; 18:57 (Abstract)

Aspergillosis

Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation (Sandur et al). 1999;18:810-13

Atherosclerosis

Does initial photopheresis have an impact on the development of graft atherosclerosis after cardiac transplantation—a 6-year follow-up (Kur et al). 1999;18:93 (Abstract)

Atrial fibrillation

Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient (Kaufman et al). 1999;18:1018-20

Atrial flutter

Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus (Pinski et al). 1999;18:292-96

Atrial septal defect

Acquired atrial septal defect after heart transplantation (Voci et al). 1999;18:921-23 (Letter)

Australia
Maximizing thoracic organ transplant (TOTX) opportunities—the importance of efficient coordination (Griffiths et al). 1999;18:86 (Abstract)

Azathioprine
Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation (Zuckermann et al). 1999;18:432-39
Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? (Delgado et al). 1999;18:607-10

B

Baboon
The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants (Lau et al). 1999;18:65-66 (Abstract)
Von Willebrand deficient swine lungs transplanted into baboons (Lau et al). 1999;18:65 (Abstract)

Bacteremia
Is it safe to utilize hearts from donors with positive blood cultures? (Matsumiya et al). 1999;18:79 (Abstract)

Balloon angioplasty
Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy (Casella et al). 1143-46

Baroreflexes
Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation (Raczak et al). 1999;18:399-405

Basiliximab
Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Biological markers
Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172 (Letter)
Profile of soluble coagulant and inflammatory markers during long-term left ventricular assist device support (Fedalen et al). 1999;18:56-57 (Abstract)
Tumor marker determination after orthotopic heart transplantation (Nägele et al). 1999;18:957-62

Biopsy
Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172 (Letter)
Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11
Hematoma of the interventricular septum following right ventricular endomyocardial biopsy for the detection of allograft rejection after heart transplantation (Salim Roussouliéres et al). 1999;18:1147-50 (Letter)
International survey of routine surveillance biopsy practices in adult heart transplantation (Aaronson et al). 1999;18:80 (Abstract)

Bleeding, nonsurgical. *See also* **Hemostasis**
Vitamin K reduces bleeding in left ventricular assist device recipients (Kaplon et al). 1999;18:346-50

Blood group compatibility
Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? (Yu et al). 1999;18:764-68

Blood pressure
Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation (Argenziano et al). 1999;18:814-17
Hypertension during support with ventricular assist devices: incidence, risk factors and management (Stanford et al). 1999;18:58 (Abstract)
A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45
Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80

Body weight
Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18:750-60
Recipient weight as an independent risk factor in heart transplantation (Mullen et al). 1999;18:92 (Abstract)

Bone marrow transplantation

Assessment of murine bone marrow transplant chimeras (Krasinskas et al). 1999;18:88 (Abstract)

Efficacy of donor specific bone marrow in reducing frequency of rejection following heart transplantation (McGurl et al). 1999;18:93 (Abstract)

Immunomodulatory effects of donor bone marrow infusion in heart or lung transplantation: five year experience (McCurry et al). 1999; 18:72 (Abstract)

Transplantation of a lobe of a lung from mother to child after previous transplantation with bone marrow (Svendsen et al). 1999;18:388-89

Brachytherapy

High dose brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi; theoretical and clinical applications (Sonett et al). 1999;18:84 (Abstract)

Bradykinin

Coronary vasomotor response to the selective B_1 kinin receptor agonist des-Arg^9-bradykinin in transplant patients (Aptecar et al). 1999;18:64 (Abstract)

Brain death

Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97

Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience (Tsui et al). 1999;18:78-79 (Abstract)

Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts (Wilhelm et al). 1999;18:68 (Abstract)

The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study (Mehra et al). 1999; 18:49 (Abstract)

Mechanisms of brain death associated myocardial dysfunction (Bittner et al). 1999;18:87 (Abstract)

Role of neural and humoral factors in cardiac dysfunction in the potential organ donor (Szabó et al). 1999;18:39 (Abstract)

Bronchi

High dose brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi; theoretical and clinical applications (Sonett et al). 1999;18:84 (Abstract)

The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model (Hausen et al). 1999;18:714-24

Bronchial-associated lymphoid tissue (BALT)

The significance of bronchial associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? (Hasegawa et al). 1999;18:41 (Abstract)

Bronchiolitis obliterans

Airway vascular changes in lung allograft recipients (Zheng et al). 1999;18:231-37

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment (Hirt et al). 1999;18:542-48

Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS (Gabbay et al). 1999; 18:51 (Abstract)

Effect of soluble complement receptor type 1 (sCR1) on experimental obliterative bronchiolitis (OB) (Kallio et al). 1999;18:52-53 (Abstract)

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

Heterogeneity and reversal of bronchiolitis obliterans syndrome (Brazelton et al). 1999;18:59-60 (Abstract)

Impact of antibodies to HLA class I molecules on the development of BOS (Smith et al). 1999; 18:51 (Abstract)

Influence of HLA matching on survival and development of obliterative bronchiolitis (OB) after lung transplantation (Novick et al). 1999; 18:50-51 (Abstract)

Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients (Jonosono et al). 1999;18:972-85

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB) (Mulligan et al). 1999;18:88 (Abstract)

Salvage by volume reduction of chronic allograft rejection in emphysema (Schulman et al). 1999; 18:107-12

Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation (El-Gamel et al). 1999;18:828-35

Bronchitis
The effect of inhaled steroids on exhaled nitric oxide in lung transplant recipients with lymphocytic bronchitis (De Soyza et al). 1999;18:45 (Abstract)
Bronchogenic carcinoma
Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

C

Cachexia
Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18:750-60
Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900
Calcium
Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18:675-83
Calcium channel blockers
Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32
Canada
Post-transplant lymphoproliferative disease (PTLD) following lung transplantation in Canadian transplant centers (Partovi et al). 1999;18:85 (Abstract)
Cancer. *See* **Malignancy**
Capillaries
Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11
Captopril
Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999;18:470-76
Carcinoembryonic antigen
Tumor marker determination after orthotopic heart transplantation (Nägele et al). 1999;18:957-62
Carcinoma. *See* **Malignancy**
Cardiac function
Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97
Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18:1054-64
Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)
Functional significance of cardiac reinnervation in heart transplant recipients (Schwaiblmair et al). 1999;18:838-44
Immunoglobulin adsorption as effective treatment of severe dilated cardiomyopathy (Müller et al). 1999;18:70-71 (Abstract)
Left ventricular diastolic function after bicaval and standard cardiac transplantation (Burgess et al). 1999;18:44-45 (Abstract)
Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure (Drazner et al). 1999;18:1126-32
Role of neural and humoral factors in cardiac dysfunction in the potential organ donor (Szabó et al). 1999;18:39 (Abstract)
A simple new model of physiologically working heterotopic rat heart transplantation provides hemodynamic performance equivalent to that of an orthotopic heart (Asfour et al). 1999;18:927-36
Cardiac reinnervation. *See* **Donor heart, reinnervation**
Cardiomyopathy
Low cardiac neuronal function and predicted value of maximum oxygen consumption predict for high risk of cardiac events in cardiomyopathy (Agostini et al). 1999;18:47 (Abstract)
QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation (Dubin et al). 1999;18:781-84
Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80
Cardiomyopathy, dilated
Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy (Belland et al). 1999;18:54 (Abstract)
Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience (Shaddy et al). 1999;18:269-74

Immunoglobulin adsorption as effective treatment of severe dilated cardiomyopathy (Müller et al). 1999;18:70-71 (Abstract)

Partial left ventriculectomy in a two-year old girl with dilated cardiomyopathy (Gradinac et al). 18:610, 1999;18:381-83

Cardiomyopathy, ischemic

Left ventricular reconstruction using the Dor procedure for ischemic aneurysm or akinetic dilatation (Marullo et al). 1999;18:42 (Abstract)

Transmyocardial laser revascularization (TMR) in ischemic cardiomyopathy (Grauhan et al). 1999;18:66 (Abstract)

Cardiomyoplasty

Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit myocardium (Atkins et al). 1999; 18:43 (Abstract)

Randomised trial of cardiomyoplasty against optimal medical therapy in class III heart failure (Keogh et al). 1999;18:67 (Abstract)

Cardioprotection

Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

Cardiotonic agents. *See* **Inotropic therapy**

Cardioversion

Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient (Kaufman et al). 1999;18:1018-20

Carvedilol

Time course of reverse left ventricular remodeling in response to carvedilol in heart failure (McCaffrey et al). 1999;18:76 (Abstract)

Catecholamines

Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80

Cats

Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97

Cell adhesion molecules

Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin (Raisky et al). 1999; 18:61 (Abstract)

Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans (Wildhirt et al). 1999;18:64-65 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)

Cell death, programmed. *See* **Apoptosis**

Cell transplantation

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium (Atkines et al). 1999;18:1173-80

Celsior preservation solution

Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91

A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:1202-10

A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function (Wittwer et al). 1999;18:1198-1201

Protective effects of Celsior in lung transplantation (Xiong et al). 1999;18:320-26

Chemokines

The effect of intra-pulmonary CXC-chemokines in the donor lung on early graft function after

lung transplantation (Fisher et al). 1999;18:88 (Abstract)
Regulatory roles of chemokines in delayed cardiac xenograft rejection (Mulligan et al). 1999; 18:59 (Abstract)

Child(ren)

Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience (Shaddy et al). 1999;18:269-74
Death after heart transplantation in children: who dies when and why (Frazier et al). 1999;18: 69-70 (Abstract)
Dobutamine stress echocardiography: experience in pediatric heart transplant recipients (Pahl et al). 1999;18:725-32
Early graft dysfunction in pediatric lung transplant recipients (Sweet et al). 1999;18:82-83 (Abstract)
Education and the transplanted child (Wray et al). 1999;18:57 (Abstract)
The effect of pre lung transplant clinical status on post transplant outcome for children with cystic fibrosis: a ten year experience (Gassas et al). 1999;18:83 (Abstract)
Evaluation of circulating Epstein-Barr virus (EBV) viral load in pediatric thoracic recipients: implications for diagnosis of posttransplant lymphoproliferative disorders (PTLD) (Webber et al). 1999;18:83 (Abstract)
Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)
Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18: 675-83
Implantable left ventricular assist devices can successfully bridge pediatric patients to transplant (Helman et al). 1999;18:89 (Abstract)
Induction immunotherapy in pediatric heart transplant recipients: a multicenter study (Boucek Jr et al). 1999;18:460-69
Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)
Late rejection greater than 1 year after pediatric heart transplantation: an ominous finding (Webber et al). 1999;18:69 (Abstract)
Medium term results of children with two hearts (Radley-Smith et al). 1999;18:84 (Abstract)
Mycophenolate mofetil in paediatric heart transplant recipients: a single center experience (Dipchand et al). 1999;18:83-84 (Abstract)
Non compliance causing late acute rejection in pediatric heart transplantation (Ringewald et al). 1999;18:70 (Abstract)
Optimal dosing of intravenous tacrolimus following pediatric heart transplantation (Robinson et al). 1999;18:786-90
Outcome of infants listed for lung and heart/lung transplantation (Ro et al). 1999;18:1232-37
Outcome of infants listed for lung or heart/lung transplantation (Ro et al). 1999;18:83 (Abstract)
Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study (Bernstein et al). 1999;18:69 (Abstract)
Partial left ventriculectomy in a two-year old girl with dilated cardiomyopathy (Gradinac et al). 18:610, 1999;18:381-83
Pediatric cardiac retransplantation: experience at a single institution (Dearani et al). 1999;18:70 (Abstract)
Pediatric heart transplant school re-entry (Rodgers et al). 1999;18:58 (Abstract)
Pulmonary volume increases with linear growth in pediatric living donor lobar lung transplant recipients (Woo et al). 1999;18:86 (Abstract)
QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation (Dubin et al). 1999;18: 781-84
The Registry of the International Society for Heart and Lung Transplantation: Third Official Pediatric Report (Boucek et al). 1999;18:1151-72 (Registry)
Risk factor analysis for inappropriate growth after pediatric heart transplantation (HTX) (Flaspohler et al). 1999;18:91 (Abstract)
Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results (Ibrahim et al). 1999;18:83 (Abstract)
Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12
Ten-year follow-up after pediatric transplantation (Parisi et al). 1999;18:275-77
Transplantation of a lobe of a lung from mother to child after previous transplantation with

bone marrow (Svendsen et al). 1999;18:388-89 (Letter)

Chimeras

Assessment of murine bone marrow transplant chimeras (Krasinskas et al). 1999;18:88 (Abstract)

Mixed hematopoietic chimerism prevents allograft vasculopathy (Kawaharada et al). 1999;18:532-40

Cholestasis

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? (Delgado et al). 1999;18:607-10

Circulatory support. *See also* **Left ventricular assist device**

Chronic aortic counterpulsation with latissimus dorsi in heart failure: clinical follow-up (Trainini et al). 1999;18:1120-25

Development of a ventricular assist device for out-of-hospital use (Mussivand et al). 1999;18:166-71

Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance (Chen et al). 1999;18:351-57

Inter-hospital transfer of patients receiving advanced mechanical circulatory support (McBride et al). 1999;18:90 (Abstract)

Mechanical unloading restores beta-adrenergic responsiveness in the failing human heart (Ogletree-Hughes et al). 1999;18:63 (Abstract)

Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmocologic circulatory support (Gronda et al). 1999;18:654-61

Cold preservation

Alteration in diastolic function following cardiac cryopreservation at subzero temperatures (Gutiérrez-Carretero et al). 1999;18:372-75

The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function (Parry et al). 1999;18:121-25

Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors (Kevelaitis et al). 1999;18:239-46

Differential time scale of fluid and solute permeability following hypothermic lung preservation (Rooney et al). 1999;18:73 (Abstract)

Donor-specific high avidity cytotoxic T-lymphocytes induced by implantation of cryopreserved human cardiac valves (Welters et al). 1999;18:53 (Abstract)

Gas exchange function one month after transplantation of lungs topically cooled for 2 hours in the non-heart-beating cadaver after failed resuscitation (Wierup et al). 1999;18:133-37

Long-term heart preservation using a new portable hypothermic perfusion apparatus (Oshima et al). 1999;18:852-61

Modulation of pulmonary Na^+ pump gene expression during cold storage and reperfusion (Kim et al). 1999;18:74 (Abstract)

A novel cell culture model for aerobic, hypothermic lung preservation for transplantation (Cardella et al). 1999;18:88 (Abstract)

Collateral circulation

Coronary artery to pulmonary artery collaterals after heart transplantation (Balfour et al). 1999;18:1027-29

Complement

Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11

Effect of soluble complement receptor type 1 (sCR1) on experimental obliterative bronchiolitis (OB) (Kallio et al). 1999;18:52-53 (Abstract)

Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)

Inhibition of hyperacute pig-to-human xenograft rejection by modulating the fluid-phase complement activation (Fiane et al). 1999;18:66 (Abstract)

Complete atrioventricular transplantation

Orthotopic heart transplantation: which technique? Comment on the prospective randomized trial of CAVT by Bainbridge et al. (Aziz et al). 1999;18:1253 (Letter)

A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty (Bainbridge et al). 1999;18:407-12

Compliance with treatment

Diagnostic value of structured interviews in assessing noncompliance with immunosuppressive therapy in heart transplant recipients (De Geest et al). 1999;18:91 (Abstract)

Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation (Dew et al). 1999;18:549-59

Impact of patient noncompliance on survival in cardiac transplant recipients (Lawless et al). 1999;18:38 (Abstract)

Non compliance causing late acute rejection in pediatric heart transplantation (Ringewald et al). 1999;18:70 (Abstract)

Computed tomography

Noninvasive cost-effective detection of cardiac allograft vasculopathy by electron beam computed tomography (EBCT) (Hummel et al). 1999;18:49 (Abstract)

Congenital heart disease

Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)

Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study (Bernstein et al). 1999;18:69 (Abstract)

Congestive cardiomyopathy. *See* **Cardiomyopathy, dilated**

Congestive heart failure. *See* **Heart failure**

Coronary angiography

Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

Coronary angioplasty

Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy (Casella et al). 1143-46

Coronary artery(ies)

Coronary artery to pulmonary artery collaterals after heart transplantation (Balfour et al). 1999;18:1027-29

Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors (Kevelaitis et al). 1999;18:239-46

Coronary vasomotor response to the selective B_1 kinin receptor agonist des-Arg^9-bradykinin in transplant patients (Aptecar et al). 1999;18:64 (Abstract)

Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34

Cytokine transcripts in coronary arteries and coronary artery-derived T-cell lines from patients with chronic rejection (Slachta et al). 1999; 18:41 (Abstract)

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

Endothelin in coronary endothelial dysfunction early after human heart transplantation (Weis et al). 1999;18:1071-79

Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients (Weis et al). 1999;18:64 (Abstract)

Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction (Rieber et al). 1999;18:65 (Abstract)

Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients (Allen-Auerbach et al). 1999;18:211-18

The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Coronary artery bypass grafting

Revascularisation for post-ischaemic heart failure: how myocardial viability affects survival (Pagano et al). 1999;18:67 (Abstract)

Coronary artery disease

Apoptosis in human cardiac allografts with transplant coronary artery disease (Xu et al). 1999; 18:90 (Abstract)

Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999;18:470-76

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Coronary arteries of human cardiac allografts with transplant coronary artery disease contain oligoclonal populations of T lymphocytes (Slachta et al). 1999;18:60 (Abstract)

Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant

recipients (Kobashigawa et al). 1999;18:50 (Abstract)

Hemoglobin A1C predicts transplant coronary artery disease incidence and severity (Kato et al). 1999;18:50 (Abstract)

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

Is the use of left ventricular assist device as a bridge to heart transplantation a risk factor for development of transplant coronary artery disease? (Radovancevic et al). 1999;18:63 (Abstract)

Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction (Rieber et al). 1999;18:65 (Abstract)

Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18:248-53

Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy (Casella et al). 1143-46

Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients (Moriguchi et al). 1999;18:76 (Abstract)

Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae (Ennen et al). 1999;18:49 (Abstract)

Coronary microcirculation

Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans (Wildhirt et al). 1999;18:64-65 (Abstract)

Coronary revascularization. *See* **Transmyocardial laser revascularization**

Coronary vascular reactivity

Coronary vasomotor response to the selective B_1 kinin receptor agonist des-Arg^9-bradykinin in transplant patients (Aptecar et al). 1999;18:64 (Abstract)

Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients (Weis et al). 1999;18:64 (Abstract)

The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Cor pulmonale

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Corrections

Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 1999;18:610

Determinants of waiting time for heart transplants in the United States (Kauffman et al). 1999;18:733

Partial left ventriculectomy in a two-year old girl with dilated cardiomyopathy (Gradinac et al). 1999;18:610

Correspondence

Acquired atrial septal defect after heart transplantation (Voci et al). 1999;18:921-23

Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172

Diphtheria by donation (Gould et al). 1999;18: 173-74

Hematoma of the interventricular septum following right ventricular endomyocardial biopsy for the detection of allograft rejection after heart transplantation (Salim Roussouliéres et al). 1999;18:1147-50

Mitral valve myxoma: an unusual reason for rejecting a donor heart (de Boer et al). 1999;18: 924-25

Orthotopic heart transplantation: which technique? Comment on the prospective randomized trial of CAVT by Bainbridge et al. (Aziz et al). 1999;18:1253

Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. (van Enckevort et al). 1999;18:496-97

Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats (Slauson et al). 1999;18:1251-52

Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (Plenz et al). 1999;18: 923-24

Summary measures: a superior method of data analysis in lung preservation studies (Clark et al). 1999;18:172-73

Transplantation of a lobe of a lung from mother to child after previous transplantation with bone marrow (Svendsen et al). 1999;18:388-89

Corticosteroids. *See* **Steroids**

Cost analysis

Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU) (Peacock et al). 1999;18:92 (Abstract)

Cost-utility analysis

Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. (van Enckevort et al). 1999;18:496-97 (Letter)

Creatinine

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation (Cook et al). 1999;18:420-24

TGF beta polymorphism does not influence the rise in creatinine following cardiac transplantation (Densem et al). 1999;18:77 (Abstract)

Cryopreservation

Alteration in diastolic function following cardiac cryopreservation at subzero temperatures (Gutiérrez-Carretero et al). 1999;18:372-75

Donor-specific high avidity cytotoxic T-lymphocytes induced by implantation of cryopreserved human cardiac valves (Welters et al). 1999; 18:53 (Abstract)

Cyclic AMP

Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection (Kulick et al). 1999;18:65 (Abstract)

Cyclic GMP

8-BR-cyclic GMP given during reperfusion improves posttransplant lung edema and free radical injury (Hillinger et al). 1999;18:74 (Abstract)

Cyclooxygenase

Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy (Belland et al). 1999; 18:54 (Abstract)

Cyclophosphamide

Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease (Balfour et al). 1999;18:492-94

Cyclophosphamide rescue therapy for chronic rejection after lung transplantation (Verleden et al). 1999;18:1139-46

Cyclosporine

The actions of cyclosporine-A on apoptosis and p53 expression in human vascular smooth muscle cells (Seta et al). 1999;18:61 (Abstract)

Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84

Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy (Freudenberger et al). 1999;18:1228-31

Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour peak levels compared to trough levels in stable heart transplant patients (Cantarovich et al). 1999;18:78 (Abstract)

Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Meiser et al). 1999;18:78 (Abstract)

Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB (Parry et al). 1999;18:441-46

Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18: 185-88

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Multicenter, double-blind, randomized study of Neoral vs Sandimmune in heart transplantation: one year results (Eisen et al). 1999;18:93 (Abstract)

Nefazodone and cyclosporine drug-drug interaction (Wright et al). 1999;18:913-15

p21 overexpression inhibits cell proliferation and enhances cyclosporine's antiproliferative effects: a novel strategy for immunosuppression (Khanna et al). 1999;18:49 (Abstract)

Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) (Klepetko et al). 1999;18: 45-46 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome (Myers et al). 1999;18:1024-26

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58

Cystic fibrosis

The effect of pre lung transplant clinical status on post transplant outcome for children with cystic fibrosis: a ten year experience (Gassas et al). 1999;18:83 (Abstract)

Optimal timing of lung transplantation in cystic fibrosis patients (Cahill et al). 1999;18:86 (Abstract)

Predictors of survival to transplant in cystic fibrosis: impact of international listing guidelines (Keenan et al). 1999;18:55 (Abstract)

Cytochrome P450

Nefazodone and cyclosporine drug-drug interaction (Wright et al). 1999;18:913-15

Cytokines

Cytokine transcripts in coronary arteries and coronary artery-derived T-cell lines from patients with chronic rejection (Slachta et al). 1999; 18:41 (Abstract)

Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection (Mannon et al). 1999;18:819-26

Induction of cardiac allograft endothelial dysfunction by cytokines in humans (Weis et al). 1999; 18:64 (Abstract)

Inflammatory cytokines and hepatic sinusoid endothelial dysfunction play a role in hyperbilirubinemia in patients following implantation of an LVAS (Nishimura et al). 1999;18:57 (Abstract)

Metallothionein: localization in human transplant endomycardium, relation to cytokines and allograft function (Baba et al). 1999;18:963-71

Cytomegalovirus (CMV)

Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX) (Zamora et al). 1999;18:81 (Abstract)

Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients (Wreghitt et al). 1999; 18:82 (Abstract)

Effects of oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients (Chan et al). 1999;18:85 (Abstract)

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

The impact of ganciclovir-resistant cytomegalovirus infection in lung transplantation (Kruger et al). 1999;18:82 (Abstract)

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Cytomegalovirus immune globulin (CMVIG)

CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation (Valantine et al). 1999;18:81 (Abstract)

Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX) (Zamora et al). 1999;18:81 (Abstract)

Cytotoxic T lymphocytes. *See* **T cells (T lymphocytes), cytotoxic**

D

Daclizumab

Use of Daclizumab decreases the frequency of early allograft rejection in de-novo heart transplant recipients (Beniaminovitz et al). 1999; 18:45 (Abstract)

Data analysis
Summary measures: a superior method of data analysis in lung preservation studies (Clark et al). 1999;18:172-73 (Letter)
Death. *See* **Mortality**
Decay accelerating factor
Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)
Deconditioning
Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900
Diastole
Alteration in diastolic function following cardiac cryopreservation at subzero temperatures (Gutiérrez-Carretero et al). 1999;18:372-75
Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit myocardium (Atkins et al). 1999; 18:43 (Abstract)
Left ventricular diastolic function after bicaval and standard cardiac transplantation (Burgess et al). 1999;18:44-45 (Abstract)
Dilated cardiomyopathy. *See* **Cardiomyopathy, dilated**
Diphtheria
Diphtheria by donation (Gould et al). 1999;18: 173-74 (Letter)
Dobutamine
Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65
Dobutamine stress echocardiography: experience in pediatric heart transplant recipients (Pahl et al). 1999;18:725-32
Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)
Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18:391-97
Dogs
Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91
Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography (Ducharme et al). 1999;18:510-16
A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:1202-10
A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)
The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18: 637-44
Donor heart, failure
Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation (Carrier et al). 1999;18:664-67
Donor heart, preservation. *See* **Organ preservation, heart**
Donor heart, reinnervation
Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation (Raczak et al). 1999;18:399-405
Functional significance of cardiac reinnervation in heart transplant recipients (Schwaiblmair et al). 1999;18:838-44
Donor lung, preservation. *See* **Organ preservation, lung**
Donor management
The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function (Parry et al). 1999;18:121-25
Does time to harvest determine outcome in heart transplantation with older allografts? (Scott et al). 1999;18:39 (Abstract)
Effect of donor age on young and older lung transplant recipients (Waddell et al). 1999; 18:85 (Abstract)
Gas exchange function one month after transplantation of lungs topically cooled for 2 hours in the non-heart-beating cadaver after failed resuscitation (Wierup et al). 1999;18:133-37
Dopamine
Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97
Doppler ultrasound
Functional and morphological findings in heart transplant recipients with a normal coronary

angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

Dor procedure

Left ventricular reconstruction using the Dor procedure for ischemic aneurysm or akinetic dilatation (Marullo et al). 1999;18:42 (Abstract)

Dose adjustment

MPA-dose adjustment based on trough levels-high and low dose pharmocokinetics in heart transplanted patients (Schmidt et al). 1999; 18:46 (Abstract)

Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection (Trull et al). 1999;18:93 (Abstract)

Drug interactions

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Nefazodone and cyclosporine drug-drug interaction (Wright et al). 1999;18:913-15

E

Echocardiography

Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography (Ducharme et al). 1999;18:510-16

Dobutamine stress echocardiography: experience in pediatric heart transplant recipients (Pahl et al). 1999;18:725-32

Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)

Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection (Moidl et al). 1999;18:194-200

Edema

Edema treatment during cardiac allograft (Johnsson et al). 1999;18:1238-42

8-BR-cyclic GMP given during reperfusion improves posttransplant lung edema and free radical injury (Hillinger et al). 1999;18:74 (Abstract)

Editorials

Suggested guidelines for the use of tacrolimus in lung-transplant recipients (Garrity et al). 1999; 18:175-76

Electrocardiography

QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation (Dubin et al). 1999;18: 781-84

Electrophysiology

Noninvasive cardiac graft monitoring: the Graz experience (Grasser et al). 1999;18:80 (Abstract)

Radiofrequency ablation of a concealed accessory pathway years after heart transplant: a case report (Sharma et al). 1999;18:792-94

Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus (Pinski et al). 1999;18:292-96

Emphysema

Acute native lung hyperinflation (ANLH) is not associated with poor outcome after single lung transplant (SLT) for emphysema (Weill et al). 1999;18:55 (Abstract)

Acute native lung hyperinflation is not associated with poor outcomes after single lung transplant for emphysema (Weill et al). 1999;18:1080-87

Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction (Moy et al). 1999;18:986-93

Salvage by volume reduction of chronic allograft rejection in emphysema (Schulman et al). 1999; 18:107-12

Employment

Return to work after heart transplantation: 12-year follow-up (Kavanagh et al). 1999;18:846-50

Endocarditis

Cardiac transplantation for prosthetic valve endocarditis in a previously transplanted heart (Galbraith et al). 1999;18:805-6

Endomyocardial biopsy. *See* **Biopsy**

Endothelin receptor antagonists

Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung isch-

emia/reperfusion injury (Stammberger et al). 1999;18:862-67

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

Synergistic effect of endothelin- and PAF antagonists on posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:74-75 (Abstract)

Endothelins

Endothelin in coronary endothelial dysfunction early after human heart transplantation (Weis et al). 1999;18:1071-79

The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients (Weis et al). 1999;18:64 (Abstract)

Sequential evaluation of big endothelin plasma concentration in patients with advanced heart failure: effects of therapy (Berger et al). 1999; 18:47 (Abstract)

Endothelium

Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure (Wensel et al). 1999;18:877-82

Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy (Belland et al). 1999; 18:54 (Abstract)

Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors (Kevelaitis et al). 1999;18:239-46

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Endothelin in coronary endothelial dysfunction early after human heart transplantation (Weis et al). 1999;18:1071-79

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Induction of cardiac allograft endothelial dysfunction by cytokines in humans (Weis et al). 1999; 18:64 (Abstract)

Inflammatory cytokines and hepatic sinusoid endothelial dysfunction play a role in hyperbilirubinemia in patients following implantation of an LVAS (Nishimura et al). 1999;18:57 (Abstract)

A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? (Cable et al). 1999;18:177-83

Prevention of endothelial cell activation in hamster-to-rat cardiac xenografts by gene transfection of Bcl-2 (Kobayashi et al). 1999;18:66 (Abstract)

Eosinophil count

Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection (Trull et al). 1999;18:93 (Abstract)

Eosinophilia

Hypersensitivity eosinophilia: a unique cause of cardiac decompensation in inotropic dependent heart failure? (Uber et al). 1999;18:43 (Abstract)

Epithelium

Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute rejection and proliferation of α-actin positive cells (Ikonen et al). 1999;18:60 (Abstract)

IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Epoprostenol

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Epstein-Barr virus (EBV)

Evaluation of circulating Epstein-Barr virus (EBV) viral load in pediatric thoracic recipients: implications for diagnosis of posttransplant lymphoproliferative disorders (PTLD) (Webber et al). 1999;18:83 (Abstract)

E-selectin

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Estrogen
Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Euro Collins solution
Comparison of Euro Collins- and low potassium dextran (Perfadex) solution in clinical lung preservation (Müller et al). 1999;18:40 (Abstract)

Exercise
Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial (Jaski et al). 1999;18:1031-40
Long term physical training in cardiac transplant candidates: is it feasible? (Ben-Gal et al). 1999; 18:75-76 (Abstract)
Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation (Lands et al). 1999;18:113-19
Resting left ventricular size predicts improved native cardiac output during exercise and the ability to exercise with the device weaned in patients with the TCI Heartmate left ventricular assist device (Maybaum et al). 1999;18:44 (Abstract)
Resting myocardial blood flow and metabolism predicts improved native left ventricular output and the ability to exercise with weaning in patients with the TCI Heartmate left ventricular assist device (Maybaum et al). 1999;18:62 (Abstract)

Exercise test
Dobutamine stress echocardiography: experience in pediatric heart transplant recipients (Pahl et al). 1999;18:725-32
Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)
Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

Extracorporeal membrane oxygenation
Temporary ECMO support following lung and heart-lung transplantation (Nguyen et al). 1999; 18:55 (Abstract)

Extracorporeal respiratory assist device
Feasibility of a pumpless extracorporeal respiratory assist device (De Somer et al). 1999;18: 41-42 (Abstract), 1999;18:1014-17

F

Famciclovir
Famciclovir treatment of chronic hepatitis B in heart transplant recipients (Wedemeyer et al). 1999;18:81 (Abstract)

Felodipine
Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Female. *See* **Women**

Fibrinogens
The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Fibrinolysis
Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation (Sartori et al). 1999;18:693-99

Fibroblast proliferative activity
Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients (Jonosono et al). 1999;18:972-85

FK-506. *See also* **Tacrolimus**
Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy (Freudenberger et al). 1999;18:1228-31

Flow cytometry
The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients (Kerman et al). 1999;18:38 (Abstract)

Follow-up studies
Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Meiser et al). 1999;18:78 (Abstract)
Does initial photopheresis have an impact on the development of graft atherosclerosis after cardiac transplantation—a 6-year follow-up (Kur et al). 1999;18:93 (Abstract)
Five-year follow-up of a randomized trial of pravastatin in heart transplant patients (Kobashigawa et al). 1999;18:71 (Abstract)

The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients (Weis et al). 1999;18:64 (Abstract)

Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients after resolution of non-ischemic heart failure (Farrar et al). 1999;18:62-63 (Abstract)

Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)

A post mortem audit of deaths occurring beyond 30 days following heart-lung transplantation (Bardsley et al). 1999;18:41 (Abstract)

Return to work after heart transplantation: 12-year follow-up (Kavanagh et al). 1999;18:846-50

Ten-year follow-up after pediatric transplantation (Parisi et al). 1999;18:275-77

Fontan procedure

Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study (Bernstein et al). 1999;18:69 (Abstract)

Foramen ovale, patent

Transcatheter closure of patent foramen ovale for hypoxemia during left ventricular assist device support (Nguyen et al). 1999;18:1021-23

Functional imaging

Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97

Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18:1054-64

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients (Allen-Auerbach et al). 1999;18:211-18

Fungal infection

Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation (Sandur et al). 1999;18:810-13

Successful eradication of mucormycosis occurring in a pulmonary allograft (Hunstad et al). 1999;18:801-4

G

Gabexate mesilate

The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)

Ganciclovir

Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX) (Zamora et al). 1999;18:81 (Abstract)

Effects of oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients (Chan et al). 1999;18:85 (Abstract)

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

The impact of ganciclovir-resistant cytomegalovirus infection in lung transplantation (Kruger et al). 1999;18:82 (Abstract)

Gastroesophageal reflux

Gastroesophageal reflux is an important cause of allograft dysfunction in lung transplant recipients (Palmer et al). 1999;18:51 (Abstract)

Gene therapy

CD4 T cell mediated rejection of cardiac allograft is Fas/FasL sensitive (Pietra et al). 1999;18:48 (Abstract)

Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999;18:48-49 (Abstract)

p21 overexpression inhibits cell proliferation and enhances cyclosporine's antiproliferative effects: a novel strategy for immunosuppression (Khanna et al). 1999;18:49 (Abstract)

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)

Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae (Ennen et al). 1999;18:49 (Abstract)

Gene transfection

Gene transfection of donor lungs prior to organ procurement increases transgene levels at

reperfusion and following transplantation (Cassivi et al). 1999;18:88-89 (Abstract)

Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts (Iwata et al). 1999;18:37 (Abstract)

Prevention of endothelial cell activation in hamster-to-rat cardiac xenografts by gene transfection of Bcl-2 (Kobayashi et al). 1999;18:66 (Abstract)

Transtracheal gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation (Cassivi et al). 1181-88

Glucose intolerance

Hemoglobin A1C predicts transplant coronary artery disease incidence and severity (Kato et al). 1999;18:50 (Abstract)

Granzyme-B

Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection (Zeevi et al). 1999;18:81-82 (Abstract)

H

Heart failure

Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure (Wensel et al). 1999;18:877-82

Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience (Shaddy et al). 1999;18:269-74

Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65

Characterization of the skeletal muscle (SM) mitochondrial respiration in severe chronic heart failure (CHF) and its relations to the ventricular oxidative capacity (Zoll et al). 1999;18:71 (Abstract)

Chronic aortic counterpulsation with latissimus dorsi in heart failure: clinical follow-up (Trainini et al). 1999;18:1120-25

Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial (Jaski et al). 1999;18:1031-40

Factors affecting outcome in patients "too well" for heart transplantation at initial assessment (Eccleshall et al). 1999;18:46 (Abstract)

Failure to wean from parenteral inotropes: a strong predictor for early mortality among patients with end stage heart disease (Park et al). 1999;18:47-48 (Abstract)

Hypersensitivity eosinophilia: a unique cause of cardiac decompensation in inotropic dependent heart failure? (Uber et al). 1999;18:43 (Abstract)

Increased p53 protein expression in human failing myocardium (Song et al). 1999;18:744-48

Intravenous (IV) inotrope and vasodilator therapy in a critical care setting utilizing a heart failure specialty team care approach (HFSTC) with "hemodynamic goal" protocols vs. a general cardiology care approach (GCC) (Albert et al). 1999;18:75 (Abstract)

Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients after resolution of non-ischemic heart failure (Farrar et al). 1999;18:62-63 (Abstract)

Long term physical training in cardiac transplant candidates: is it feasible? (Ben-Gal et al). 1999; 18:75-76 (Abstract)

Low cardiac neuronal function and predicted value of maximum oxygen consumption predict for high risk of cardiac events in cardiomyopathy (Agostini et al). 1999;18:47 (Abstract)

Mechanical unloading restores beta-adrenergic responsiveness in the failing human heart (Ogletree-Hughes et al). 1999;18:63 (Abstract)

Mechanisms of brain death associated myocardial dysfunction (Bittner et al). 1999;18:87 (Abstract)

Outpatient inotropic therapy in refractory heart failure (Oliva et al). 1999;18:75 (Abstract)

Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU) (Peacock et al). 1999;18:92 (Abstract)

Prognostic value of circulating levels of interleukin-6 in patients with congestive heart failure (Roig et al). 1999;18:91 (Abstract)

Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation (Berger et al). 1999;18:75 (Abstract)

Prognostic value of the relative lymphocyte concentration and white blood cell count in heart failure (Rayburn et al). 1999;18:47 (Abstract)

Randomised trial of cardiomyoplasty against optimal medical therapy in class III heart failure (Keogh et al). 1999;18:67 (Abstract)

Refining the criteria for heart transplant listing and status: a multi-institutional risk factor analysis for rehospitalization following listing (Kirklin et al). 1999;18:47 (Abstract)

Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure (Drazner et al). 1999;18:1126-32

Revascularisation for post-ischaemic heart failure: how myocardial viability affects survival (Pagano et al). 1999;18:67 (Abstract)

Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (Plenz et al). 1999;18: 923-24 (Letter)

Reversal of the heart failure phenotype by mechanical unloading (DiIulio et al). 1999;18: 89-90 (Abstract)

Sequential evaluation of big endothelin plasma concentration in patients with advanced heart failure: effects of therapy (Berger et al). 1999; 18:47 (Abstract)

Sexuality of patients with advanced heart failure and their spouses or partners (Westlake et al). 1999;18:1133-38

Sudden death and tailored medical therapy in elective candidates for heart transplantation (Nägele et al). 1999;18:869-75

Time course of reverse left ventricular remodeling in response to carvedilol in heart failure (McCaffrey et al). 1999;18:76 (Abstract)

Treatment differences and clinical outcomes of advanced heart failure (HF) patients with a critical care admission using specialist team protocols vs. general cardiology care (Albert et al). 1999;18:76 (Abstract)

The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension (Pamboukian et al). 1999;18:367-70

Heart-lung transplantation

CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation (Valantine et al). 1999;18:81 (Abstract)

Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients (Wreghitt et al). 1999; 18:82 (Abstract)

Education and the transplanted child (Wray et al). 1999;18:57 (Abstract)

Outcome of infants listed for lung and heart/lung transplantation (Ro et al). 1999;18:1232-37

Outcome of infants listed for lung or heart/lung transplantation (Ro et al). 1999;18:83 (Abstract)

A post mortem audit of deaths occurring beyond 30 days following heart-lung transplantation (Bardsley et al). 1999;18:41 (Abstract)

Recurrent *Pneumocystic carinii* colonization in a heart-lung transplantation recipient on long-term trimethoprin-sulfamethoxazole prophylaxis (Faul et al). 1999;18:384-87

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18: 611-26

Temporary ECMO support following lung and heart-lung transplantation (Nguyen et al). 1999; 18:55 (Abstract)

What are the attitudes of potential heart and heart-lung patients to xenotransplantation? (Long et al). 1999;18:92 (Abstract)

Heart rate

Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation (Raczak et al). 1999;18:399-405

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats (Wada et al). 1999;18:499-508

Heart transplantation

Acquired atrial septal defect after heart transplantation (Voci et al). 1999;18:921-23 (Letter)

Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin (Raisky et al). 1999; 18:61 (Abstract)

Age before beauty: the use of "older" donor hearts for cardiac transplantation (Young JB). 1999;18:488-90

Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans (Wildhirt et al). 1999;18:64-65 (Abstract)

An analysis of the effect of age on survival after heart transplant (Borkon et al). 1999;18:668-73

Anti-CD3:F(ab′)2-idarubicin conjugates prolong mouse cardiac allografts (Mottram et al). 1999; 18:94 (Abstract)

Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84

Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy (Freudenberger et al). 1999;18:1228-31

Apoptosis in human cardiac allografts with transplant coronary artery disease (Xu et al). 1999; 18:90 (Abstract)

Apoptosis in rat cardiac allograft is predominantly associated with cells of the immune response (Agelan et al). 1999;18:40 (Abstract)

Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18:750-60

Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation (Argenziano et al). 1999;18:814-17

Arterial baroreflex modulation of heart rate in patients early after heart transplantation: lack of parasympathetic reinnervation (Raczak et al). 1999;18:399-405

Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80

Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65

Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999; 18:470-76

Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18: 1054-64

Cardiac transplantation for prosthetic valve endocarditis in a previously transplanted heart (Galbraith et al). 1999;18:805-6

Cardiac transplant outcome between patients supported on a left ventricular assist device versus intravenous inotropic therapy (Jaski et al). 1999;18:37 (Abstract)

Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172 (Letter)

Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient (Kaufman et al). 1999;18:1018-20

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

Characterization of the natural history of cervical heterotopic heart transplantation with echocardiography (Ducharme et al). 1999;18:510-16

Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour peak levels compared to trough levels in stable heart transplant patients (Cantarovich et al). 1999;18:78 (Abstract)

Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients (Kallinowski et al). 1999;18:190-93

CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation (Valantine et al). 1999;18:81 (Abstract)

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring (Meiser et al). 1999;18: 143-48

A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)

Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial (Jaski et al). 1999;18:1031-40

Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Meiser et al). 1999;18:78 (Abstract)

Coronary arteries of human cardiac allografts with transplant coronary artery disease contain oligoclonal populations of T lymphocytes (Slachta et al). 1999;18:60 (Abstract)

Coronary artery to pulmonary artery collaterals after heart transplantation (Balfour et al). 1999;18:1027-29

Coronary vasomotor response to the selective B_1 kinin receptor agonist des-Arg^9-bradykinin in transplant patients (Aptecar et al). 1999;18:64 (Abstract)

Criteria for selecting type of bridge to heart transplantation: the University of Arizona experience (Arabia et al). 1999;18:89 (Abstract)

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB (Parry et al). 1999;18:441-46

Death after heart transplantation in children: who dies when and why (Frazier et al). 1999;18: 69-70 (Abstract)

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats (Wada et al). 1999;18:499-508

Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11

Determinants of waiting time for heart transplants in the United States (Kauffman et al). 18:733 (Correction), 1999;18:414-19

Development and spectrum of PTLD in 691 cardiac transplant (Htx) recipients receiving induction therapy (Mallinger et al). 1999;18:77 (Abstract)

Development of a simple risk model for predicting survival after adult orthotopic heart transplantation (Anyanwu et al). 1999;18:37-38 (Abstract)

Diagnostic value of structured interviews in assessing noncompliance with immunosuppressive therapy in heart transplant recipients (De Geest et al). 1999;18:91 (Abstract)

Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype (McLean et al). 1999;18:68 (Abstract)

Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients (Wreghitt et al). 1999; 18:82 (Abstract)

Dobutamine stress echocardiography: experience in pediatric heart transplant recipients (Pahl et al). 1999;18:725-32

Does cardiac transplantation affect gynecologic and reproductive outcomes? (Eisenring et al). 1999;18:58-59 (Abstract)

Does initial photopheresis have an impact on the development of graft atherosclerosis after cardiac transplantation—a 6-year follow-up (Kur et al). 1999;18:93 (Abstract)

Does time to harvest determine outcome in heart transplantation with older allografts? (Scott et al). 1999;18:39 (Abstract)

Does University of Wisconsin solution harm the transplanted heart? (Stringham et al). 1999;18: 587-95

Domino heart transplantation: 10 years experience (Ongcharit et al). 1999;18:37 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)

Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation (Dew et al). 1999;18:549-59

Edema treatment during cardiac allograft (Johnsson et al). 1999;18:1238-42

Education and the transplanted child (Wray et al). 1999;18:57 (Abstract)

Effect of histocompatibility, sensitization and other risk factors on the outcome of 14,535 cardiac transplants (TNX) reported to the UNOS scientific registry (Thompson et al). 1999;18:38-39 (Abstract)

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation (Cook et al). 1999;18:420-24

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18:185-88

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients (Chait et al). 1999;18:58 (Abstract)

Efficacy of donor specific bone marrow in reducing frequency of rejection following heart transplantation (McGurl et al). 1999;18:93 (Abstract)

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients (Onsager et al). 1999;18:448-54

Endothelin in coronary endothelial dysfunction early after human heart transplantation (Weis et al). 1999;18:1071-79

Evaluation of a mentorship programme for heart transplant patients (Pennington et al). 1999; 18:91 (Abstract)

Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)

Factors affecting outcome in patients "too well" for heart transplantation at initial assessment (Eccleshall et al). 1999;18:46 (Abstract)

Famciclovir treatment of chronic hepatitis B in heart transplant recipients (Wedemeyer et al). 1999;18:81 (Abstract)

Five-year follow-up of a randomized trial of pravastatin in heart transplant patients (Kobashigawa et al). 1999;18:71 (Abstract)

Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients (Laufer et al). 1999;18:94 (Abstract)

Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18: 391-97

Functional responses of anti-CD25 blocked T-cells during cardiac rejection (Baan et al). 1999;18:69 (Abstract)

Functional significance of cardiac reinnervation in heart transplant recipients (Schwaiblmair et al). 1999;18:838-44

Gender mismatch is not associated with reduced survival after heart transplantation (Smedira et al). 1999;18:44 (Abstract)

Genetic polymorphism of transforming growth factor-β (CODON 25) and development of cardiac allograft vascular disease (Pethig et al). 1999;18:52 (Abstract)

Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience (Tsui et al). 1999;18:78-79 (Abstract)

Hematoma of the interventricular septum following right ventricular endomyocardial biopsy for the detection of allograft rejection after heart transplantation (Salim Roussouliéres et al). 1999;18:1147-50 (Letter)

Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients (Kobashigawa et al). 1999;18:50 (Abstract)

Hemoglobin A1C predicts transplant coronary artery disease incidence and severity (Kato et al). 1999;18:50 (Abstract)

Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality (Sheffield et al). 1999;18:39 (Abstract)

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? (Delgado et al). 1999;18:607-10

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

Immunologic assessment of risk for rejections after heart transplantation (Wang et al). 1999; 18:80 (Abstract)

Immunomodulatory effects of donor bone marrow infusion in heart or lung transplantation: five year experience (McCurry et al). 1999; 18:72 (Abstract)

The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial (Mehra et al). 1999;18:76 (Abstract)

Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts (Wilhelm et al). 1999;18:68 (Abstract)

The impact of early myocardial endothelin expression on functional and morphological coronary alterations during follow-up in cardiac transplant recipients (Weis et al). 1999;18:64 (Abstract)

The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study (Mehra et al). 1999; 18:49 (Abstract)

The impact of HLA sensitization and donor cause of death in heart transplantation (Cook et al). 1999;18:38 (Abstract)

Impact of patient noncompliance on survival in cardiac transplant recipients (Lawless et al). 1999;18:38 (Abstract)

Implantable left ventricular assist devices can successfully bridge pediatric patients to transplant (Helman et al). 1999;18:89 (Abstract)

Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW) (Baxter et al). 1999;18: 769-73

Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation (Zuckermann et al). 1999;18:93 (Abstract)

Increased intragraft expression of TGF-β mRNA in patients with graft vascular disease after clinical heart transplantation (de Groot-Kruseman et al). 1999;18:52 (Abstract)

Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection (Mannon et al). 1999;18:819-26

Induction immunotherapy in pediatric heart transplant recipients: a multicenter study (Boucek Jr et al). 1999;18:460-69

Induction of cardiac allograft endothelial dysfunction by cytokines in humans (Weis et al). 1999; 18:64 (Abstract)

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Influenza vaccination in heart transplant recipients (Fraund et al). 1999;18:220-24

International survey of routine surveillance biopsy practices in adult heart transplantation (Aaronson et al). 1999;18:80 (Abstract)

Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts (Iwata et al). 1999;18:37 (Abstract)

Intravascular ultrasound has prognostic impact after heart transplantation: a multivariable analysis in a large patient cohort (Klauss et al). 1999;18:50 (Abstract)

Is it safe to utilize hearts from donors with positive blood cultures? (Matsumiya et al). 1999;18:79 (Abstract)

Is the use of donor hearts with left ventricular hypertrophy acceptable? (Marelli et al). 1999; 18:87 (Abstract)

Is the use of left ventricular assist device as a bridge to heart transplantation a risk factor for development of transplant coronary artery disease? (Radovancevic et al). 1999;18:63 (Abstract)

IVIG postpones alloimmunization in LVAD and artificial heart recipients (McKellar et al). 1999; 18:57 (Abstract)

Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)

Late rejection greater than 1 year after pediatric heart transplantation: an ominous finding (Webber et al). 1999;18:69 (Abstract)

Left ventricular diastolic function after bicaval and standard cardiac transplantation (Burgess et al). 1999;18:44-45 (Abstract)

Long-term heart preservation using a new portable hypothermic perfusion apparatus (Oshima et al). 1999;18:852-61

Long term physical training in cardiac transplant candidates: is it feasible? (Ben-Gal et al). 1999; 18:75-76 (Abstract)

Low producers of TGF beta are protected from cardiac transplant vasculopathy (Densem et al). 1999;18:52 (Abstract)

Mechanisms of brain death associated myocardial dysfunction (Bittner et al). 1999;18:87 (Abstract)

Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction (Rieber et al). 1999;18:65 (Abstract)

Medium term results of children with two hearts (Radley-Smith et al). 1999;18:84 (Abstract)

Metallothionein: localization in human transplant endomycardium, relation to cytokines and allograft function (Baba et al). 1999;18:963-71

Mitral valve myxoma: an unusual reason for rejecting a donor heart (de Boer et al). 1999;18: 924-25 (Letter)

MPA-dose adjustment based on trough levels-high and low dose pharmocokinetics in heart transplanted patients (Schmidt et al). 1999; 18:46 (Abstract)

Multicenter, double-blind, randomized study of Neoral vs Sandimmune in heart transplantation: one year results (Eisen et al). 1999;18:93 (Abstract)

Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18:248-53

Mycophenolate mofetil for secondary prevention of allograft vasculopathy following heart transplantation: a prospective, randomized, intravascular ultrasound controlled trial (Pethig et al). 1999;18:77-78 (Abstract)

Mycophenolate mofetil in paediatric heart transplant recipients: a single center experience (Dipchand et al). 1999;18:83-84 (Abstract)

Mycophenolic acid concentrations are associated with cardiac allograft rejection (DeNofrio et al). 1999;18:46 (Abstract)

Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)

Native heart complications after heterotropic heart transplantation: insight into the potential risk of left ventricular assist device (Tagusari et al). 1999;18:1111-19

A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dt_{max} (Dambrin et al). 1999;18:524-30

New UNOS rules: historical background and implications for transplantation management (Renlund et al). 1999;18:1065-70

Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation (Carrier et al). 1999;18:664-67

Non compliance causing late acute rejection in pediatric heart transplantation (Ringewald et al). 1999;18:70 (Abstract)

Noninvasive cardiac graft monitoring: the Graz experience (Grasser et al). 1999;18:80 (Abstract)

Noninvasive cost-effective detection of cardiac allograft vasculopathy by electron beam computed tomography (EBCT) (Hummel et al). 1999;18:49 (Abstract)

Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection (Moidl et al). 1999;18:194-200

Optimal dosing of intravenous tacrolimus following pediatric heart transplantation (Robinson et al). 1999;18:786-90

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection (Park et al). 1999;18:1224-27

Orthotopic heart transplantation: which technique? Comment on the prospective randomized trial of CAVT by Bainbridge et al. (Aziz et al). 1999;18:1253 (Letter)

Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study (Bernstein et al). 1999;18:69 (Abstract)

Outcomes with hepatitis C following cardiac transplantation—a multi-institutional study (Lake et al). 1999;18:81 (Abstract)

Pediatric cardiac retransplantation: experience at a single institution (Dearani et al). 1999;18:70 (Abstract)

Pediatric heart transplant school re-entry (Rodgers et al). 1999;18:58 (Abstract)

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation (Pisani et al). 1999;18:701-6

Predictors of quality of life in patients at one year after heart transplantation (Grady et al). 1999; 18:202-10

Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients (Moriguchi et al). 1999;18:76 (Abstract)

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmocologic circulatory support (Gronda et al). 1999;18:654-61

Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation (Berger et al). 1999;18:75 (Abstract)

Prophylactic and preemptive strategies for control of Legionnaires' disease in heart transplant recipients. A single center 10-years survey in a high-risk environment (Hummel et al). 1999; 18:77 (Abstract)

A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty (Bainbridge et al). 1999;18:407-12

Psychiatric disorders and outcome following cardiac transplantation (Skotzko et al). 1999;18: 952-56

Psychological evaluation as a prognostic factor among patients candidates for cardiac transplantation (Moscoloni et al). 1999;18:58 (Abstract)

QT dispersion predicts ventricular arrhythmia in pediatric cardiomyopathy patients referred for heart transplantation (Dubin et al). 1999;18: 781-84

Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats (Slauson et al). 1999;18:1251-52 (Letter)

Radiofrequency ablation of a concealed accessory pathway years after heart transplant: a case report (Sharma et al). 1999;18:792-94

Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus (Pinski et al). 1999;18:292-96

Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection (Trull et al). 1999;18:93 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Recipient weight as an independent risk factor in heart transplantation (Mullen et al). 1999;18:92 (Abstract)

Refining the criteria for heart transplant listing and status: a multi-institutional risk factor analysis for rehospitalization following listing (Kirklin et al). 1999;18:47 (Abstract)

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18:611-26

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation (Sartori et al). 1999;18:693-99

Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients (Allen-Auerbach et al). 1999;18:211-18

Return to work after heart transplantation: 12-year follow-up (Kavanagh et al). 1999;18:846-50

Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80

Risk factor analysis for inappropriate growth after pediatric heart transplantation (HTX) (Flaspohler et al). 1999;18:91 (Abstract)

Risk factor analysis for skin cancer in heart transplant (HT) recipients (Belloni et al). 1999; 18:77 (Abstract)

The role of donor age and ischemic time on survival following orthotopic heart transplantation (Del Rizzo et al). 1999;18:310-19

The role of flow cytometry detected IgG and IgM anti-donor antibodies in cardiac allograft recipients (Kerman et al). 1999;18:38 (Abstract)

The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Should advanced recipient age be contraindicated in cardiac transplantation? Continued analysis of a single center experience (Hoercher et al). 1999;18:45 (Abstract)

The significance of HLA matching in cardiac transplantation (Ketheesan et al). 1999;18:226-29

A simple new model of physiologically working heterotopic rat heart transplantation provides hemodynamic performance equivalent to that of an orthotopic heart (Asfour et al). 1999;18: 927-36

Soluble rat class I MHC proteins induce prolonged survival of rat cardiac allografts (Perez et al). 1999;18:68 (Abstract)

Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results (Ibrahim et al). 1999;18:83 (Abstract)

Successful orthotopic pig heart transplantation from non-heart beating donors (Martin et al). 1999;18:597-605

Sudden death and tailored medical therapy in elective candidates for heart transplantation (Nägele et al). 1999;18:869-75

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12

A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation (Carrier et al). 1999; 18:1218-23

Ten-year follow-up after pediatric transplantation (Parisi et al). 1999;18:275-77

TGF beta polymorphism does not influence the rise in creatinine following cardiac transplantation (Densem et al). 1999;18:77 (Abstract)

Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (Gummert et al). 1999;18:53-54 (Abstract)

Three year results of the double-blind randomized multicenter trial of mycophenolate mofetil in heart transplant patients (Keogh et al). 1999; 18:53 (Abstract)

Transforming growth factor-beta (TGF-β) and allograft vasculopathy following heart transplantation (Aziz et al). 1999;18:37 (Abstract)
Transplantation of "thymoheart" allografts in miniature swine (Menard et al). 1999;18:71 (Abstract)
Tumor marker determination after orthotopic heart transplantation (Nägele et al). 1999;18:957-62
Use of Daclizumab decreases the frequency of early allograft rejection in de-novo heart transplant recipients (Beniaminovitz et al). 1999; 18:45 (Abstract)
Use of inhaled nitric oxide in cardiac transplantation (Williams et al). 1999;18:44 (Abstract)
Valve-sparing repair after aortic root dissection following heart transplantation (Teebken et al). 1999;18:807-9
Variations in cardiac transplantation: comparisons between the United Kingdom and the United States (Anyanwu et al). 1999;18:297-303
What are the attitudes of potential heart and heart-lung patients to xenotransplantation? (Long et al). 1999;18:92 (Abstract)

Heart Transplant Mentor Program
Evaluation of a mentorship programme for heart transplant patients (Pennington et al). 1999; 18:91 (Abstract)

Heart valve transplantation
Donor-specific high avidity cytotoxic T-lymphocytes induced by implantation of cryopreserved human cardiac valves (Welters et al). 1999; 18:53 (Abstract)

Heart ventricle. *See* **Left; Right; Ventricular; Ventriculectomy**

Hemodynamics
Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients (Kobashigawa et al). 1999;18:50 (Abstract)
Hemodynamic guided inotropic tailoring does not appear to impact long term survival among patients requiring chronic home inotropic therapy (Pathak et al). 1999;18:43 (Abstract)
Intravenous (IV) inotrope and vasodilator therapy in a critical care setting utilizing a heart failure specialty team care approach (HFSTC) with "hemodynamic goal" protocols vs. a general cardiology care approach (GCC) (Albert et al). 1999;18:75 (Abstract)
A simple new model of physiologically working heterotopic rat heart transplantation provides hemodynamic performance equivalent to that of an orthotopic heart (Asfour et al). 1999;18:927-36
Treatment differences and clinical outcomes of advanced heart failure (HF) patients with a critical care admission using specialist team protocols vs. general cardiology care (Albert et al). 1999;18:76 (Abstract)

Hemolytic-uremic syndrome
Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome (Myers et al). 1999;18:1024-26

Hemostasis
Profile of soluble coagulant and inflammatory markers during long-term left ventricular assist device support (Fedalen et al). 1999;18:56-57 (Abstract)
A prospective study of haemostatic changes after implantation of the novacor LVAS (Hunt et al). 1999;18:43 (Abstract)
Vitamin K reduces bleeding in left ventricular assist device recipients (Kaplon et al). 1999;18: 346-50

Hepatitis B
Famciclovir treatment of chronic hepatitis B in heart transplant recipients (Wedemeyer et al). 1999;18:81 (Abstract)
Recurrence of hepatitis B after single lung transplantation (Stamenkovic et al). 1999;18:1246-50

Hepatitis C
Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality (Sheffield et al). 1999;18:39 (Abstract)
Hepatitis C virus infection and lung transplantation: a survey of practices (Cotler et al). 1999; 18:456-58
Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? (Delgado et al). 1999;18:607-10
Outcomes with hepatitis C following cardiac transplantation—a multi-institutional study (Lake et al). 1999;18:81 (Abstract)

Hepatitis G
Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients (Kallinowski et al). 1999;18:190-93

Herpesvirus 4, human. *See* **Epstein-Barr virus (EBV)**

Histocompatibility antigens
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization (Stringham et al). 1999;18:160-65
Effect of histocompatibility, sensitization and other risk factors on the outcome of 14,535 cardiac transplants (TNX) reported to the

UNOS scientific registry (Thompson et al). 1999;18:38-39 (Abstract)
Effects of MHC class II antigens on the development of cardiac allograft vasculopathy in miniature swine (Mawulawde et al). 1999;18:53 (Abstract)
IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)
Impact of antibodies to HLA class I molecules on the development of BOS (Smith et al). 1999; 18:51 (Abstract)
The impact of HLA sensitization and donor cause of death in heart transplantation (Cook et al). 1999;18:38 (Abstract)
Indirect allorecognition of HLA class II allopeptides in lung allograft recipients (Reznik et al). 1999;18:68 (Abstract)
Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)
Soluble rat class I MHC proteins induce prolonged survival of rat cardiac allografts (Perez et al). 1999;18:68 (Abstract)

Histocompatibility testing

HLA class II matching: significant impact on long term outcome of lung transplantation (van den Berg et al). 1999;18:85 (Abstract)
Influence of HLA matching on survival and development of obliterative bronchiolitis (OB) after lung transplantation (Novick et al). 1999; 18:50-51 (Abstract)
The significance of HLA matching in cardiac transplantation (Ketheesan et al). 1999;18:226-29

Histopathology

Histopathology of resected myocardium is correlated with survival after partial left ventriculectomy—a clue to indication for PLV versus transplantation (Kawaguchi et al). 1999;18:67 (Abstract)

HLA expression

Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)

HLA matching

Effect of histocompatibility, sensitization and other risk factors on the outcome of 14,535 cardiac transplants (TNX) reported to the UNOS scientific registry (Thompson et al). 1999;18:38-39 (Abstract)
HLA class II matching: significant impact on long term outcome of lung transplantation (van den Berg et al). 1999;18:85 (Abstract)
Influence of HLA matching on survival and development of obliterative bronchiolitis (OB) after lung transplantation (Novick et al). 1999; 18:50-51 (Abstract)
The significance of HLA matching in cardiac transplantation (Ketheesan et al). 1999;18:226-29

HLA sensitization

Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization (Stringham et al). 1999;18:160-65
Impact of antibodies to HLA class I molecules on the development of BOS (Smith et al). 1999; 18:51 (Abstract)
The impact of HLA sensitization and donor cause of death in heart transplantation (Cook et al). 1999;18:38 (Abstract)
Indirect allorecognition of HLA class II allopeptides in lung allograft recipients (Reznik et al). 1999;18:68 (Abstract)
Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results (Ibrahim et al). 1999;18:83 (Abstract)

HOE 642

Successful orthotopic pig heart transplantation from non-heart beating donors (Martin et al). 1999;18:597-605

Homocysteine

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation (Cook et al). 1999;18:420-24

Human leukocyte antigens. *See* **HLA**

Humoral immunity

Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11

Hyperbilirubinemia

Inflammatory cytokines and hepatic sinusoid endothelial dysfunction play a role in hyperbilirubinemia in patients following implantation of an LVAS (Nishimura et al). 1999;18:57 (Abstract)

Hyperlipidemia

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12

Hyperplasia

High dose brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi; theoretical and clinical applications (Sonett et al). 1999;18:84 (Abstract)

Hypersensitivity eosinophilia

Hypersensitivity eosinophilia: a unique cause of cardiac decompensation in inotropic dependent heart failure? (Uber et al). 1999;18:43 (Abstract)

Hypertension

Hypertension during support with ventricular assist devices: incidence, risk factors and management (Stanford et al). 1999;18:58 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80

Hypertension, pulmonary

Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure (Wensel et al). 1999;18:877-82

Pulmonary artery stenosis 5 years after single lung transplantation in primary pulmonary hypertension (Waurick et al). 1999;18:1243-45

Pulmonary hypertension: pathophysiology as a basis for clinical decision making (Rabinovitch). 1999;18:1041-53

Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension (Bîrsan et al). 1999;18:304-9

The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension (Pamboukian et al). 1999;18:367-70

Hypoplastic left heart syndrome

Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)

Hypotension

Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation (Argenziano et al). 1999;18:814-17

Hypothermic preservation

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

Differential time scale of fluid and solute permeability following hypothermic lung preservation (Rooney et al). 1999;18:73 (Abstract)

Long-term heart preservation using a new portable hypothermic perfusion apparatus (Oshima et al). 1999;18:852-61

A novel cell culture model for aerobic, hypothermic lung preservation for transplantation (Cardella et al). 1999;18:88 (Abstract)

Hypoxemia

Transcatheter closure of patent foramen ovale for hypoxemia during left ventricular assist device support (Nguyen et al). 1999;18:1021-23

I

Ibutilide

Cardioversion of atrial fibrillation with ibutilide in an orthotopic heart transplant patient (Kaufman et al). 1999;18:1018-20

Immunity, humoral. *See* **Antibodies; Humoral immunity**

Immunoglobulin

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

Immunoglobulin adsorption

Immunoglobulin adsorption as effective treatment of severe dilated cardiomyopathy (Müller et al). 1999;18:70-71 (Abstract)

Immunoglobulin G, intravenous

IVIG postpones alloimmunization in LVAD and artificial heart recipients (McKellar et al). 1999; 18:57 (Abstract)

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation (Pisani et al). 1999;18:701-6

Immunosuppressive therapy

Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84

Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant (Chaparro et al). 1999;18:46 (Abstract)

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring (Meiser et al). 1999;18: 143-48

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation (Zuckermann et al). 1999;18:432-39

Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Meiser et al). 1999;18:78 (Abstract)

Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease (Balfour et al). 1999;18:492-94

Cyclophosphamide rescue therapy for chronic rejection after lung transplantation (Verleden et al). 1999;18:1139-46

Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34

Cyclosporine inhibits long-term survival in cardiac allografts treated with monoclonal antibody against CD45RB (Parry et al). 1999;18:441-46

Diagnostic value of structured interviews in assessing noncompliance with immunosuppressive therapy in heart transplant recipients (De Geest et al). 1999;18:91 (Abstract)

Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)

Effect of immunosuppressive therapy, serum creatinine, and time after transplant on plasma total homocysteine in patients following heart transplantation (Cook et al). 1999;18:420-24

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18: 185-88

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Multicenter, double-blind, randomized study of Neoral vs Sandimmune in heart transplantation: one year results (Eisen et al). 1999;18:93 (Abstract)

Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18:248-53

A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats (Ikonen et al). 1999;18:73 (Abstract)

Optimal dosing of intravenous tacrolimus following pediatric heart transplantation (Robinson et al). 1999;18:786-90

Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection (Park et al). 1999;18:1224-27

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation (Pisani et al). 1999;18:701-6

p21 overexpression inhibits cell proliferation and enhances cyclosporine's antiproliferative effects: a novel strategy for immunosuppression (Khanna et al). 1999;18:49 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation (Sartori et al). 1999;18:693-99

Successful cardiac transplantation of pre-sensitized children without a prospective crossmatch: preliminary results (Ibrahim et al). 1999;18:83 (Abstract)

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome (Myers et al). 1999;18:1024-26

Suggested guidelines for the use of tacrolimus in lung-transplant recipients (Garrity et al). 1999; 18:175-76

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12

A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation (Carrier et al). 1999; 18:1218-23

VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival (Gummert et al). 1999;18:72 (Abstract)

Induction immunotherapy

Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Development and spectrum of PTLD in 691 cardiac transplant (Htx) recipients receiving induction therapy (Mallinger et al). 1999;18:77 (Abstract)

Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation (Zuckermann et al). 1999;18:93 (Abstract)

Induction immunotherapy in pediatric heart transplant recipients: a multicenter study (Boucek Jr et al). 1999;18:460-69

A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation (Carrier et al). 1999; 18:1218-23

Infant, newborn

Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18: 675-83

Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)

Outcome of infants listed for lung and heart/lung transplantation (Ro et al). 1999;18:1232-37

Outcome of infants listed for lung or heart/lung transplantation (Ro et al). 1999;18:83 (Abstract)

Infection

Cardiac transplantation for prosthetic valve endocarditis in a previously transplanted heart (Galbraith et al). 1999;18:805-6

Clinical relevance of hepatitis G virus (HGV) infection in heart transplant patients (Kallinowski et al). 1999;18:190-93

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX) (Zamora et al). 1999;18:81 (Abstract)

Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients (Wreghitt et al). 1999; 18:82 (Abstract)

Diphtheria by donation (Gould et al). 1999;18: 173-74 (Letter)

Effects of oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients (Chan et al). 1999;18:85 (Abstract)

Evaluation of circulating Epstein-Barr virus (EBV) viral load in pediatric thoracic recipients: implications for diagnosis of posttransplant lymphoproliferative disorders (PTLD) (Webber et al). 1999;18:83 (Abstract)

Famciclovir treatment of chronic hepatitis B in heart transplant recipients (Wedemeyer et al). 1999;18:81 (Abstract)

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality (Sheffield et al). 1999;18:39 (Abstract)

Hepatitis C virus infection and lung transplantation: a survey of practices (Cotler et al). 1999; 18:456-58

Hepatitis C virus-related fibrosing cholestatic hepatitis after cardiac transplantation: is azathioprine a contributory factor? (Delgado et al). 1999;18:607-10

The impact of ganciclovir-resistant cytomegalovirus infection in lung transplantation (Kruger et al). 1999;18:82 (Abstract)

Is it safe to utilize hearts from donors with positive blood cultures? (Matsumiya et al). 1999;18:79 (Abstract)

Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation (Sandur et al). 1999;18:810-13

Noninvasive cardiac graft monitoring: the Graz experience (Grasser et al). 1999;18:80 (Abstract)

Outcomes with hepatitis C following cardiac transplantation—a multi-institutional study (Lake et al). 1999;18:81 (Abstract)

Recurrence of hepatitis B after single lung transplantation (Stamenkovic et al). 1999;18:1246-50

Recurrent *Pneumocystic carinii* colonization in a heart-lung transplantation recipient on long-term trimethoprin-sulfamethoxazole prophylaxis (Faul et al). 1999;18:384-87

Successful eradication of mucormycosis occurring in a pulmonary allograft (Hunstad et al). 1999; 18:801-4

Infection control

Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections (Choi et al). 1999;18: 1103-10

Prophylactic and preemptive strategies for control of Legionnaires' disease in heart transplant recipients. A single center 10-years survey in a high-risk environment (Hummel et al). 1999; 18:77 (Abstract)

Influenza vaccine

Influenza vaccination in heart transplant recipients (Fraund et al). 1999;18:220-24

Infusions, intravenous

Intravenous (IV) inotrope and vasodilator therapy in a critical care setting utilizing a heart failure specialty team care approach (HFSTC) with "hemodynamic goal" protocols vs. a general cardiology care approach (GCC) (Albert et al). 1999;18:75 (Abstract)

A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation (Carrier et al). 1999; 18:1218-23

Inosine monophosphate dehydrogenase

VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival (Gummert et al). 1999;18:72 (Abstract)

Inotropic therapy

Cardiac transplant outcome between patients supported on a left ventricular assist device versus intravenous inotropic therapy (Jaski et al). 1999;18:37 (Abstract)

Comprehensive concept to support right ventricular function following left ventricular assist device implantation (Wagner et al). 1999;18:89 (Abstract)

Failure to wean from parenteral inotropes: a strong predictor for early mortality among patients with end stage heart disease (Park et al). 1999;18:47-48 (Abstract)

Hemodynamic guided inotropic tailoring does not appear to impact long term survival among patients requiring chronic home inotropic therapy (Pathak et al). 1999;18:43 (Abstract)

Hypersensitivity eosinophilia: a unique cause of cardiac decompensation in inotropic dependent heart failure? (Uber et al). 1999;18:43 (Abstract)

Intravenous (IV) inotrope and vasodilator therapy in a critical care setting utilizing a heart failure specialty team care approach (HFSTC) with "hemodynamic goal" protocols vs. a general cardiology care approach (GCC) (Albert et al). 1999;18:75 (Abstract)

Outpatient inotropic therapy in refractory heart failure (Oliva et al). 1999;18:75 (Abstract)

The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension (Pamboukian et al). 1999;18:367-70

Intercellular adhesion molecules

Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin (Raisky et al). 1999; 18:61 (Abstract)

Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans (Wildhirt et al). 1999;18:64-65 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Myocardial HLA and ICAM-1 staining pattern in biopsies from transplanted hearts. Three years follow-up (Wojnicz et al). 1999;18:40 (Abstract)

Interferon

High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection (Zeevi et al). 1999;18:82 (Abstract)

IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Lung allograft dysfunction correlates with γ-interferon gene expression in bronchoalveolar lavage (Ross et al). 1999;18:627-35

Interleukins

Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection (Zeevi et al). 1999;18:81-82 (Abstract)

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Metallothionein: localization in human transplant endomycardium, relation to cytokines and allograft function (Baba et al). 1999;18:963-71

Prognostic value of circulating levels of interleukin-6 in patients with congestive heart failure (Roig et al). 1999;18:91 (Abstract)

The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB) (Mulligan et al). 1999;18:88 (Abstract)

Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (Plenz et al). 1999;18: 923-24 (Letter)

T cell activation in left ventricular assist device (LVAD) recipients occurs via a CD95-dependent pathway, and results in loss of Th1 cells and high levels of circulating IL-10 (Ankersmit et al). 1999;18:56 (Abstract)

International Lung Transplant Database

The International Lung Transplant Database: demographics and outcomes in 826 lung transplant recipients (Doyle et al). 1999;18:86 (Abstract)

International Society for Heart and Lung Transplantation

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18: 611-26

The Registry of the International Society for Heart and Lung Transplantation: Third Official Pediatric Report (Boucek et al). 1999;18:1151-72 (Registry)

Intravascular ultrasound. *See* **Ultrasound, intravascular**

Ischemia

Domino heart transplantation: 10 years experience (Ongcharit et al). 1999;18:37 (Abstract)

Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18: 675-83

Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function (Wittwer et al). 1999;18:1198-1201

Influence of graft ischemic time and donor age on survival after lung transplantation (Novick et al). 1999;18:425-31

Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption (Brenner et al). 1999; 18:59 (Abstract)

The role of donor age and ischemic time on survival following orthotopic heart transplantation (Del Rizzo et al). 1999;18:310-19

Successful orthotopic pig heart transplantation from non-heart beating donors (Martin et al). 1999;18:597-605

Vascular function in the cadaver up to six hours after cardiac arrest (Bolys et al). 1999;18:582-86

Ischemia-reperfusion injury

Alveolar recruitment prevents rapid-perfusion-induced injury of lung transplants (DeCampos et al). 1999;18:1096-1102

Apoptosis induced by ischemia and reperfusion in experimental lung transplantation (Stammberger et al). 1999;18:79 (Abstract)

Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80

Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91

Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:862-67

Early mediators of lung ischaemia-reperfusion injury (Onwu et al). 1999;18:74 (Abstract)

The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18: 637-44

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)

Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts (Iwata et al). 1999;18:37 (Abstract)

In-vivo measurement of oxygen free radical production correlates with pulmonary reperfusion injury (Wagner et al). 1999;18:74 (Abstract)

Modulation of pulmonary Na^+ pump gene expression during cold storage and reperfusion (Kim et al). 1999;18:74 (Abstract)

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

Selective adenosine-A_{2A} activation reduces lung reperfusion injury following transplantation (Ross et al). 1999;18:72 (Abstract), 1999;18: 994-1002

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Synergistic effect of endothelin- and PAF antagonists on posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:74-75 (Abstract)

J

Jehovah's Winesses

Lung transplantation in a Jehovah's Witness (Conte et al). 1999;18:796-99

L

Laser revascularization. *See* **Transmyocardial laser revascularization**

Lazaroid U-74389G

Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91

Left ventricular assist device

Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy (Belland et al). 1999; 18:54 (Abstract)

Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization (Stringham et al). 1999;18:160-65

Bridge-to-transplant (BTT) experience with the Novacor left ventricular assist system (LVAS): results of a multicenter US study (Kormos et al). 1999;18:63 (Abstract)

Cardiac transplant outcome between patients supported on a left ventricular assist device versus intravenous inotropic therapy (Jaski et al). 1999;18:37 (Abstract)

Comparison of functional capacity in patients with end-stage heart failure following implantation of a left ventricular assist device versus heart transplantation: results of the experience with left ventricular assist device with exercise trial (Jaski et al). 1999;18:1031-40

Comprehensive concept to support right ventricular function following left ventricular assist device implantation (Wagner et al). 1999;18:89 (Abstract)

Development of an infection-resistant LVAD driveline: a novel approach to the prevention of device-related infections (Choi et al). 1999;18: 1103-10

Development of a ventricular assist device for out-of-hospital use (Mussivand et al). 1999;18: 166-71

Does LVAD bridging-to-transplantation increase graft vasculopathy? (Kaplon et al). 1999;18:63 (Abstract)

Immunohistochemical analysis of vascular prostheses implanted with the left ventricular assist system (Fastenau et al). 1999;18:916-20

Implantable left ventricular assist devices can successfully bridge pediatric patients to transplant (Helman et al). 1999;18:89 (Abstract)

Inflammatory cytokines and hepatic sinusoid endothelial dysfunction play a role in hyperbilirubinemia in patients following implantation of an LVAS (Nishimura et al). 1999;18:57 (Abstract)

Inter-hospital transfer of patients receiving advanced mechanical circulatory support (McBride et al). 1999;18:90 (Abstract)

Is the use of left ventricular assist device as a bridge to heart transplantation a risk factor for development of transplant coronary artery disease? (Radovancevic et al). 1999;18:63 (Abstract)

IVIG postpones alloimmunization in LVAD and artificial heart recipients (McKellar et al). 1999; 18:57 (Abstract)

Long term home discharge support with Novacor LVAS (Jansen et al). 1999;18:67-68 (Abstract)

Metallothionein is involved in reverse remodeling after prolonged left ventricular assist device support (Baba et al). 1999;18:57 (Abstract)

Native heart complications after heterotropic heart transplantation: insight into the potential risk of left ventricular assist device (Tagusari et al). 1999;18:1111-19

Profile of soluble coagulant and inflammatory markers during long-term left ventricular assist device support (Fedalen et al). 1999;18:56-57 (Abstract)

A prospective study of haemostatic changes after implantation of the novacor LVAS (Hunt et al). 1999;18:43 (Abstract)

Resting left ventricular size predicts improved native cardiac output during exercise and the ability to exercise with the device weaned in patients with the TCI Heartmate left ventricular assist device (Maybaum et al). 1999;18:44 (Abstract)

Resting myocardial blood flow and metabolism predicts improved native left ventricular output and the ability to exercise with weaning in patients with the TCI Heartmate left ventricular assist device (Maybaum et al). 1999;18:62 (Abstract)

Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (Plenz et al). 1999;18: 923-24 (Letter)

Reversal of the heart failure phenotype by mechanical unloading (DiIulio et al). 1999;18: 89-90 (Abstract)

T cell activation in left ventricular assist device (LVAD) recipients occurs via a CD95-dependent pathway, and results in loss of Th1 cells and high levels of circulating IL-10 (Ankersmit et al). 1999;18:56 (Abstract)

T cell apoptosis and defects in cellular immunity induced by exposure to biomaterials: implications for left ventricular assist device (LVAD) implantation (Ankersmit et al). 1999;18:56 (Abstract)

Transcatheter closure of patent foramen ovale for hypoxemia during left ventricular assist device support (Nguyen et al). 1999;18:1021-23

Vitamin K reduces bleeding in left ventricular assist device recipients (Kaplon et al). 1999;18: 346-50

Left ventricular failure

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension (Bîrsan et al). 1999;18:304-9

Left ventricular hypertrophy

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

Left ventricular reconstruction

Left ventricular reconstruction using the Dor procedure for ischemic aneurysm or akinetic dilatation (Marullo et al). 1999;18:42 (Abstract)

Legionnaire's disease

Prophylactic and preemptive strategies for control of Legionnaires' disease in heart transplant recipients. A single center 10-years survey in a high-risk environment (Hummel et al). 1999; 18:77 (Abstract)

Letters. *See* **Correspondence**

Leukocytes

Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype (McLean et al). 1999;18:68 (Abstract)

Lipids

The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial (Mehra et al). 1999;18:76 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12

Living donor lobar transplantation

Early graft dysfunction in pediatric lung transplant recipients (Sweet et al). 1999;18:82-83 (Abstract)

Pulmonary volume increases with linear growth in pediatric living donor lobar lung transplant recipients (Woo et al). 1999;18:86 (Abstract)

Transplantation of a lobe of a lung from mother to child after previous transplantation with bone marrow (Svendsen et al). 1999;18:388-89

LPD (low potassium dextran) preservation solution

LPD solution in clinical lung transplantation (Strüber et al). 1999;18:87 (Abstract)

Lung disease

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients (Lok). 1999;18: 884-89

Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration (De Meester et al). 1999;18:563-71

Mechanical ventilation as a bridge to lung transplantation (O'Brien et al). 1999;18:255-63

Lung transplantation

Acute native lung hyperinflation (ANLH) is not associated with poor outcome after single lung transplant (SLT) for emphysema (Weill et al). 1999;18:55 (Abstract)

Acute native lung hyperinflation is not associated with poor outcomes after single lung transplant for emphysema (Weill et al). 1999;18:1080-87

Airway vascular changes in lung allograft recipients (Zheng et al). 1999;18:231-37

Alveolar recruitment prevents rapid-perfusion-induced injury of lung transplants (DeCampos et al). 1999;18:1096-1102

Analysis of risk factors for chronic lung rejection from a twelve-center, multinational database (Brazelton et al). 1999;18:59 (Abstract)

Antilymphocyte globulin (ALG) vs. placebo in immunosuppression in lung transplant (Chaparro et al). 1999;18:46 (Abstract)

Apoptosis induced by ischemia and reperfusion in experimental lung transplantation (Stammberger et al). 1999;18:79 (Abstract)

Assessment of health related quality of life in pulmonary transplantation: application of a simple generic tool (Anyanwu et al). 1999;18:51 (Abstract)

Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32

Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction (Moy et al). 1999;18:986-93

CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation (Valantine et al). 1999;18:81 (Abstract)

Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:862-67

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation (Zuckermann et al). 1999;18:432-39

Comparison of Euro Collins- and low potassium dextran (Perfadex) solution in clinical lung preservation (Müller et al). 1999;18:40 (Abstract)

The contribution of donor management and modified cold blood lung perfusate to post-transplant lung function (Parry et al). 1999;18:121-25

Cooperative procurement for lung transplantation improves organ utilization without increasing complications (Iannettoni et al). 1999;18: 86-87 (Abstract)

Cyclophosphamide rescue therapy for chronic rejection after lung transplantation (Verleden et al). 1999;18:1139-46

Cytomegalovirus immune globulin (CMVIG) in combination with ganciclovir provides cost-effective prophylaxis of CMV after lung transplantation (LTX) (Zamora et al). 1999;18:81 (Abstract)

Decreased survival associated with size mismatching in lung transplantation (Park et al). 1999;18:60 (Abstract)

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment (Hirt et al). 1999;18:542-48

Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS (Gabbay et al). 1999; 18:51 (Abstract)

Differential time scale of fluid and solute permeability following hypothermic lung preservation (Rooney et al). 1999;18:73 (Abstract)

Differentiation of human cytomegalovirus (CMV) glycoprotein B and glycoprotein H types by restriction fragment length polymorphism-association of glycoprotein types with CMV disease in heart, heart-lung and lung transplant recipients (Wreghitt et al). 1999; 18:82 (Abstract)

Diphtheria by donation (Gould et al). 1999;18: 173-74 (Letter)

Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? (Yu et al). 1999;18:764-68

Donor pre-treatment with inhaled nitric oxide attenuates acute lung injury following single

lung transplantation (Sudarshan et al). 1999; 18:78 (Abstract)

Early graft dysfunction in pediatric lung transplant recipients (Sweet et al). 1999;18:82-83 (Abstract)

Effective treatment of lymphoproliferative disease following lung transplantation using a monoclonal anti-CD20 B-cell antibody (Cook et al). 1999;18:84-85 (Abstract)

Effect of donor age on young and older lung transplant recipients (Waddell et al). 1999; 18:85 (Abstract)

The effect of intra-pulmonary CXC-chemokines in the donor lung on early graft function after lung transplantation (Fisher et al). 1999;18:88 (Abstract)

The effect of pre lung transplant clinical status on post transplant outcome for children with cystic fibrosis: a ten year experience (Gassas et al). 1999;18:83 (Abstract)

The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18: 637-44

The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)

Effects of oral ganciclovir on the prevention of cytomegalovirus infection in lung transplant recipients (Chan et al). 1999;18:85 (Abstract)

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients (Onsager et al). 1999;18:448-54

Five years of living lobar donation for bilateral lung transplantation: long term results in 137 donors (Uppal et al). 1999;18:54 (Abstract)

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

Gas exchange function one month after transplantation of lungs topically cooled for 2 hours in the non-heart-beating cadaver after failed resuscitation (Wierup et al). 1999;18:133-37

Gastroesophageal reflux is an important cause of allograft dysfunction in lung transplant recipients (Palmer et al). 1999;18:51 (Abstract)

Gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation (Cassivi et al). 1999;18:88-89 (Abstract)

Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience (Tsui et al). 1999;18:78-79 (Abstract)

Hepatitis C virus infection and lung transplantation: a survey of practices (Cotler et al). 1999; 18:456-58

Heterogeneity and reversal of bronchiolitis obliterans syndrome (Brazelton et al). 1999;18:59-60 (Abstract)

High dose brachytherapy to prevent recurrent benign hyperplasia in lung transplant bronchi; theoretical and clinical applications (Sonett et al). 1999;18:84 (Abstract)

High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection (Zeevi et al). 1999;18:82 (Abstract)

The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model (Hausen et al). 1999;18:714-24

HLA class II matching: significant impact on long term outcome of lung transplantation (van den Berg et al). 1999;18:85 (Abstract)

Human lung preservation can be extended beyond eight hours using UW solution (Love et al). 1999;18:87 (Abstract)

Immunomodulatory effects of donor bone marrow infusion in heart or lung transplantation: five year experience (McCurry et al). 1999; 18:72 (Abstract)

Impact of antibodies to HLA class I molecules on the development of BOS (Smith et al). 1999; 18:51 (Abstract)

The impact of ganciclovir-resistant cytomegalovirus infection in lung transplantation (Kruger et al). 1999;18:82 (Abstract)

Improved results for retransplantation in acute and late pulmonary graft failure (Harringer et al). 1999;18:56 (Abstract)

Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function (Wittwer et al). 1999;18:1198-1201

Indirect allorecognition of HLA class II allopeptides in lung allograft recipients (Reznik et al). 1999;18:68 (Abstract)

Influence of graft ischemic time and donor age on survival after lung transplantation (Novick et al). 1999;18:425-31

Influence of HLA matching on survival and development of obliterative bronchiolitis (OB)

after lung transplantation (Novick et al). 1999; 18:50-51 (Abstract)
Inhaled nitric oxide in early severe allograft lung dysfunction (Planas et al). 1999;18:55 (Abstract)
Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)
The International Lung Transplant Database: demographics and outcomes in 826 lung transplant recipients (Doyle et al). 1999;18:86 (Abstract)
LPD solution in clinical lung transplantation (Strüber et al). 1999;18:87 (Abstract)
Lung allograft dysfunction correlates with γ-interferon gene expression in bronchoalveolar lavage (Ross et al). 1999;18:627-35
Lung transplantation in a Jehovah's Witness (Conte et al). 1999;18:796-99
Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration (De Meester et al). 1999;18:563-71
Maintaining or improving nutritional parameters for patients awaiting lung transplantation (Endres et al). 1999;18:91 (Abstract)
Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation (Lands et al). 1999;18:113-19
Measurement of fibroblast proliferative activity in bronchoalveolar lavage fluid in the analysis of obliterative bronchiolitis among lung transplant recipients (Jonosono et al). 1999;18:972-85
Mechanical ventilation as a bridge to lung transplantation (O'Brien et al). 1999;18:255-63
A nation-wide list would cause major redistribution of cadaveric lungs (Ely et al). 1999;18: 55-56 (Abstract)
Native lung pneumonectomy for invasive pulmonary aspergillosis following lung transplantation (Sandur et al). 1999;18:810-13
A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats (Ikonen et al). 1999;18:73 (Abstract)
Optimal timing of lung transplantation in cystic fibrosis patients (Cahill et al). 1999;18:86 (Abstract)
Outcome of infants listed for lung and heart/lung transplantation (Ro et al). 1999;18:1232-37
Outcome of infants listed for lung or heart/lung transplantation (Ro et al). 1999;18:83 (Abstract)
Patterns and significance of CD44 expression in lung allografts (Zander et al). 1999;18:646-52
Post-transplant lymphoproliferative disease (PTLD) following lung transplantation in Canadian transplant centers (Partovi et al). 1999; 18:85 (Abstract)
Predictors of survival to transplant in cystic fibrosis: impact of international listing guidelines (Keenan et al). 1999;18:55 (Abstract)
Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. (van Enckevort et al). 1999;18:496-97 (Letter)
Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) (Klepetko et al). 1999;18: 45-46 (Abstract)
Protective effects of Celsior in lung transplantation (Xiong et al). 1999;18:320-26
Pulmonary artery stenosis 5 years after single lung transplantation in primary pulmonary hypertension (Waurick et al). 1999;18:1243-45
Pulmonary hypertension: pathophysiology as a basis for clinical decision making (Rabinovitch). 1999;18:1041-53
Pulmonary volume increases with linear growth in pediatric living donor lobar lung transplant recipients (Woo et al). 1999;18:86 (Abstract)
Recurrence of hepatitis B after single lung transplantation (Stamenkovic et al). 1999;18:1246-50
Reductions in type 1 fibre proportions and oxidative enzyme activity in skeletal muscle exist pre & post lung transplantation (Morton et al). 1999;18:52 (Abstract)
The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18: 611-26
The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB) (Mulligan et al). 1999;18:88 (Abstract)
Results of expandable metal stent placement in lung transplant recipients (Baz et al). 1999; 18:60 (Abstract)
Results of lung transplantation following lung volume reduction surgery (Wisser et al). 1999; 18:67 (Abstract)
Salvage by volume reduction of chronic allograft rejection in emphysema (Schulman et al). 1999; 18:107-12
Selective adenosine-A_{2A} activation reduces lung reperfusion injury following transplantation

(Ross et al). 1999;18:72 (Abstract), 1999;18: 994-1002

The significance of bronchial associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? (Hasegawa et al). 1999;18:41 (Abstract)

Successful eradication of mucormycosis occurring in a pulmonary allograft (Hunstad et al). 1999; 18:801-4

Successful lung transplantation with the use of marginal donors (Bhorade et al). 1999;18:79 (Abstract)

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome (Myers et al). 1999;18:1024-26

Suggested guidelines for the use of tacrolimus in lung-transplant recipients (Garrity et al). 1999; 18:175-76

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58

Temporary ECMO support following lung and heart-lung transplantation (Nguyen et al). 1999; 18:55 (Abstract)

Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation (El-Gamel et al). 1999;18:828-35

Transforming growth factor-beta (TGF-β1) genotype and lung allograft fibrosis (El-Gamel et al). 1999;18:517-22

Transient left ventricular failure following bilateral lung transplantation for pulmonary hypertension (Bîrsan et al). 1999;18:304-9

Transplantation of a lobe of a lung from mother to child after previous transplantation with bone marrow (Svendsen et al). 1999;18:388-89

Transtracheal gene transfection of donor lungs prior to organ procurement increases transgene levels at reperfusion and following transplantation (Cassivi et al). 1181-88

Lung volume reduction surgery

Impact of morphology and ventilatory mechanics upon early functional outcome after lung volume reduction surgery (Wisser et al). 1999; 18:42 (Abstract)

Loss of pulmonary function gains after lung volume reduction surgery (Kesten et al). 1999;18:266-68

Results of lung transplantation following lung volume reduction surgery (Wisser et al). 1999; 18:67 (Abstract)

Salvage by volume reduction of chronic allograft rejection in emphysema (Schulman et al). 1999; 18:107-12

Lymphoproliferative disease. *See* **Post-transplant lymphoproliferative disease**

M

Macrophages

Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV (Fischbein et al). 1999;18:40-41 (Abstract)

Magnetic resonance imaging

Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18: 1054-64

Magnetic resonance spectroscopy

Bio-energetic response of the heart to dopamine following brain death-related reduced myocardial workload: a phosphorus-31 magnetic resonance spectroscopy study in the cat (Bruinsma et al). 1999;18:1189-97

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Malignancy

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Risk factor analysis for skin cancer in heart transplant (HT) recipients (Belloni et al). 1999; 18:77 (Abstract)

Tumor marker determination after orthotopic heart transplantation (Nägele et al). 1999;18: 957-62

Malononitrilamide

Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats (Slauson et al). 1999;18:1251-52 (Letter)

Mechanical ventilation

Mechanical ventilation as a bridge to lung transplantation (O'Brien et al). 1999;18:255-63

Medical management

Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65

Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients (Lok). 1999;18:884-89

Outpatient inotropic therapy in refractory heart failure (Oliva et al). 1999;18:75 (Abstract)

Randomised trial of cardiomyoplasty against optimal medical therapy in class III heart failure (Keogh et al). 1999;18:67 (Abstract)

Sudden death and tailored medical therapy in elective candidates for heart transplantation (Nägele et al). 1999;18:869-75

Time course of reverse left ventricular remodeling in response to carvedilol in heart failure (McCaffrey et al). 1999;18:76 (Abstract)

Treatment differences and clinical outcomes of advanced heart failure (HF) patients with a critical care admission using specialist team protocols vs. general cardiology care (Albert et al). 1999;18:76 (Abstract)

The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension (Pamboukian et al). 1999;18:367-70

Mental health. *See* **Psychosocial factors**

Mentors

Evaluation of a mentorship programme for heart transplant patients (Pennington et al). 1999; 18:91 (Abstract)

Metallothionein

Metallothionein: localization in human transplant endomycardium, relation to cytokines and allograft function (Baba et al). 1999;18:963-71

Metallothionein is involved in reverse remodeling after prolonged left ventricular assist device support (Baba et al). 1999;18:57 (Abstract)

Metoprolol

Beta-blocker treatment of dilated cardiomyopathy with congestive heart failure in children: a multi-institutional experience (Shaddy et al). 1999;18:269-74

Mice

Anti-CD3:F(ab′)2-idarubicin conjugates prolong mouse cardiac allografts (Mottram et al). 1999; 18:94 (Abstract)

Assessment of murine bone marrow transplant chimeras (Krasinskas et al). 1999;18:88 (Abstract)

CD4 T cell mediated rejection of cardiac allograft is Fas/FasL sensitive (Pietra et al). 1999;18:48 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Donor specific spleen cells mediate allograft survival by a different mechanism than bone marrow (Goldstein et al). 1999;18:69 (Abstract)

Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection (Mannon et al). 1999;18:819-26

Orthotopic aortic transplantation in mice: a new model of allograft arteriosclerosis (Dambrin et al). 1999;18:946-51

Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV (Fischbein et al). 1999;18:40-41 (Abstract)

Milrinone

The use of milrinone and pre-transplant assessment of patients with congestive heart failure and pulmonary hypertension (Pamboukian et al). 1999;18:367-70

Minipigs

The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)

Effects of MHC class II antigens on the development of cardiac allograft vasculopathy in miniature swine (Mawulawde et al). 1999;18:53 (Abstract)

Transplantation of "thymoheart" allografts in miniature swine (Menard et al). 1999;18:71 (Abstract)

Monkeys. *See* **Primates**

Monoclonal antibodies. *See* **Antibodies, monoclonal**

Mortality

Death after heart transplantation in children: who dies when and why (Frazier et al). 1999;18: 69-70 (Abstract)

Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation (Dew et al). 1999;18:549-59

Failure to wean from parenteral inotropes: a strong predictor for early mortality among patients with end stage heart disease (Park et al). 1999;18:47-48 (Abstract)

Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality (Sheffield et al). 1999;18:39 (Abstract)

A post mortem audit of deaths occurring beyond 30 days following heart-lung transplantation (Bardsley et al). 1999;18:41 (Abstract)

Sudden death and tailored medical therapy in elective candidates for heart transplantation (Nägele et al). 1999;18:869-75

Mucormycosis

Successful eradication of mucormycosis occurring in a pulmonary allograft (Hunstad et al). 1999; 18:801-4

Multiglycosidorum tripterygii

Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18:248-53

Mycophenolate mofetil

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring (Meiser et al). 1999;18: 143-48

Comparison between mycophenolate mofetil- and azathioprine-based immunosuppressions in clinical lung transplantation (Zuckermann et al). 1999;18:432-39

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18: 185-88

MPA-dose adjustment based on trough levels-high and low dose pharmocokinetics in heart transplanted patients (Schmidt et al). 1999; 18:46 (Abstract)

Mycophenolate mofetil for secondary prevention of allograft vasculopathy following heart transplantation: a prospective, randomized, intravascular ultrasound controlled trial (Pethig et al). 1999;18:77-78 (Abstract)

Mycophenolate mofetil in paediatric heart transplant recipients: a single center experience (Dipchand et al). 1999;18:83-84 (Abstract)

Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) (Klepetko et al). 1999;18: 45-46 (Abstract)

Three year results of the double-blind randomized multicenter trial of mycophenolate mofetil in heart transplant patients (Keogh et al). 1999; 18:53 (Abstract)

Mycophenolic acid

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring (Meiser et al). 1999;18:143-48

Mycophenolic acid concentrations are associated with cardiac allograft rejection (DeNofrio et al). 1999;18:46 (Abstract)

Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (Gummert et al). 1999;18:53-54 (Abstract)

Myocardial infarction

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium (Atkines et al). 1999;18:1173-80

Myocardial ischemia

Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit myocardium (Atkins et al). 1999; 18:43 (Abstract)

Transmyocardial laser revascularisation in class IV angina—a randomized trial (Spratt et al). 1999;18:42 (Abstract)

Myocardial protection

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

Myocarditis

Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance (Chen et al). 1999;18:351-57

Reversal of myocardial interleukin-6-mRNA expression following long-term left ventricular assist device support for myocarditis-associated low output syndrome (Plenz et al). 1999;18: 923-24 (Letter)

Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices (Brilakis et al). 1999;18:43-44 (Abstract)

Myocardium

Altered myocardial and endothelial expression of cyclooxygenase-2 after prolonged mechanical support in patients with severe idiopathic dilated cardiomyopathy (Belland et al). 1999; 18:54 (Abstract)

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Histopathology of resected myocardium is correlated with survival after partial left ventriculectomy—a clue to indication for PLV versus transplantation (Kawaguchi et al). 1999;18:67 (Abstract)

Mechanisms of brain death associated myocardial dysfunction (Bittner et al). 1999;18:87 (Abstract)

Revascularisation for post-ischaemic heart failure: how myocardial viability affects survival (Pagano et al). 1999;18:67 (Abstract)

Myxoma

Mitral valve myxoma: an unusual reason for rejecting a donor heart (de Boer et al). 1999;18: 924-25 (Letter)

N

Natural killer (NK) cells

Immunologic assessment of risk for rejections after heart transplantation (Wang et al). 1999; 18:80 (Abstract)

Nefazodone

Nefazodone and cyclosporine drug-drug interaction (Wright et al). 1999;18:913-15

Neoral

Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Clinical benefit of Neoral dose monitoring with cyclosporine 2-hour peak levels compared to trough levels in stable heart transplant patients (Cantarovich et al). 1999;18:78 (Abstract)

Multicenter, double-blind, randomized study of Neoral vs Sandimmune in heart transplantation: one year results (Eisen et al). 1999;18:93 (Abstract)

The Netherlands

Prospective cost-utility analysis of lung transplantation in the Netherlands: a comment on the pilot study by Gartner et al. (van Enckevort et al). 1999;18:496-97 (Letter)

Neurohumoral factors

Role of neural and humoral factors in cardiac dysfunction in the potential organ donor (Szabó et al). 1999;18:39 (Abstract)

Neutrophil elastase inhibitor

The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18: 637-44

Neutrophils

The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18: 637-44

Nifedipine

Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32

Nitric oxide

Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS (Gabbay et al). 1999; 18:51 (Abstract)

The effect of inhaled steroids on exhaled nitric oxide in lung transplant recipients with lymphocytic bronchitis (De Soyza et al). 1999;18:45 (Abstract)

A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? (Cable et al). 1999;18:177-83

Nitric oxide inhalation

Comprehensive concept to support right ventricular function following left ventricular assist device implantation (Wagner et al). 1999;18:89 (Abstract)

Donor pre-treatment with inhaled nitric oxide attenuates acute lung injury following single lung transplantation (Sudarshan et al). 1999; 18:78 (Abstract)

The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)

Inhaled nitric oxide in early severe allograft lung dysfunction (Planas et al). 1999;18:55 (Abstract)

Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation (Carrier et al). 1999;18:664-67

Use of inhaled nitric oxide in cardiac transplantation (Williams et al). 1999;18:44 (Abstract)

Nitric oxide synthase

Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS (Gabbay et al). 1999; 18:51 (Abstract)

Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not required for efficient rejection (Mannon et al). 1999;18:819-26

Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts (Iwata et al). 1999;18:37 (Abstract)

Nitroglycerin

Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW) (Baxter et al). 1999;18:769-73

Nuclear factor κB

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

Nutrition

Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18:750-60

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18:185-88

Maintaining or improving nutritional parameters for patients awaiting lung transplantation (Endres et al). 1999;18:91 (Abstract)

O

Obesity

Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18:750-60

Obliterative bronchiolitis. *See* **Bronchiolitis obliterans**

Obstructive airway disease

Causes of allograft dysfunction after single lung transplantation for emphysema: extrinsic restriction versus intrinsic obstruction (Moy et al). 1999;18:986-93

ONO-5046·Na

The effects of a neutrophil elastase inhibitor (ONO-5046·Na) and neutrophil depletion using a granulotrap (G-1) column on lung reperfusion injury in dogs (Tomizawa et al). 1999;18:637-44

Organ allocation/distribution

Cooperative procurement for lung transplantation improves organ utilization without increasing complications (Iannettoni et al). 1999;18:86-87 (Abstract)

Determinants of waiting time for heart transplants in the United States (Kauffman et al). 18:733 (Correction), 1999;18:414-19

Effect of donor age on young and older lung transplant recipients (Waddell et al). 1999;18:85 (Abstract)

Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration (De Meester et al). 1999;18:563-71

Maximizing thoracic organ transplant (TOTX) opportunities—the importance of efficient coordination (Griffiths et al). 1999;18:86 (Abstract)

A nation-wide list would cause major redistribution of cadaveric lungs (Ely et al). 1999;18:55-56 (Abstract)

New UNOS rules: historical background and implications for transplantation management (Renlund et al). 1999;18:1065-70

Predictors of survival to transplant in cystic fibrosis: impact of international listing guidelines (Keenan et al). 1999;18:55 (Abstract)

Public and professional attitudes toward xenotransplantation and other options to increase organ availability (Hull). 1999;18:92 (Abstract)

Variations in cardiac transplantation: comparisons between the United Kingdom and the United States (Anyanwu et al). 1999;18:297-303

What are the attitudes of potential heart and heart-lung patients to xenotransplantation? (Long et al). 1999;18:92 (Abstract)

Organ preservation

Effects of prolonged storage time in xenotransplantation (Brenner et al). 1999;18:1211-17

Vascular function in the cadaver up to six hours after cardiac arrest (Bolys et al). 1999;18:582-86

Organ preservation, heart

Alteration in diastolic function following cardiac cryopreservation at subzero temperatures (Gutiérrez-Carretero et al). 1999;18:372-75

Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80

Cardioprotective effects of lazaroid U-74389G on ischemia-reperfusion injury in canine hearts (Takahashi et al). 1999;18:285-91

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:1202-10

A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)

Coronary endothelial dysfunction of isolated hearts subjected to prolonged cold storage: patterns and contributing factors (Kevelaitis et al). 1999;18:239-46

Does University of Wisconsin solution harm the transplanted heart? (Stringham et al). 1999;18: 587-95

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

Effects of endothelin A and B receptor antagonists on myocardial and endothelial injury during reperfusion after heart transplantation (Szabó et al). 1999;18:54 (Abstract)

Extracellular calcium concentration affects susceptibility to global ischemic injury in newborn but not adult hearts (Wittnich et al). 1999;18: 675-83

Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW) (Baxter et al). 1999;18: 769-73

Intraoperative liposome-mediated gene transfection of nitric oxide synthase (ecNOS) reduces ischemia-reperfusion injury in transplanted hearts (Iwata et al). 1999;18:37 (Abstract)

Long-term heart preservation using a new portable hypothermic perfusion apparatus (Oshima et al). 1999;18:852-61

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

The role of donor age and ischemic time on survival following orthotopic heart transplantation (Del Rizzo et al). 1999;18:310-19

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Organ preservation, lung

Alveolar recruitment prevents rapid-perfusion-induced injury of lung transplants (DeCampos et al). 1999;18:1096-1102

Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32

Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:862-67

Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91

Comparison of Euro Collins- and low potassium dextran (Perfadex) solution in clinical lung preservation (Müller et al). 1999;18:40 (Abstract)

Differential time scale of fluid and solute permeability following hypothermic lung preservation (Rooney et al). 1999;18:73 (Abstract)

Does PGE_1 attenuate potassium-induced vasoconstriction in initial pulmonary artery flush on lung preservation? (Sasaki et al). 1999;18:139-42

Early graft dysfunction in pediatric lung transplant recipients (Sweet et al). 1999;18:82-83 (Abstract)

Early mediators of lung ischaemia-reperfusion injury (Onwu et al). 1999;18:74 (Abstract)

The effects of inhaled nitric oxide, gabexate mesilate (FOY), and retrograde perfusion in the lung grafts from non-heart-beating minipig donors (Luh et al). 1999;18:62 (Abstract)

8-BR-cyclic GMP given during reperfusion improves posttransplant lung edema and free radical injury (Hillinger et al). 1999;18:74 (Abstract)

Gas exchange function one month after transplantation of lungs topically cooled for 2 hours in the non-heart-beating cadaver after failed resuscitation (Wierup et al). 1999;18:133-37

Human lung preservation can be extended beyond eight hours using UW solution (Love et al). 1999;18:87 (Abstract)

Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function (Wittwer et al). 1999;18:1198-1201

In-vivo measurement of oxygen free radical production correlates with pulmonary reperfusion injury (Wagner et al). 1999;18:74 (Abstract)

LPD solution in clinical lung transplantation (Strüber et al). 1999;18:87 (Abstract)

Modulation of pulmonary Na^+ pump gene expression during cold storage and reperfusion (Kim et al). 1999;18:74 (Abstract)

A novel cell culture model for aerobic, hypothermic lung preservation for transplantation (Cardella et al). 1999;18:88 (Abstract)

Protective effects of Celsior in lung transplantation (Xiong et al). 1999;18:320-26

Selective adenosine-A_{2A} activation reduces lung reperfusion injury following transplantation (Ross et al). 1999;18:72 (Abstract), 1999;18: 994-1002

Summary measures: a superior method of data analysis in lung preservation studies (Clark et al). 1999;18:172-73 (Letter)

Synergistic effect of endothelin- and PAF antagonists on posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:74-75 (Abstract)

Osteoporosis

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Outcomes. *See* **also Prognostic factors; Risk stratification**

Acute native lung hyperinflation (ANLH) is not associated with poor outcome after single lung transplant (SLT) for emphysema (Weill et al). 1999;18:55 (Abstract)

An analysis of the effect of age on survival after heart transplant (Borkon et al). 1999;18:668-73

Are preoperative obesity and cachexia risk factors for post heart transplant morbidity and mortality: a multi-institutional study of preoperative weight-height indices (Grady et al). 1999;18: 750-60

Assessment of health related quality of life in pulmonary transplantation: application of a simple generic tool (Anyanwu et al). 1999;18:51 (Abstract)

Cardiac transplant outcome between patients supported on a left ventricular assist device versus intravenous inotropic therapy (Jaski et al). 1999;18:37 (Abstract)

CMVIG favorably affects long-term outcome after heart, heart-lung and lung transplantation (Valantine et al). 1999;18:81 (Abstract)

Death after heart transplantation in children: who dies when and why (Frazier et al). 1999;18: 69-70 (Abstract)

Decreased survival associated with size mismatching in lung transplantation (Park et al). 1999;18:60 (Abstract)

Development of post lung transplant obliterative bronchiolitis is characterized by increased exhaled nitric oxide, upregulation of iNOS and downregulation of cNOS (Gabbay et al). 1999; 18:51 (Abstract)

Does cardiac transplantation affect gynecologic and reproductive outcomes? (Eisenring et al). 1999;18:58-59 (Abstract)

Does the donor-recipient ABO blood group compatibility status predict subsequent lung transplantation outcomes? (Yu et al). 1999;18:764-68

Does time to harvest determine outcome in heart transplantation with older allografts? (Scott et al). 1999;18:39 (Abstract)

Domino heart transplantation: 10 years experience (Ongcharit et al). 1999;18:37 (Abstract)

Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation (Dew et al). 1999;18:549-59

Effect of histocompatibility, sensitization and other risk factors on the outcome of 14,535 cardiac transplants (TNX) reported to the UNOS scientific registry (Thompson et al). 1999;18:38-39 (Abstract)

The effect of pre lung transplant clinical status on post transplant outcome for children with cystic fibrosis: a ten year experience (Gassas et al). 1999;18:83 (Abstract)

Factors affecting outcome in patients "too well" for heart transplantation at initial assessment (Eccleshall et al). 1999;18:46 (Abstract)

Five years of living lobar donation for bilateral lung transplantation: long term results in 137 donors (Uppal et al). 1999;18:54 (Abstract)

Gastroesophageal reflux is an important cause of allograft dysfunction in lung transplant recipients (Palmer et al). 1999;18:51 (Abstract)

Gender mismatch is not associated with reduced survival after heart transplantation (Smedira et al). 1999;18:44 (Abstract)

Hemodynamic guided inotropic tailoring does not appear to impact long term survival among

patients requiring chronic home inotropic therapy (Pathak et al). 1999;18:43 (Abstract)
Hepatitis C virus (HCV) positive donor hearts: impact on morbidity and mortality (Sheffield et al). 1999;18:39 (Abstract)
HLA class II matching: significant impact on long term outcome of lung transplantation (van den Berg et al). 1999;18:85 (Abstract)
The impact of HLA sensitization and donor cause of death in heart transplantation (Cook et al). 1999;18:38 (Abstract)
Impact of morphology and ventilatory mechanics upon early functional outcome after lung volume reduction surgery (Wisser et al). 1999; 18:42 (Abstract)
Impact of patient noncompliance on survival in cardiac transplant recipients (Lawless et al). 1999;18:38 (Abstract)
Improved results for retransplantation in acute and late pulmonary graft failure (Harringer et al). 1999;18:56 (Abstract)
Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance (Chen et al). 1999;18:351-57
Influence of HLA matching on survival and development of obliterative bronchiolitis (OB) after lung transplantation (Novick et al). 1999; 18:50-51 (Abstract)
The International Lung Transplant Database: demographics and outcomes in 826 lung transplant recipients (Doyle et al). 1999;18:86 (Abstract)
Is the use of donor hearts with left ventricular hypertrophy acceptable? (Marelli et al). 1999; 18:87 (Abstract)
Late functional outcome after transplantation (Tx) versus Norwood 3 stage palliation (Nw) for infants with hypoplastic left heart syndrome (HLHS) (Bando et al). 1999;18:70 (Abstract)
Late rejection greater than 1 year after pediatric heart transplantation: an ominous finding (Webber et al). 1999;18:69 (Abstract)
Left ventricular diastolic function after bicaval and standard cardiac transplantation (Burgess et al). 1999;18:44-45 (Abstract)
Lung transplant waiting list: differential outcome of type of end-stage lung disease, one year after registration (De Meester et al). 1999;18:563-71
Medium term results of children with two hearts (Radley-Smith et al). 1999;18:84 (Abstract)
Optimal timing of lung transplantation in cystic fibrosis patients (Cahill et al). 1999;18:86 (Abstract)
Outcome of infants listed for lung or heart/lung transplantation (Ro et al). 1999;18:83 (Abstract)
Outcome of listing for cardiac transplantation for failed Fontan: a multi-institutional study (Bernstein et al). 1999;18:69 (Abstract)
Outcomes with hepatitis C following cardiac transplantation—a multi-institutional study (Lake et al). 1999;18:81 (Abstract)
Patient outcome and costs following an acute heart failure (HF) management program in an emergency department (ED) observation unit (OU) (Peacock et al). 1999;18:92 (Abstract)
Pediatric cardiac retransplantation: experience at a single institution (Dearani et al). 1999;18:70 (Abstract)
A post mortem audit of deaths occurring beyond 30 days following heart-lung transplantation (Bardsley et al). 1999;18:41 (Abstract)
Predictors of quality of life in patients at one year after heart transplantation (Grady et al). 1999; 18:202-10
Reductions in type 1 fibre proportions and oxidative enzyme activity in skeletal muscle exist pre & post lung transplantation (Morton et al). 1999;18:52 (Abstract)
The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18: 611-26
Results of expandable metal stent placement in lung transplant recipients (Baz et al). 1999; 18:60 (Abstract)
Results of lung transplantation following lung volume reduction surgery (Wisser et al). 1999; 18:67 (Abstract)
Return to work after heart transplantation: 12-year follow-up (Kavanagh et al). 1999;18:846-50
The role of donor age and ischemic time on survival following orthotopic heart transplantation (Del Rizzo et al). 1999;18:310-19
Should advanced recipient age be contraindicated in cardiac transplantation? Continued analysis of a single center experience (Hoercher et al). 1999;18:45 (Abstract)
Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices (Brilakis et al). 1999;18:43-44 (Abstract)
Ten-year follow-up after pediatric transplantation (Parisi et al). 1999;18:275-77
Three year results of the double-blind randomized multicenter trial of mycophenolate mofetil in heart transplant patients (Keogh et al). 1999; 18:53 (Abstract)

Treatment differences and clinical outcomes of advanced heart failure (HF) patients with a critical care admission using specialist team protocols vs. general cardiology care (Albert et al). 1999;18:76 (Abstract)

Variations in cardiac transplantation: comparisons between the United Kingdom and the United States (Anyanwu et al). 1999;18:297-303

Oxidative stress

Changes in oxidative stress and cellular redox potential during myocardial storage for transplantation: experimental studies (Cargnoni et al). 1999;18:478-86

8-BR-cyclic GMP given during reperfusion improves posttransplant lung edema and free radical injury (Hillinger et al). 1999;18:74 (Abstract)

In-vivo measurement of oxygen free radical production correlates with pulmonary reperfusion injury (Wagner et al). 1999;18:74 (Abstract)

P

Pediatrics. *See* **Child(ren)**

Perfadex

Comparison of Euro Collins- and low potassium dextran (Perfadex) solution in clinical lung preservation (Müller et al). 1999;18:40 (Abstract)

Improvement of pulmonary preservation with Celsior and Perfadex: impact of storage time on early post-ischemic lung function (Wittwer et al). 1999;18:1198-1201

Pheochromocytoma

Reversible catecholamine-induced cardiomyopathy in a heart transplant candidate without persistant or paroxysmal hypertension (Brilakis et al). 1999;18:376-80

Pigs

Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)

Feasibility of a pumpless extracorporeal respiratory assist device (De Somer et al). 1999;18: 1014-17

Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption (Brenner et al). 1999; 18:59 (Abstract)

Successful orthotopic pig heart transplantation from non-heart beating donors (Martin et al). 1999;18:597-605

Plasmapheresis

Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibody prior to cardiac transplantation (Pisani et al). 1999;18:701-6

Platelet-activating factor

Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999;18:470-76

Combined treatment with endothelin- and PAF-antagonists reduces posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:862-67

Synergistic effect of endothelin- and PAF antagonists on posttransplant lung ischemia/reperfusion injury (Stammberger et al). 1999;18:74-75 (Abstract)

Platelet adhesion

Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)

Pneumocystis carinii

Recurrent *Pneumocystic carinii* colonization in a heart-lung transplantation recipient on long-term trimethoprin-sulfamethoxazole prophylaxis (Faul et al). 1999;18:384-87

Pneumothorax

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Polymerase chain reaction assay

Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection (Zeevi et al). 1999;18:81-82 (Abstract)

Positron emission tomography

Relationship between coronary function by positron emission tomography and temporal changes in morphology by intravascular ultrasound (IVUS) in transplant recipients (Allen-Auerbach et al). 1999;18:211-18

Post-transplant lymphoproliferative disease

Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease (Balfour et al). 1999;18:492-94

Development and spectrum of PTLD in 691 cardiac transplant (Htx) recipients receiving induction therapy (Mallinger et al). 1999;18:77 (Abstract)

Effective treatment of lymphoproliferative disease following lung transplantation using a

monoclonal anti-CD20 B-cell antibody (Cook et al). 1999;18:84-85 (Abstract)
Evaluation of circulating Epstein-Barr virus (EBV) viral load in pediatric thoracic recipients: implications for diagnosis of posttransplant lymphoproliferative disorders (PTLD) (Webber et al). 1999;18:83 (Abstract)
Post-transplant lymphoproliferative disease (PTLD) following lung transplantation in Canadian transplant centers (Partovi et al). 1999; 18:85 (Abstract)

Potassium
Does PGE_1 attenuate potassium-induced vasoconstriction in initial pulmonary artery flush on lung preservation? (Sasaki et al). 1999;18:139-42

Pravastatin
Five-year follow-up of a randomized trial of pravastatin in heart transplant patients (Kobashigawa et al). 1999;18:71 (Abstract)
The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial (Mehra et al). 1999;18:76 (Abstract)

Prednisone
Cyclophosphamide/prednisone for combination immunosuppression and therapy of lymphoproliferative disease (Balfour et al). 1999;18:492-94

Primates
Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)
The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model (Hausen et al). 1999;18:714-24
Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

Probucol
Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80

Prognostic factors. *See* **also Outcomes; Risk stratification**
Factors affecting outcome in patients "too well" for heart transplantation at initial assessment (Eccleshall et al). 1999;18:46 (Abstract)
Failure to wean from parenteral inotropes: a strong predictor for early mortality among patients with end stage heart disease (Park et al). 1999;18:47-48 (Abstract)
High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection (Zeevi et al). 1999;18:82 (Abstract)
Low cardiac neuronal function and predicted value of maximum oxygen consumption predict for high risk of cardiac events in cardiomyopathy (Agostini et al). 1999;18:47 (Abstract)
Predictors of quality of life in patients at one year after heart transplantation (Grady et al). 1999; 18:202-10
Predictors of survival to transplant in cystic fibrosis: impact of international listing guidelines (Keenan et al). 1999;18:55 (Abstract)
Prognostic indices in heart transplant candidates after the first hospitalization triggered by the need for intravenous pharmocologic circulatory support (Gronda et al). 1999;18:654-61
Prognostic value of circulating levels of interleukin-6 in patients with congestive heart failure (Roig et al). 1999;18:91 (Abstract)
Prognostic value of low versus high dosage of angiotensin converting enzyme inhibitors in patients awaiting heart transplantation (Berger et al). 1999;18:75 (Abstract)
Prognostic value of the relative lymphocyte concentration and white blood cell count in heart failure (Rayburn et al). 1999;18:47 (Abstract)
Psychological evaluation as a prognostic factor among patients candidates for cardiac transplantation (Moscoloni et al). 1999;18:58 (Abstract)
Refining the criteria for heart transplant listing and status: a multi-institutional risk factor analysis for rehospitalization following listing (Kirklin et al). 1999;18:47 (Abstract)
Sequential evaluation of big endothelin plasma concentration in patients with advanced heart failure: effects of therapy (Berger et al). 1999; 18:47 (Abstract)

Prostacyclin
Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65
Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91

Prostaglandins
Bridging to heart transplantation: prostaglandin E_1 versus prostacyclin versus dobutamine (Stanek et al). 1999;18:358-65

Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91

Does PGE_1 attenuate potassium-induced vasoconstriction in initial pulmonary artery flush on lung preservation? (Sasaki et al). 1999;18:139-42

Prosthetic valve endocarditis

Cardiac transplantation for prosthetic valve endocarditis in a previously transplanted heart (Galbraith et al). 1999;18:805-6

P-selectin

Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin (Raisky et al). 1999; 18:61 (Abstract)

Alterations of the coronary microcirculation by soluble adhesion molecules P-selectin and ICAM-1 after cardiac transplantation in humans (Wildhirt et al). 1999;18:64-65 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18: 735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Psychosocial factors

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Early post-transplant medical compliance and mental health predict physical morbidity and mortality one to three years after heart transplantation (Dew et al). 1999;18:549-59

Education and the transplanted child (Wray et al). 1999;18:57 (Abstract)

Lung transplantation in a Jehovah's Witness (Conte et al). 1999;18:796-99

Pediatric heart transplant school re-entry (Rodgers et al). 1999;18:58 (Abstract)

Psychiatric disorders and outcome following cardiac transplantation (Skotzko et al). 1999;18: 952-56

Psychological evaluation as a prognostic factor among patients candidates for cardiac transplantation (Moscoloni et al). 1999;18:58 (Abstract)

Pulmonary embolism

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

Pulmonary fibrosis

Transforming growth factor-beta (TGF-β1) genotype and lung allograft fibrosis (El-Gamel et al). 1999;18:517-22

Pulmonary fibrosis, idiopathic

Interstitial lung disease clinics for the management of idiopathic pulmonary fibrosis: a potential advantage to patients (Lok). 1999;18:884-89

Pulmonary hypertension. *See* **Hypertension, pulmonary**

Q

Quality of life

Assessment of health related quality of life in pulmonary transplantation: application of a simple generic tool (Anyanwu et al). 1999;18:51 (Abstract)

Predictors of quality of life in patients at one year after heart transplantation (Grady et al). 1999; 18:202-10

R

Rabbits

Five years results of a prospective randomized study comparing a rabbit ATG versus a monoclonal anti-CD25 antibody in de novo cardiac transplant recipients (Laufer et al). 1999;18:94 (Abstract)

Myogenic cell transplantation improves in vivo regional performance in infarcted rabbit myocardium (Atkines et al). 1999;18:1173-80

Radiofrequency catheter ablation

Radiofrequency ablation of a concealed accessory pathway years after heart transplant: a case report (Sharma et al). 1999;18:792-94

Radiofrequency catheter ablation of atrial flutter after orthotopic heart transplantation: insights into the redefined critical isthmus (Pinski et al). 1999;18:292-96

RANTES

Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection (Zeevi et al). 1999;18:81-82 (Abstract)

Rapamycin. *See also* **SDZ RAD**

Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

Rats

Anti-LFA-1α reduces the dose of cyclosporine A needed to produce immunosuppression in the heterotopic cardiac transplanted rats (Harrison et al). 1999;18:279-84

Apoptosis induced by ischemia and reperfusion in experimental lung transplantation (Stammberger et al). 1999;18:79 (Abstract)

Apoptosis in rat cardiac allograft is predominantly associated with cells of the immune response (Agelan et al). 1999;18:40 (Abstract)

Attenuation of reperfusion injury with probucol in the heterotopic rat cardiac isograft (Rabkin et al). 1999;18:775-80

Calcium channel blocker enhances lung preservation (Sasaki et al). 1999;18:127-32

Cardiac function of transplanted rat hearts using a working heart model assessed by magnetic resonance imaging (Yoshida et al). 1999;18: 1054-64

Combined use of prostacyclin and higher perfusate temperatures further enhances the superior lung preservation by Celsior solution in the isolated rat lung (Wittwer et al). 1999;18:684-91

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats (Wada et al). 1999;18:499-508

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment (Hirt et al). 1999;18:542-48

Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype (McLean et al). 1999;18:68 (Abstract)

Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)

The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18:185-88

Effect of soluble complement receptor type 1 (sCR1) on experimental obliterative bronchiolitis (OB) (Kallio et al). 1999;18:52-53 (Abstract)

Effects of Celsior preservation solution on myocardial performance and coronary vasomotor function after 2 h of global ischemia in isolated rat hearts (Wildhirt et al). 1999;18:40 (Abstract)

Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Ganciclovir and rat cytomegalovirus (RCMV) antisera prophylaxis prevent RCMV infection-enhanced experimental obliterative bronchiolitis (OB) in the rat (Tikkanen et al). 1999;18:62 (Abstract)

Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999; 18:48-49 (Abstract)

IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts (Wilhelm et al). 1999;18:68 (Abstract)

Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)

Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Mixed hematopoietic chimerism prevents allograft vasculopathy (Kawaharada et al). 1999;18: 532-40

A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dt_{max} (Dambrin et al). 1999;18:524-30

A novel approach to test immunosuppressive drugs in heterotopically transplanted lung fragments in rats (Ikonen et al). 1999;18:73 (Abstract)

Optimized cardiac graft preservation: a comparative experimental study using P-31 magnetic resonance spectroscopy and biochemical analysis (Bernard et al). 1999;18:572-80

Pressure mediated delivery of decoy NF-κB binding oligodeoxynucleotides decreases reperfusion injury in rodent cardiac allografts (Feeley et al). 1999;18:48 (Abstract)

Quality effect in heterotopic cardiac allografts in malononitrilamide treated rats (Slauson et al). 1999;18:1251-52 (Letter)

RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)

The regulatory role of IL-10 in experimental obliterative bronchiolitis (OB) (Mulligan et al). 1999;18:88 (Abstract)

A simple new model of physiologically working heterotopic rat heart transplantation provides

hemodynamic performance equivalent to that of an orthotopic heart (Asfour et al). 1999;18: 927-36

Soluble rat class I MHC proteins induce prolonged survival of rat cardiac allografts (Perez et al). 1999;18:68 (Abstract)

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58

Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (Gummert et al). 1999;18:53-54 (Abstract)

Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae (Ennen et al). 1999;18:49 (Abstract)

Registry

The Registry of the International Society for Heart and Lung Transplantation: Sixteenth Official Report-1999 (Hosenpud et al). 1999;18: 611-26

The Registry of the International Society for Heart and Lung Transplantation: Third Official Pediatric Report (Boucek et al). 1999;18:1151-72 (Registry)

Reinnervation, cardiac. *See* **Donor heart, reinnervation**

Rejection, cardiac allograft

Acute rejection of cardiac allografts deficient in ICAM-1 and P-selectin (Raisky et al). 1999; 18:61 (Abstract)

Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172 (Letter)

CD4 T cell mediated rejection of cardiac allograft is Fas/FasL sensitive (Pietra et al). 1999;18:48 (Abstract)

Cytokine transcripts in coronary arteries and coronary artery-derived T-cell lines from patients with chronic rejection (Slachta et al). 1999; 18:41 (Abstract)

Detection of acute cardiac rejection by analysis of heart rate variability in heterotopically transplanted rats (Wada et al). 1999;18:499-508

Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies (Behr et al). 1999;18:904-11

Differences in rejection of rat heart transplants are determined by passenger leukocyte genotype (McLean et al). 1999;18:68 (Abstract)

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Donor and recipient contributions of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:61 (Abstract)

Efficacy of donor specific bone marrow in reducing frequency of rejection following heart transplantation (McGurl et al). 1999;18:93 (Abstract)

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients (Onsager et al). 1999;18:448-54

Functional responses of anti-CD25 blocked T-cells during cardiac rejection (Baan et al). 1999;18:69 (Abstract)

Hematoma of the interventricular septum following right ventricular endomyocardial biopsy for the detection of allograft rejection after heart transplantation (Salim Roussouliéres et al). 1999;18:1147-50 (Letter)

Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients (Kobashigawa et al). 1999;18:50 (Abstract)

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

Immunologic assessment of risk for rejections after heart transplantation (Wang et al). 1999; 18:80 (Abstract)

The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial (Mehra et al). 1999;18:76 (Abstract)

Impact of donor brain death on tempo and intensity of acute rejection of rat cardiac allografts (Wilhelm et al). 1999;18:68 (Abstract)

Inducible nitric oxide synthase promotes cytokine expression in cardiac allografts but is not re-

quired for efficient rejection (Mannon et al). 1999;18:819-26

Late rejection greater than 1 year after pediatric heart transplantation: an ominous finding (Webber et al). 1999;18:69 (Abstract)

Mycophenolic acid concentrations are associated with cardiac allograft rejection (DeNofrio et al). 1999;18:46 (Abstract)

A new rejection criteria in the heterotopically placed rat heart by non-invasive measurement of Dp/Dt_{max} (Dambrin et al). 1999;18:524-30

Non compliance causing late acute rejection in pediatric heart transplantation (Ringewald et al). 1999;18:70 (Abstract)

Noninvasive cardiac graft monitoring: the Graz experience (Grasser et al). 1999;18:80 (Abstract)

Noninvasive monitoring of peak filling rate with acoustic quantification echocardiography accurately detects acute cardiac allograft rejection (Moidl et al). 1999;18:194-200

Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection (Park et al). 1999;18:1224-27

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection (Trull et al). 1999;18:93 (Abstract)

Therapeutic monitoring of mycophenolic acid (MPA): assays of immune function in peripheral blood predict efficacy for inhibition of histologic graft rejection (Gummert et al). 1999;18:53-54 (Abstract)

Use of Daclizumab decreases the frequency of early allograft rejection in de-novo heart transplant recipients (Beniaminovitz et al). 1999; 18:45 (Abstract)

Rejection, pulmonary allograft. *See also* **Bronchiolitis obliterans**

Analysis of risk factors for chronic lung rejection from a twelve-center, multinational database (Brazelton et al). 1999;18:59 (Abstract)

Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)

Competitive RT-PCR for Granzyme-B, IL-15 and RANTES for molecular diagnosis of lung allograft rejection (Zeevi et al). 1999;18:81-82 (Abstract)

Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection (Kulick et al). 1999;18:65 (Abstract)

Cyclophosphamide rescue therapy for chronic rejection after lung transplantation (Verleden et al). 1999;18:1139-46

Development of obliterative bronchiolitis after allogeneic rat lung transplantation: implication of acute rejection and the time point of treatment (Hirt et al). 1999;18:542-48

Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients (Onsager et al). 1999;18:448-54

High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection (Zeevi et al). 1999;18:82 (Abstract)

The histology of subcutaneously implanted donor bronchial rings correlates with rejection scores of lung allografts in a primate lung transplant model (Hausen et al). 1999;18:714-24

Loss of airway goblet cells is associated with respiratory epithelial injury in a rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Patterns and significance of CD44 expression in lung allografts (Zander et al). 1999;18:646-52

Salvage by volume reduction of chronic allograft rejection in emphysema (Schulman et al). 1999; 18:107-12

The significance of bronchial associated lymphoid tissue in human lung transplantation: is there an association with acute and chronic rejection? (Hasegawa et al). 1999;18:41 (Abstract)

Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58

Rejection, tracheal allograft

Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute rejection and proliferation of α-actin positive cells (Ikonen et al). 1999;18:60 (Abstract)

IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

Rejection, xenograft
Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection (Kulick et al). 1999;18:65 (Abstract)
Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption (Brenner et al). 1999; 18:59 (Abstract)
Inhibition of hyperacute pig-to-human xenograft rejection by modulating the fluid-phase complement activation (Fiane et al). 1999;18:66 (Abstract)
A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? (Cable et al). 1999;18:177-83
Regulatory roles of chemokines in delayed cardiac xenograft rejection (Mulligan et al). 1999; 18:59 (Abstract)
Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts (Briffa et al). 1999;18:66 (Abstract)
Reproduction
Does cardiac transplantation affect gynecologic and reproductive outcomes? (Eisenring et al). 1999;18:58-59 (Abstract)
Respiratory support
Feasibility of a pumpless extracorporeal respiratory assist device (De Somer et al). 1999;18: 41-42 (Abstract), 1999;18:1014-17
Mechanical ventilation as a bridge to lung transplantation (O'Brien et al). 1999;18:255-63
Revascularization, coronary. *See also* **Transmyocardial laser revascularization**
Revascularisation for post-ischaemic heart failure: how myocardial viability affects survival (Pagano et al). 1999;18:67 (Abstract)
Right heart failure
Nitric oxide inhalation in the treatment of primary graft failure following heart transplantation (Carrier et al). 1999;18:664-67
Right ventricular function
Comprehensive concept to support right ventricular function following left ventricular assist device implantation (Wagner et al). 1999;18:89 (Abstract)
Risk stratification. *See also* **Outcomes; Prognostic factors**
Analysis of risk factors for chronic lung rejection from a twelve-center, multinational database (Brazelton et al). 1999;18:59 (Abstract)
Development of a simple risk model for predicting survival after adult orthotopic heart transplantation (Anyanwu et al). 1999;18:37-38 (Abstract)
Immunologic assessment of risk for rejections after heart transplantation (Wang et al). 1999; 18:80 (Abstract)
Intravascular ultrasound has prognostic impact after heart transplantation: a multivariable analysis in a large patient cohort (Klauss et al). 1999;18:50 (Abstract)
Recipient weight as an independent risk factor in heart transplantation (Mullen et al). 1999;18:92 (Abstract)
Refining the criteria for heart transplant listing and status: a multi-institutional risk factor analysis for rehospitalization following listing (Kirklin et al). 1999;18:47 (Abstract)
Risk factor analysis for inappropriate growth after pediatric heart transplantation (HTX) (Flaspohler et al). 1999;18:91 (Abstract)
Risk factor analysis for skin cancer in heart transplant (HT) recipients (Belloni et al). 1999; 18:77 (Abstract)

S

Salicylic acid
Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)
Sandimmune
Multicenter, double-blind, randomized study of Neoral vs Sandimmune in heart transplantation: one year results (Eisen et al). 1999;18:93 (Abstract)
SDZ RAD
Basiliximab (αIL2R Mab) induction therapy combined with subtherapeutic doses of Neoral and SDZ RAD successfully prevents allograft rejection in a nonhuman primate lung transplant model (Hausen et al). 1999;18:73 (Abstract)
Suppression of acute rejection in allogeneic rat lung transplantation: a study of the efficacy and pharmacokinetics of rapamycin derivative (SDZ RAD) used alone and in combination with a microemulsion formulation of cyclosporine (Hausen et al). 1999;18:150-58
Sexuality
Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients (Chait et al). 1999;18:58 (Abstract)

Sexuality of patients with advanced heart failure and their spouses or partners (Westlake et al). 1999;18:1133-38

Sildenafil citrate

Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients (Chait et al). 1999;18:58 (Abstract)

Simvastatin

The immunomodulatory role of Simvastatin and Pravastatin on cardiac allograft rejection: a prospective randomized trial (Mehra et al). 1999;18:76 (Abstract)

Skeletal muscle, function

Maximal exercise capacity and peripheral skeletal muscle function following lung transplantation (Lands et al). 1999;18:113-19

Reductions in type 1 fibre proportions and oxidative enzyme activity in skeletal muscle exist pre & post lung transplantation (Morton et al). 1999;18:52 (Abstract)

Skeletal muscle, physiology

Characterization of the skeletal muscle (SM) mitochondrial respiration in severe chronic heart failure (CHF) and its relations to the ventricular oxidative capacity (Zoll et al). 1999;18:71 (Abstract)

Skin cancer

Risk factor analysis for skin cancer in heart transplant (HT) recipients (Belloni et al). 1999; 18:77 (Abstract)

Sodium nitroprusside

Acetylcholine but not sodium nitroprusside exerts vasodilation in pulmonary hypertension secondary to chronic congestive heart failure (Wensel et al). 1999;18:877-82

Sodium pump

Modulation of pulmonary Na^+ pump gene expression during cold storage and reperfusion (Kim et al). 1999;18:74 (Abstract)

Spleen cells

Donor specific spleen cells mediate allograft survival by a different mechanism than bone marrow (Goldstein et al). 1999;18:69 (Abstract)

Steroids

Comorbidities in end-stage lung disease (Minaie et al). 1999;18:891-900

The effect of inhaled steroids on exhaled nitric oxide in lung transplant recipients with lymphocytic bronchitis (De Soyza et al). 1999;18:45 (Abstract)

Oral steroid pulse without taper for the treatment of asymptomatic moderate cardiac allograft rejection (Park et al). 1999;18:1224-27

Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) (Klepetko et al). 1999;18: 45-46 (Abstract)

Randomised trial of blood eosinophil count (EOS) monitoring to guide steroid dose adjustment in the control of heart allograft rejection (Trull et al). 1999;18:93 (Abstract)

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation (Sartori et al). 1999;18:693-99

Sulfasalazine

Sulfasalazine inhibits reperfusion injury and prolongs allograft survival in rat cardiac transplants (Feeley et al). 1999;18:1088-95

Survival. *See* **Outcomes**

Systole

Differential effects of cellular cardiomyoplasty on systolic and diastolic performance in cryoinjured rabbit myocardium (Atkins et al). 1999; 18:43 (Abstract)

Influence of felodipine on left ventricular hypertrophy and systolic function in orthotopic heart transplant recipients: possible interaction with cyclosporine medication (Schwitter et al). 1999; 18:1003-13

T

Tacrolimus

Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy (Freudenberger et al). 1999;18:1228-31

Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring (Meiser et al). 1999;18: 143-48

Comparison of long-term effects between tacrolimus and cyclosporine based immunosuppression after HTx (Meiser et al). 1999;18:78 (Abstract)

Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients (Onsager et al). 1999;18:448-54

MPA-dose adjustment based on trough levels-high and low dose pharmocokinetics in heart transplanted patients (Schmidt et al). 1999; 18:46 (Abstract)

Optimal dosing of intravenous tacrolimus following pediatric heart transplantation (Robinson et al). 1999;18:786-90

Prospective randomized two-center trial comparing cyclosporine A (CSA) vs. tacrolimus (TAC), in combination with mycophenolate mofetil (MMF) and steroids after lung transplantation (LTX) (Klepetko et al). 1999;18: 45-46 (Abstract)

A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus (Taylor et al). 1999;18:336-45

Successful use of cyclosporine in a lung transplant recipient with tacrolimus-associated hemolytic uremic syndrome (Myers et al). 1999;18:1024-26

Suggested guidelines for the use of tacrolimus in lung-transplant recipients (Garrity et al). 1999; 18:175-76

Tacrolimus-based triple-drug immunosuppression minimizes serum lipid elevations in pediatric cardiac transplant recipients (Penson et al). 1999;18:707-12

T cells (T lymphocytes)

Coronary arteries of human cardiac allografts with transplant coronary artery disease contain oligoclonal populations of T lymphocytes (Slachta et al). 1999;18:60 (Abstract)

Cytokine transcripts in coronary arteries and coronary artery-derived T-cell lines from patients with chronic rejection (Slachta et al). 1999; 18:41 (Abstract)

Functional responses of anti-CD25 blocked T-cells during cardiac rejection (Baan et al). 1999;18:69 (Abstract)

High frequency of intragraft IFN-γ producing CD8+ T cells is predictive of lung allograft rejection (Zeevi et al). 1999;18:82 (Abstract)

Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

T cell activation in left ventricular assist device (LVAD) recipients occurs via a CD95-dependent pathway, and results in loss of Th1 cells and high levels of circulating IL-10 (Ankersmit et al). 1999;18:56 (Abstract)

T cell apoptosis and defects in cellular immunity induced by exposure to biomaterials: implications for left ventricular assist device (LVAD) implantation (Ankersmit et al). 1999;18:56 (Abstract)

Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV (Fischbein et al). 1999;18:40-41 (Abstract)

T cells (T lymphocytes), cytotoxic

Donor-specific high avidity cytotoxic T-lymphocytes induced by implantation of cryopreserved human cardiac valves (Welters et al). 1999; 18:53 (Abstract)

Immunologic assessment of risk for rejections after heart transplantation (Wang et al). 1999; 18:80 (Abstract)

Thrombosis

Relation between long-term steroid treatment after heart transplantation, hypofibrinolysis and myocardial microthrombi generation (Sartori et al). 1999;18:693-99

Thromboxane

Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34

Effects of thromboxane synthase inhibition on hyperacute rejection of lungs (HALR) transgenic for human decay accelerating factor (hDAF) (Blair et al). 1999;18:54 (Abstract)

Inhibition of thromboxane A2 and platelet adhesion with salicylic acid effectively ameliorates reperfusion injury following acute double lung transplantation in the rat (Hausen et al). 1999; 18:79-80 (Abstract)

Thymoglobuline

Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation (Zuckermann et al). 1999;18:93 (Abstract)

Thymus

Transplantation of "thymoheart" allografts in miniature swine (Menard et al). 1999;18:71 (Abstract)

Thyroglobulin

A 10 year experience with intravenous thyroglobulin in induction of immunosuppression following heart transplantation (Carrier et al). 1999; 18:1218-23

Toxicology

Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience (Tsui et al). 1999;18:78-79 (Abstract)

Trachea transplantation

Epithelial re-growth prevents luminal occlusion in orthotopic tracheal allografts despite acute re-

jection and proliferation of α-actin positive cells (Ikonen et al). 1999;18:60 (Abstract)
IL-6 and IFN-γ expression parallels recovery of the epithelium in a heterotopic rat model of allograft rejection (Wan et al). 1999;18:90 (Abstract)
Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

Transforming growth factor β (TGF-β)
Genetic polymorphism of transforming growth factor-β (CODON 25) and development of cardiac allograft vascular disease (Pethig et al). 1999;18:52 (Abstract)
Increased intragraft expression of TGF-β mRNA in patients with graft vascular disease after clinical heart transplantation (de Groot-Kruseman et al). 1999;18:52 (Abstract)
Low producers of TGF beta are protected from cardiac transplant vasculopathy (Densem et al). 1999;18:52 (Abstract)
TGF beta polymorphism does not influence the rise in creatinine following cardiac transplantation (Densem et al). 1999;18:77 (Abstract)
Transforming growth factor-beta (TGF-β) and allograft vasculopathy following heart transplantation (Aziz et al). 1999;18:37 (Abstract)
Transforming growth factor beta (TGF-β) and obliterative bronchiolitis following pulmonary transplantation (El-Gamel et al). 1999;18:828-35
Transforming growth factor-beta (TGF-β1) genotype and lung allograft fibrosis (El-Gamel et al). 1999;18:517-22

Transfusions
Avoidance of cellular blood product transfusions in LVAD recipients does not prevent HLA allosensitization (Stringham et al). 1999;18:160-65

Transfusions, donor-specific
The effect of nutritional immunomodulation on cardiac allograft survival in rats receiving mycophenalate mofetil, cyclosporine A, and donor-specific transfusion (Gibson et al). 1999;18:185-88

Transmyocardial laser revascularization
Transmyocardial laser revascularisation in class IV angina—a randomized trial (Spratt et al). 1999;18:42 (Abstract)
Transmyocardial laser revascularization (TMR) in ischemic cardiomyopathy (Grauhan et al). 1999;18:66 (Abstract)

Trimethoprim-sulfamethoxazole
Recurrent *Pneumocystic carinii* colonization in a heart-lung transplantation recipient on long-term trimethoprin-sulfamethoxazole prophylaxis (Faul et al). 1999;18:384-87

Troponin T
Cardiac troponin T is not a marker of biopsy proven cellular rejection (Vazquez-Rodriguez et al). 18:610, 1999;18:172 (Letter)

Tumor markers
Tumor marker determination after orthotopic heart transplantation (Nägele et al). 1999;18:957-62

Tumor suppressor gene
The actions of cyclosporine-A on apoptosis and p53 expression in human vascular smooth muscle cells (Seta et al). 1999;18:61 (Abstract)
Increased p53 protein expression in human failing myocardium (Song et al). 1999;18:744-48

U

Ultrasound, intracoronary
Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18:391-97

Ultrasound, intravascular
Functional and morphological findings in heart transplant recipients with a normal coronary angiogram: an analysis by dobutamine stress echocardiography, intracoronary Doppler and intravascular ultrasound (Spes et al). 1999;18:391-97
The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study (Mehra et al). 1999;18:49 (Abstract)
Intravascular ultrasound has prognostic impact after heart transplantation: a multivariable analysis in a large patient cohort (Klauss et al). 1999;18:50 (Abstract)
Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction (Rieber et al). 1999;18:65 (Abstract)
Mycophenolate mofetil for secondary prevention of allograft vasculopathy following heart transplantation: a prospective, randomized, intravascular ultrasound controlled trial (Pethig et al). 1999;18:77-78 (Abstract)
Relationship between coronary function by positron emission tomography and temporal

changes in morphology by intravascular ultrasound (IVUS) in transplant recipients (Allen-Auerbach et al). 1999;18:211-18

Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

United Kingdom

Heart and lung transplantation from poisoned brain-dead donors: a 10-year United Kingdom experience (Tsui et al). 1999;18:78-79 (Abstract)

Variations in cardiac transplantation: comparisons between the United Kingdom and the United States (Anyanwu et al). 1999;18:297-303

United Network for Organ Sharing

New UNOS rules: historical background and implications for transplantation management (Renlund et al). 1999;18:1065-70

United States

Variations in cardiac transplantation: comparisons between the United Kingdom and the United States (Anyanwu et al). 1999;18:297-303

University of Wisconsin preservation solution

A comparative study of Celsior and University of Wisconsin solutions based on 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:1202-10

A comparative study of the Celsior and the University of Wisconsin solution based upon 12-hr preservation followed by transplantation in canine models (Mohara et al). 1999;18:39 (Abstract)

Does University of Wisconsin solution harm the transplanted heart? (Stringham et al). 1999;18: 587-95

Human lung preservation can be extended beyond eight hours using UW solution (Love et al). 1999;18:87 (Abstract)

Improved cardiac preservation by the addition of nitroglycerine to colloid-free University of Wisconsin solution (MUW) (Baxter et al). 1999;18: 769-73

V

Vascular cell adhesion molecules

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Vascular function

Vascular function in the cadaver up to six hours after cardiac arrest (Bolys et al). 1999;18:582-86

Vascular prostheses

Immunohistochemical analysis of vascular prostheses implanted with the left ventricular assist system (Fastenau et al). 1999;18:916-20

Vascular smooth muscle

The actions of cyclosporine-A on apoptosis and p53 expression in human vascular smooth muscle cells (Seta et al). 1999;18:61 (Abstract)

Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Increased or de novo expression of ICAM-1, VCAM-1 and E-selectin on cytomegalovirus-infected endothelial and vascular smooth muscle cells is induced by IL-1β release (Dengler et al). 1999;18:61 (Abstract)

Vasculopathy, allograft

Donor and recipient contribution of ICAM-1 and P-selectin in parenchymal rejection and graft arteriosclerosis: insights from double knockout mice (Räisänen-Sokolowski et al). 1999;18:735-43

Vasculopathy, aortic allograft

Gene therapy with soluble Fas decreases AGA in a rat aortic allograft model (Wang et al). 1999; 18:48-49 (Abstract)

Mixed hematopoietic chimerism prevents allograft vasculopathy (Kawaharada et al). 1999;18: 532-40

RacCA gene transfer supresses the development of aortic allograft arteriosclersosis in the rat (Wang et al). 1999;18:48 (Abstract)

Sirolimus (rapamycin) blood levels correlate with prevention of graft vascular disease (GVD) in monkey aortic transplants as monitored by intravascular ultrasound (Ikonen et al). 1999; 18:72 (Abstract)

Vasculopathy, cardiac allograft

Apoptosis in human cardiac allografts with transplant coronary artery disease (Xu et al). 1999; 18:90 (Abstract)

Captopril and platelet-activating factor (PAF) antagonist prevent cardiac allograft vasculopathy in rats: role of endogenous PAF and PAF-like compounds (Crawford et al). 1999;18: 470-76

Coronary arteries of human cardiac allografts with transplant coronary artery disease contain oligoclonal populations of T lymphocytes (Slachta et al). 1999;18:60 (Abstract)

Does initial photopheresis have an impact on the development of graft atherosclerosis after cardiac transplantation—a 6-year follow-up (Kur et al). 1999;18:93 (Abstract)

Does LVAD bridging-to-transplantation increase graft vasculopathy? (Kaplon et al). 1999;18:63 (Abstract)

Dose and time relationship of cyclosporine on chronic graft vascular disease after transplantation in a rat cardiac isograft model (Teranishi et al). 1999;18:73 (Abstract)

Effects of estrogen on nitric oxide synthase expression in rat aorta allograft and smooth muscle cells (Saito et al). 1999;18:937-45

Effects of MHC class II antigens on the development of cardiac allograft vasculopathy in miniature swine (Mawulawde et al). 1999;18:53 (Abstract)

Genetic polymorphism of transforming growth factor-β (CODON 25) and development of cardiac allograft vascular disease (Pethig et al). 1999;18:52 (Abstract)

Hemodynamic compromising rejection is associated with increased incidence of transplant coronary artery disease in cardiac transplant recipients (Kobashigawa et al). 1999;18:50 (Abstract)

Hemoglobin A1C predicts transplant coronary artery disease incidence and severity (Kato et al). 1999;18:50 (Abstract)

IgM to IgG anti-HLA class II antibody switching in cardiac transplant recipients reflects T cell responses to donor HLA-DR peptides and is associated with increased risk of cellular rejection and coronary artery disease (Lietz et al). 1999;18:80 (Abstract)

The impact of explosive brain death on the genesis of cardiac allograft vasculopathy: an intravascular ultrasound study (Mehra et al). 1999; 18:49 (Abstract)

Improved prevention of graft arteriosclerosis with thymoglobuline induction therapy in patients after cardiac transplantation (Zuckermann et al). 1999;18:93 (Abstract)

Increased intragraft expression of TGF-β mRNA in patients with graft vascular disease after clinical heart transplantation (de Groot-Kruseman et al). 1999;18:52 (Abstract)

Intravascular ultrasound has prognostic impact after heart transplantation: a multivariable analysis in a large patient cohort (Klauss et al). 1999;18:50 (Abstract)

Is the use of left ventricular assist device as a bridge to heart transplantation a risk factor for development of transplant coronary artery disease? (Radovancevic et al). 1999;18:63 (Abstract)

Low producers of TGF beta are protected from cardiac transplant vasculopathy (Densem et al). 1999;18:52 (Abstract)

Mechanisms of coronary artery remodeling in heart transplant recipients. A serial study with intravascular ultrasound and three-dimensional vessel reconstruction (Rieber et al). 1999;18:65 (Abstract)

Multiglycosidorum tripterygii, a new immunosuppressant, suppresses coronary arteriosclerosis after heart transplantation (Hachida et al). 1999;18:248-53

Mycophenolate mofetil for secondary prevention of allograft vasculopathy following heart transplantation: a prospective, randomized, intravascular ultrasound controlled trial (Pethig et al). 1999;18:77-78 (Abstract)

Noninvasive cost-effective detection of cardiac allograft vasculopathy by electron beam computed tomography (EBCT) (Hummel et al). 1999;18:49 (Abstract)

Pressure-wire guided balloon angioplasty in allograft coronary vasculopathy (Casella et al). 1143-46

Pretransplant panel reactive antibodies are associated with increased risk of transplant coronary artery disease (TCAD) in cardiac transplant recipients (Moriguchi et al). 1999;18:76 (Abstract)

Prevention of chronic rejection by nonselective endothelin receptor antagonist (Sihvola et al). 1999;18:61-62 (Abstract)

The role of lipids and fibrinogen in coronary vasomotor dysfunction after cardiac transplantation (Weis et al). 1999;18:50 (Abstract)

Stat4-mediated Th1 responses promote the development of graft arteriosclerosis (Koglin et al). 1999;18:71 (Abstract)

Temporal pattern of T lymphocyte and macrophage infiltration in a nonimmunosuppressed model of CAV (Fischbein et al). 1999;18:40-41 (Abstract)

Transforming growth factor-beta (TGF-β) and allograft vasculopathy following heart transplantation (Aziz et al). 1999;18:37 (Abstract)

Use of sequence specific oligodeoxynucleotides to inhibit myointimal proliferation associated with graft coronary artery disesae (Ennen et al). 1999;18:49 (Abstract)

Vasoconstriction
Cyclosporine-induced coronary artery constriction: dissociation between thromboxane release and coronary vasospasm (Braun-Dullaeus et al). 1999;18:328-34
Does PGE_1 attenuate potassium-induced vasoconstriction in initial pulmonary artery flush on lung preservation? (Sasaki et al). 1999;18:139-42

Vasodilation
Arginine vasopressin in the management of vasodilatory hypotension after cardiac transplantation (Argenziano et al). 1999;18:814-17

Vasospasm
A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mechanism for graft vasospasm? (Cable et al). 1999;18:177-83

Ventricular assist device. *See also* **Left ventricular assist device**
Criteria for selecting type of bridge to heart transplantation: the University of Arizona experience (Arabia et al). 1999;18:89 (Abstract)
Development of a ventricular assist device for out-of-hospital use (Mussivand et al). 1999;18:166-71
Hypertension during support with ventricular assist devices: incidence, risk factors and management (Stanford et al). 1999;18:58 (Abstract)
Improved survival in patients with acute myocarditis using external pulsatile mechanical ventricular assistance (Chen et al). 1999;18:351-57
Inter-hospital transfer of patients receiving advanced mechanical circulatory support (McBride et al). 1999;18:90 (Abstract)
Long-term follow-up of Thoratec ventricular assist device bridge-to-recovery patients after resolution of non-ischemic heart failure (Farrar et al). 1999;18:62-63 (Abstract)
Survival outcomes of patients with giant cell myocarditis bridged by ventricular assist devices (Brilakis et al). 1999;18:43-44 (Abstract)

Ventricular function
Evaluation of regional wall motion abnormalities and ventricular function in pediatric heart transplant patients using dobutamine stress echocardiography (Donofrio et al). 1999;18:84 (Abstract)

Ventricular transplantation with atrioplasty
A prospective randomized trial of complete atrioventricular transplantation versus ventricular transplantation with atrioplasty (Bainbridge et al). 1999;18:407-12

Ventriculectomy, partial left
Histopathology of resected myocardium is correlated with survival after partial left ventriculectomy—a clue to indication for PLV versus transplantation (Kawaguchi et al). 1999;18:67 (Abstract)
Partial left ventriculectomy in a two-year old girl with dilated cardiomyopathy (Gradinac et al). 18:610, 1999;18:381-83

Viagra
Efficacy and safety of sildenafil citrate (Viagra) in male heart transplant patients (Chait et al). 1999;18:58 (Abstract)

Vitamin K
Vitamin K reduces bleeding in left ventricular assist device recipients (Kaplon et al). 1999;18:346-50

von Willebrand factor
Von Willebrand deficient swine lungs transplanted into baboons (Lau et al). 1999;18:65 (Abstract)

VX-497
VX-497 inhibits IMPDH and is the first rationally synthesized immunosuppressant to prolong allograft survival (Gummert et al). 1999;18:72 (Abstract)

W

Waiting times
Determinants of waiting time for heart transplants in the United States (Kauffman et al). 18:733 (Correction), 1999;18:414-19

Women
Does cardiac transplantation affect gynecologic and reproductive outcomes? (Eisenring et al). 1999;18:58-59 (Abstract)

X

Xenograft
Cyclic AMP stimulation protects a porcine pulmonary xenograft from hyperacute rejection (Kulick et al). 1999;18:65 (Abstract)
Effects of prolonged storage time in xenotransplantation (Brenner et al). 1999;18:1211-17
Influence of ischemic time on hyperacute xenograft rejection in a working pig heart model with immunoadsorption (Brenner et al). 1999;18:59 (Abstract)
Inhibition of hyperacute pig-to-human xenograft rejection by modulating the fluid-phase complement activation (Fiane et al). 1999;18:66 (Abstract)
A model of xenograft hyperacute rejection attenuates endothelial nitric oxide production: a mech-

anism for graft vasospasm? (Cable et al). 1999;18: 177-83

Prevention of endothelial cell activation in hamster-to-rat cardiac xenografts by gene transfection of Bcl-2 (Kobayashi et al). 1999;18:66 (Abstract)

Public and professional attitudes toward xenotransplantation and other options to increase organ availability (Hull). 1999;18:92 (Abstract)

Regulatory roles of chemokines in delayed cardiac xenograft rejection (Mulligan et al). 1999; 18:59 (Abstract)

The role of antibodies in dysfunction of pig-to-baboon pulmonary transplants (Lau et al). 1999;18:65-66 (Abstract)

Von Willebrand deficient swine lungs transplanted into baboons (Lau et al). 1999;18:65 (Abstract)

What are the attitudes of potential heart and heart-lung patients to xenotransplantation? (Long et al). 1999;18:92 (Abstract)

Xenogeneic antibodies are not necessary for chronic rejection of vascularised xenografts (Briffa et al). 1999;18:66 (Abstract)